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Abstract 
Introduction 
Recent research has generated discussion upon the historically noted association 
between tuberculosis (TB) and diabetes mellitus (DM). However, evidence on the 
direction of the association, its magnitude, specificity and impact remains sparse.  
The primary aim of this thesis was to identify whether rates of TB (all sub-types, 
pulmonary (PTB) and extra pulmonary (EPTB)) are raised amongst those with DM (all 
sub-types, type 1 (T1DM) and type 2 (T2DM)), or the converse. Further to this, to 
estimate the magnitude and direction of any such associations. 
A secondary aim of the thesis was to investigate whether key TB outcomes differ 
amongst those with co-morbid DM and TB comparative to those with TB disease alone. 
Methods 
The Oxford Record Linkage Study (ORLS) is a database containing records of all 
hospital admissions and all deaths (regardless of where they occurred), in defined 
populations within the former Oxford National Health Service Region. ORLS1 covers 
the years 1963 to 1998 and ORLS2 covers the years 1999 to 2008, the two databases are 
not linkable.  
The Health Improvement Network (THIN) is a database containing electronic medical 
records collected at General Practice clinics throughout the United Kingdom (UK). 
Retrospective cohort analyses were carried out using data from ORLS1, ORLS2 and 
THIN.  
All patients in the datasets were classified as exposed to (having had) or unexposed to 
(not having had) TB (all sub-types, PTB or EPTB) and exposed or unexposed to DM 
(all sub-types, T1DM or T2DM).  
In the ORLS1 and ORLS2 datasets, standardised rate ratios (RR) and corresponding 
95% confidence intervals (95% CI) were calculated and compared for DM (all sub-
types, T1DM and T2DM) in individuals who have had and have not had TB (all sub-
types, PTB or EPTB). Similarly, RR and 95% CI were calculated and compared for TB 
(all sub-types, PTB or EPTB) in patients with and without DM (all sub-types, T1DM 
and T2DM). 
Within THIN datasets, the incidence rate ratio (IRR) and 95% CI of DM (all sub-types, 
T1DM and T2DM) were calculated using negative binomial regression, with TB (all 
sub-types, PTB or EPTB) as an explanatory variable. Similarly, the IRR and 95% CI for 
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TB (all sub-types, PTB or EPTB) were calculated using negative binomial regression, 
with DM (all sub-types, T1DM or T2DM) as an explanatory variable. 
Systematic searching was performed to identify studies comparing TB outcomes 
amongst those with and without DM. Data from these studies were utilised to inform 
meta-analyses that assessed all cause mortality, bacterial clearance rate and TB relapse 
or recurrence rate amongst individuals with DM and co-morbid TB comparative to 
those with TB alone. 
Results 
Significant increases in TB rates (all sub-types) and pulmonary tuberculosis (PTB) rates 
were identified amongst individuals with DM comparative to those without DM within 
the Oxford Record Linkage Study datasets.  
The RR of TB (all sub-types) was increased amongst individuals with DM (all sub-
types) compared to those without in ORLS1 (RR 1.77 (95% CI 1.45-2.15), P-value 
<0.001) and ORLS2 (RR 2.56 (95% CI 1.78-3.69), P-value <0.001). The RR of PTB 
was also increased amongst individuals with DM (all sub-types) compared to those 
without in ORLS1 (RR 1.72 (95% CI 1.22-2.37), P-value <0.001) and ORLS2 (RR 3.33 
(95% CI 1.51-6.62), P-value 0.001). There was a statistically significant elevation of 
risk for TB amongst those with T2DM compared to those without in ORLS1 (RR 1.58 
(95%CI1.15-2.14), P-value 0.003) and ORLS2 (RR 3.33 (95% CI 1.51-6.62), P-value 
0.001).  
There was no significant association between the rates of TB amongst those with T1DM 
compared to those without in ORLS1. The ORLS 2 dataset was too small to complete 
this analysis. No significant association was found between the rate of EPTB amongst 
those with DM comparative to those without in either ORLS1 or ORLS2. There was 
also no significant association between having had TB (all sub-types, PTB or EPTB) 
and subsequent risk of DM (all sub-types, T1DM or T2DM) in either ORLS1 or 
ORLS2. 
In THIN dataset the risk of TB (all sub-types) was found to be increased amongst 
individuals with DM (all sub-types), T1DM and T2DM when compared to those 
without. Thus, the IRR of TB (all sub-types) were significantly increased amongst 
individuals with DM (all sub-types) (IRR 1.50 (95%CI 1.27-1.76) P-value <0.001), 
T1DM (IRR 1.46 (95%CI 1.10-1.92) P-value 0.008) and T2DM (IRR 1.54 (95%CI 
1.30-1.82) P-value < 0.001) compared to those without DM. 
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The rate of PTB amongst individuals with DM (all sub-types), T1DM, or T2DM 
compared to those without were not significantly raised within THIN. 
The rate of EPTB was raised amongst those with T1DM (IRR 2.09 (95%CI 1.19-3.66), 
P-value 0.010) but was not raised amongst those with DM (all sub-types) (IRR 1.43 
(95% CI 0.99-2.07), P-value 0.055) or those with T2DM (IRR 1.39 (95%CI 0.93-2.06), 
P-value 0.11) when compared to those without DM. 
In THIN dataset the rates of DM (all sub-types), T1DM and T2DM were found to be 
raised amongst individuals who have had TB (all sub-types), PTB and EPTB when 
compared to those who have not. The rate of DM (all sub-types) was increased amongst 
those who have had TB (all sub-types) (IRR 5.65 (95% CI 5.19-6.16) P-value <0.001), 
PTB (IRR 5.74 (95% CI 5.08-6.50) P-value <0.001) and EPTB (IRR 4.66 (95% CI 
3.94-5.51) P-value <0.001) when compared to those who have not had TB. The rate of 
T1DM was increased amongst those who have had TB (all sub-types) (IRR 5.49 (95% 
CI 5.02-6.02) P-value <0.001), EPTB (IRR 0.84 (95% CI 0.35-2.03) P-value <0.001) 
but not amongst those who have had PTB (IRR 1.09 (95% CI 0.62-1.93) P-value 0.77) 
when compared to those who have not had TB. The rate of T2DM was increased 
amongst those who have had TB (all sub-types) (IRR 2.21 (95% CI 1.68-2.91) P-value 
<0.001), PTB (IRR 5.38 (95% CI 4.73-6.12) P-value <0.001) and EPTB (IRR 4.36 
(95% CI 3.65-5.22) P-value <0.001) when compared to those who have not had TB. 
However, within THIN dataset these estimates of association were being promoted by a 
significant age by TB interaction effect. 
Utilising systematic review techniques, twenty five studies were identified which 
reported upon TB outcomes amongst those with compared to without DM. Meta-
analyses showed individuals with co-morbid TB and DM had no significant difference 
in bacterial clearance rate after 2-3 months of treatment (1,675 participants, 6 trials, 
Relative Risk (RR) 1.38 (95% CI 0.97-1.97)), no significant difference in risk of TB 
recurrence & relapse (1,225 participants, 4 trials RR 1.20 (95% CI 0.93-1.54)), but a 
statistically significant increased risk of all cause mortality (12,128 participants, 18 
trials, RR 1.97 (95% CI 1.53-2.55)) comparative to those with TB in isolation. 
Discussion  
TB risk is increased in those with compared to those without DM within a UK setting. 
However, it remains unclear if risk of PTB and EPTB are raised amongst those with 
DM comparative to those without. It also remains unclear as to whether risk of DM is 
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increased amongst those who have had TB comparative to those who have never had 
TB. 
Individuals with co-morbid disease are at a greater risk of mortality during active TB 
disease than those with TB alone, however risk of TB relapse and recurrence are the 
same.  
Consideration of the association between DM and TB may become more important for 
improving TB control and TB treatment as DM prevalence rises in the UK and globally. 
In areas where TB is endemic TB screening amongst those with DM and TB 
prophylaxis may be needed to reduce or stabilise numbers developing active disease. 
Also, the increasing numbers suffering from co-morbid TB and DM will need 
heightened clinical attention in order to improve TB mortality outcomes. 
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Chapter Overviews 
Chapter 1  
This chapter contains information to contextualise the whole presented body of work; 
the aims, the chosen methodologies, the results and the critical discussions upon the 
results.  
Section 1.1, the introduction, briefly presents; the main themes of the thesis, the 
academic motivations behind the work and highlights the recent increase in research 
output upon the association between DM and TB. 
It was not within the remit of this doctoral work to give a review of all published 
literature upon DM and, or TB. A search of Medline alone for articles with either, or 
both diseases catalogued as the main focus retrieves over 243,000 citations (December 
(Dec) 2011). Instead the first two sections of the background, sections 1.2 and 1.3, give 
a brief narrative overview of each disease. These narrative overviews are intended to 
give readers an understanding of each disease as it occurs in isolation before any 
detailed discussion upon their possible association occurs. It is to be noted that parts of 
these overviews focus upon facets of each disease as is relevant in a UK setting. This is 
to give specific background to the candidate’s work which assesses the magnitude and 
direction of the association between DM and TB in subsets of the UK population. 
Section three of the background, section 1.4, begins with a short synopsis on systematic 
review methodology which acts as an introduction for a review of evidence to date upon 
the magnitude and direction of the association between DM and TB. The section ends 
with a discussion upon further findings from this review; a summary of key publications 
identified that focus on topics other than the association’s directionality and magnitude. 
The literature review and synopsis of further findings allow the analyses presented in 
this thesis to be framed within an appropriate body of contemporaneous research.  
The final section of the background, section 1.5, outlines the aims, hypotheses and 
objectives of the research completed by the candidate. 
Chapter 2 
The second chapter of this thesis outlines the different data sources and methodologies 
utilised for each set of analyses completed and presented within this body of work. 
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The first section, section 2.1, outlines in brief the study design and data sources that 
have been used to test hypotheses 1 to 6 given in full in section 1.5.2. This is in order to 
give readers an understanding of research possibilities given the available data. 
Section 2.2 describes the methods employed whilst interrogating data from a regional 
UK database (ORLS) to test hypotheses 1 to 6. 
Section 2.3 outlines the methods utilised to test hypothesis 1 to 6 using data from a 
nationally representative UK database (THIN). 
The final section of chapter 2, section 2.4, builds upon the brief introduction to 
systematic review given in the background section 1.4 and describes the specific 
systematic review and meta-analysis techniques used to test hypothesis 7.  
Strengths and weaknesses with the data and the methods applied are not discussed in 
chapter 2 but are given further thought in chapter 4. 
Chapter 3 
This chapter outlines individually and gives an overall summary of the results found 
from work completed as set out in chapter 2.  
The first section of chapter 3, section 3.1, details the results found whilst testing 
hypotheses 1 to 6 using data from the ORLS database.  
The second section of chapter 3, section 3.2, details the results identified whilst testing 
hypotheses 1 to 6 utilising data from THIN database.  
The third section of chapter 3, section 3.3, details the results found upon completing a 
systematic review of TB outcomes amongst individuals with and without DM (testing 
hypothesis 7). 
Chapter 4 
The last chapter contains a critical discussion upon the whole body of research 
completed and presented within the thesis. 
The first section of chapter 4 (4.1) summarises the research aims and methods used to 
achieve these.  
The second section of chapter 4 (4.2) contains the discussion upon the research findings 
of the whole body of work. In section 4.2.1 the principal findings from the work 
completed utilising the ORLS and THIN database is outlined and discussed in relation 
to the findings of other published studies (as identified in chapter 1). This puts the 
results found into context with other contemporary research. A discussion upon the 
strengths and the weaknesses of these analyses is also completed. In section 4.2.2 the 
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principal findings from the completed systematic review are outlined and discussed in 
relation to the findings of other published studies (as identified in chapter 1). The 
strengths and the weaknesses of the review are then discussed. Section 4.2.3, discusses 
the plausible biological pathways surrounding the findings of this body of work. With 
the final section of chapter 4, section 4.2.4, discussing the need for further research.
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Chapter 1. Introduction and Background 
1.1 Introduction 
1.1.1 Why study disease associations? 
The World Health Organization (WHO) defines epidemiology as  
“the study of the distribution and determinants of health-related states or events, 
including disease, and the application of this study to the control of diseases and other 
health problems”.1  
Some diseases co-occur within populations at either an increased or decreased 
frequency than would be expected due to chance given the background frequency of 
each disease.
2
 Some of these disease associations and dissociations are commonly 
known for example: sickle cell anaemia and a decreased risk of malarial infection
3
; 
Infection with human papillomavirus and an increased risk of cervical cancer
4
; 
Helicobacter pylori infection and an increased risk of stomach ulcers and cancer.
5
 
However, many disease associations are yet to be identified or fully evidentially 
validated such as the possible association between Crohn’s disease and multiple 
sclerosis or between DM and herpes virus 8.
6-8
  
Disease associations or dissociations may occur due to: a direct causal relationship 
when the presence of a certain disease causes another disease to be more or less likely 
to develop, an indirect causal relationship when the presence of a certain disease affects 
a third variable (perhaps an environmental or genetic factor) causing another disease to 
be more or less likely to occur, or, a common third variable which increases or 
decreases the risk of both diseases through separate mechanisms.
2
  
It is important to study disease associations as identifying both associations and 
dissociations can lead to advancement of knowledge upon disease sequalae, aetiology 
and differences in disease outcome. This in turn can give insights into possible methods 
for disease prevention, control or management.
2
 For example the knowledge that 
infection with Human immunodeficiency virus (HIV)  increases risk of active TB led to 
adaption of TB diagnosis and prevention programmes as well as both TB and HIV 
management programmes in order to improve disease prevention, identification and 
treatment.
9 10
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1.1.2 Why investigate a historically noted association between TB & DM? 
Reports of diseases which today would be recognised as TB or DM go back to 
antiquity. Evidence of TB was found in skeletal remains which dated back to 8,000 
years before Christ
11
 and narrative reports of disease akin to what we now term DM can 
be found within the works of many of the great physicians from early civilisations.
12 13
 
That an association exists between these diseases has also been documented throughout 
history. In Richard Morton’s Phthisiologia: a treatise on consumption he stated that an 
association between TB and DM has been known since Roman times
14
, Susruta also 
noted within his works that a relationship exists between the two diseases and Avicenna 
remarked in his Canon of Medicine that ‘phthisis’ is often complicated by DM.13 15 
Although an association between TB and DM has been noted historically
12 14
 and is 
cited in key texts
16
, until very recently, the association along with its possible effects 
and implications had become somewhat forgotten in policy and practice. The 
association was either entirely unmentioned or only briefly mentioned in UK and global 
guidelines for both TB and DM.
17-22
 Perhaps this past omission is unsurprising as 
although rates of both diseases have been increasing
23 24
 high quality, quantitative 
evidence demonstrating the existence, direction, magnitude and relevance of an 
association between them was both sparse and difficult to access usually having been 
reported in publications as a studies minor, or secondary, rather than major, or primary, 
research findings.
25
  
A meta-analysis, published in 2008 as part of a systematic review, found an increased 
risk of active TB amongst individuals with DM upon statistical pooling of data from 
three pre-existing cohort studies which assessed the association (RR 3.11, 95% CI  2.27- 
4.26).
25
 However, the external validity of this pooled risk estimation is somewhat 
questionable with two of the three cohort studies contributing to the estimation having 
been completed amongst populations of individuals with renal failure (renal failure 
itself being a risk factor for TB).
26 27
 
It is important to further the available research upon the existence and magnitude of this 
association until enough evidence is available to produce robust risk estimates that can 
be used to inform policy appropriately within differing settings and perhaps lead to 
information upon disease aetiology and sequelae. 
It is conceivable that as well as DM leading to an increased risk of TB that the converse 
association exists (TB leads to an increased risk of DM) however this phenomenon is 
much less commonly discussed amidst published literature.
28 29
 Perhaps this is because 
3 
 
the biological plausibility of such an association is less coherent.
28 29
 Some studies have 
shown induced hyperglycaemia and, or, impaired glucose tolerance (IGT) occurring 
during the early phase of TB.
30-32
 This occurrence may be noteworthy as in 20-50% of 
individuals with IGT progression to overt DM is known to ensue after approximately 3-
5 years.
33-36
 However interpreting the true importance of observed hyperglycaemia 
amongst populations of individuals with TB is complicated as hyperglycaemia is often 
seen to be intermittent or to reverse after the early phase of TB infection.
30 32 37 38
 It 
could be that amongst this population hyperglycaemia is occurring as a side effect of 
treatment with Rifampicin and Isoniazid
39-41
, or, that the hyperglycaemia being 
observed is ‘stress  hyperglycaemia’42 43 rather than being a true indication of metabolic 
dysfunction.  
Thus, it is also essential to further the available research upon the direction of this 
association until enough evidence is available to produce confident conclusions that can 
be used to inform policy appropriately and also perhaps lead to advances in knowledge 
upon TB and DM aetiology and sequelae. 
1.1.3 Investigating the magnitude and effect of an association within the UK 
If an association exists between TB and DM it would undoubtedly have the most 
detrimental public health effect in low to middle income countries, such as India, where 
the fastest increases in DM are predicted to occur and where the burden of TB is high.
44-
46
 However, that is not to say that an effect within middle to high income countries such 
as the UK would be negligible
47
 especially amongst population sub-groups already at 
high risk of each disease such as those of Asian ethnicity.
47-50
  
Within the UK, as has occurred elsewhere, there has been an increase in the prevalence 
of diagnosed DM.
23
 Masso-Gonzalez and colleagues calculated, using general practice 
(GP) data, that between 1996 and 2005 DM prevalence increased by 1.5% (from 2.8% 
to 4.3%).
23
 This rise in DM prevalence was seen to be underlined by an increasing 
incidence of DM.
23
 Modelling projects have shown that there has likely been an 
increase in the prevalence of undiagnosed DM
51
, they estimate that in England in 2010  
there were in total (undiagnosed and diagnosed) 3.1 million adults with DM and project 
that this number will rise to 4.6 million by 2030.
51 52
 Alongside this increasing burden 
of chronic disease within the UK; TB remains to be a cause of morbidity and mortality. 
In fact, over the past decade, incidence of TB in the UK has increased from 11.4 to 13.6 
per 100,000 population.
24 53
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The prevention and treatment of both TB and DM present major public health 
challenges in all settings across the globe. Given the rising incidence trends of both 
diseases in the UK it is particularly pertinent to understand the association in detail 
within this setting so that any relevant information can be utilised to aid local TB and 
DM prevention and control. 
1.1.4 Why investigate the effect of co-morbidity on TB outcomes? 
It was estimated that globally between 150 and 171 million people had DM in 2000 and,  
as is projected for the UK, the global prevalence of DM is projected to dramatically 
increase by 2030.
46 51 54
 Alongside the epidemic proportions of individuals with DM 
over a third of the global population is latently infected with TB.
55
 In 2010 there were 
8.8 million active disease episodes and 1.45 million deaths attributable to TB 
worldwide.
56
  
Given these figures, if DM is indeed found in association with TB it is plausible that a 
substantial proportion of new TB cases will be amongst individuals with DM.
47 57 58
 
Thus, identifying whether there are any implications for individuals who have these 
diseases concurrently is important for clinical guidance and practice. In particular it is 
important to know whether, and if so how, clinically relevant TB outcomes such as 
sputum clearance rate, and mortality are affected amongst this potentially large sub-
group of individuals.
59-62
 
1.1.5 A burgeoning area of research 
Since the publication of the afore mentioned systematic review
25
 upon the magnitude of 
the association between DM and TB (and the inception of this body of work) there have 
been approximately 100 articles published discussing or investigating; the existence of 
any associations, the magnitude of any associations, and the relevance of any such 
associations within modern times.
47 58 60 63-153
 As is perhaps inevitable following these 
publications there has also been new health policy and guideline papers produced.
129 154
 
However, it is only the minority of these publications which report new evidence upon 
the association. Thus even with the influx of recent publications upon the association 
between TB and DM the investigations as set out in this thesis still add to a relatively 
small body of research. In particular the analyses presented within this thesis contribute 
to a highly limited body of work investigating the directionality and specificity by 
disease sub-type of the association. 
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At the onset of this doctoral project it was believed that completion of a comprehensive 
systematic review upon the differences in TB outcomes amongst those with and without 
DM would be an entirely novel piece of work, there were no existing comprehensive 
publications of this nature. However, a systematic review reporting upon the differences 
in TB outcomes amongst those with and without DM has since been published.
121
 The 
differences in methodology and findings between this systematic review and our own 
have been finitely outlined within the discussion chapter of this thesis.  
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1.2 & 1.3 A narrative overview of TB and of DM 
In order to contextualise further discussion upon the association between TB and DM a 
brief overview of each disease as it occurs in isolation is now given. The information 
presented outlines the sub-types, aetiology, diagnostic guidelines, standard treatments 
and patterning of TB and DM. Information has been assimilated (as for a narrative 
review) from key research articles, standard texts and publications produced by 
pertinent organisations and governing bodies. Parts of each overview do give focus to 
aspects of TB or DM as is relevant in a UK setting. This is to put into context the 
research presented in this thesis which assesses the magnitude and direction of the 
association between TB and DM in subsets of the UK population. 
  
7 
 
1.2 TB: a brief overview  
1.2.1 Mycobacterium tuberculosis 
TB is a chronic infectious bacterial disease which is caused when the obligate 
intracellular human parasite Mycobacterium tuberculosis (M.tuberculosis) colonises a 
host.
155
 The aetiological agent M.tuberculosis is an acid fast, gram positive, rod shaped 
bacterium, 0.5 to 3 micrometres in size which was first isolated by Robert Koch in 
1882
156
, and is depicted in Figure 1.  
Figure 1: Coloured scanning electron micrograph of M.tuberculosis
157
 
 
M.tuberculosis is a slow growing, aerobic bacterium with a lipid rich, hydrophobic cell 
wall and has relatively simple nutritional requirements for growth.
155
  
1.2.2 M.tuberculosis transmission and disease outcomes 
Host to host transmission of TB occurs when an individual inhales M.tuberculosis 
bacteria that have been expelled into the air in tiny aerosolised droplets of saliva by an 
individual with active infectious TB whilst coughing or spluttering.
55 155
 
There are three main outcomes that can ensue after TB transmission has occurred; 
bacterial elimination where bacteria are eradicated and no disease state develops, latent 
TB infection or a form of active TB infection as is portrayed in Figure 2.
158
  
Latent TB 
The UK’s health protection agency (HPA), the body which carries out infectious disease 
surveillance and provides reference microbiology and microbial epidemiology services 
within the UK
159
, defines latent TB as follows:  
“Latent TB is a disease state where viable bacteria are present in a host but are not 
causing active disease. These dormant bacteria retain the potential to reactivate, 
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replicate and cause active disease. Latent TB may be the result of TB infection which 
has never progressed to cause active disease or old active TB disease that has become 
inactive.”160 161  
After primary infection with M.tuberculosis it is estimated that approximately 90% of 
individuals will go on to develop latent TB, depicted in Figure2.
55 155 162 163
 Individuals 
with latent TB tend to have no signs or symptoms of disease and are not infectious 
unless disease re-activation occurs.
164
 
Active TB 
The HPA defines active TB as follows:  
“Active TB is a disease state where bacteria are continually replicating and an 
individual is showing clinical signs of disease, whether or not it is infectious.”160 161  
Active disease which occurs straight after an individual is infected with TB is known as 
‘primary progressive TB’.55 155 162 Some individuals, especially in endemic areas, will 
develop ‘primary progressive TB’ after re-infection with the same or an alternate strain 
of M.tuberculosis.
165
 Primary progressive TB occurs in approximately 10% of 
individuals after their primary infection, depicted in Figure 2.
163
  
Active disease which occurs due to reactivation of latent TB is known as ‘secondary’ or 
‘reactivation TB’.55 155 162 Reactivation TB occurs in approximately 10% of individuals 
who develop latent TB, depicted in Figure 2.
158 166
  
  
Figure 2: Percentage expected to develop each TB outcome after exposure and their diagnostic test status163 
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It is very difficult to distinguish previous primary TB infection from re-infection or 
indeed from reactivation TB.
165
 
Dependent upon the situ of the infection active TB can be further categorised as 
pulmonary or extra pulmonary.
55 155 162
 PTB tends to occur more commonly than EPTB 
although rates are dependent upon a population at risks socio-demographic 
characteristics and co-morbidities.
160 167
  
The signs and symptoms of active TB are non-specific but commonly include; malaise, 
fatigue, fever with chills and night sweats, chest pain, wasting of lean mass and fat due 
to anorexia and metabolic disturbances caused by the inflammatory process and 
immune response to the disease, dyspnoea or orthopnoea in extensive disease and a 
cough that becomes productive and leads to haemoptysis.
55 155 162 164 168
 
1.2.3 Pathogenesis 
Whether, and which of these described disease states arises is dependent upon the 
complex interplay that occurs between the hosts immune system and the bacteria’s 
virulence factors. Current scientific knowledge of which remains incomplete.
160 169
  
Innate immune defences 
In order to cause an infection and avoid elimination the M.tuberculosis bacterium must 
first pass the physical defences of the upper respiratory tract (URT) including those of 
the nose, nasal cavity, turbinates, and pharynx.
170
 Bacterium must avoid impingement, 
or expulsion by mucocilliary action or the cough and sneeze reflexes.
155 171
 Within the 
URT many antimicrobial substances are present and active in the clearance of 
mycobacterium.
172
 Antimicrobials of the Cathelicidin and Defensin family in particular 
have been shown to be active in lysing M.tuberculosis bacilli.
172
  
If M.tuberculosis bacilli pass through the URT they then face the defences of the lower 
respiratory tract (LRT). Only particles less than 10µm can physically pass into the LRT 
which is made up of the larynx, trachea, bronchi and the lungs.
155 169 173 174
 As in the 
URT, the LRT employs mucocilliary and antimicrobial action in order to eliminate 
M.tuberculosis bacilli as they pass through the trachea and bronchi.
174
 The bronchioles 
and alveoli are covered in a fluid layer that contains antimicrobial substances,
175
 
immunoglobulins
176
 and molecules of both the alternative and classical complement 
pathway.
177 178
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Cellular immune response 
Once within the LRT M.tuberculosis are likely to come into contact with any number of 
host immune cells all of which can mediate different immune responses after initial 
interaction with the bacterium.
155 169
  
M.tuberculosis may be taken up into host immune cells such as macrophages, dendrites 
or pneumocytes via phagocytosis as is depicted in Figure 3.
155 169 179
 This process can 
occur via a number of mechanisms as multiple components of the bacterial cell wall act 
as ligands for alternate host cell receptors which when stimulated all facilitate bacterial 
uptake.
170 180 181
 
When M.tuberculosis are engulfed they enter immune cells within a phagosome, an 
endocytic vacuole, which once in the cell fuses with another type of vacuole known as a 
lysosome resulting in the formation of a phago-lysosome.
155 182
 Within the phago-
lysosome the bacteria will encounter a hostile environment, acidic with an abundance of 
toxic reactive oxygen and nitrogen species, lysosomal enzymes and toxic peptides.
155
 
Exposure to this environment can destroy M.tuberculosis.
182
 However some 
M.tuberculosis bacilli are able to survive within phagocytic cells by blocking phago-
lysosomal fusion and thus exposure to the hostile environment found within these 
vacuoles.
155
 Scientific understanding upon how M.tuberculosis arrests phagolysosomal 
fusion is at present incomplete. Macrophages that are unable to destroy M.tuberculosis 
become an ideal environment for the bacteria to ‘hide’ within and replicate within. 
Dendritic cells which phagocytose M.tuberculosis but are unable to kill the bacilli 
migrate to the draining lymph nodes where they present bacterial antigens to naïve 
effector thymocyte cells (T-Cells).
183 184
 Presentation of bacterial antigen to naïve 
effector T-Cells causes T-Cell activation. Active T-Cells can migrate into the 
circulatory system where they remain until they are attracted to sites of TB infection 
such as the lung by inflammatory mediators.
184
 
Once activated and at the site of TB infection CD8+ T cells (cluster of differentiation 8 
positive) and CD4+ T Cells (cluster of differentiation 4 positive) can control TB 
infection although the mechanisms through which this is achieved again are not fully 
understood.
185
 What is known is that CD4+ T Cells can produce cytokines such as 
tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) which activate 
macrophages enabling the killing of M.tuberculosis bacteria.
185
 Also that CD8+ T Cells 
can destroy 
12 
 
Figure 3: M.tuberculosis from infection to transmission186 
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infected macrophages and M.tuberculosis bacilli by releasing cytotoxic mediators such 
as granulysin, perforins and granzymes.
185
 Some M.tuberculosis bacteria are able to 
cause persistent infection by subverting the dendritic immune response which brings 
about T-Cell activation.
187
 
Granuloma formation 
Whilst T-Cell activation is occurring infected macrophages in the lung are producing 
chemokines which attract inactivated monocytes, lymphocytes, and neutrophils to the 
site of TB infection.
171 188
 These cells are unable to destroy bacteria but can create 
fibrous lesions which are able to contain M.tuberculosis bacteria halting their spread.
171 
188
  
Within these granulomatous lesions a caseous necrotic environment, acidic with low 
oxygen and limited nutrients, develops. This hostile environment restricts replication of 
the M.tuberculosis bacteria but does not necessarily destroy them (latency).
189
 Lesions 
that have undergone fibrosis and calcification can remain dormant for years. However 
under certain circumstances bacteria can become active again. If bacteria re-activate 
lesions can become liquid causing their fibrous walls to rupture and bacteria amidst 
necrotic material to drain back into the bronchi or circulatory system.
189
 If bacteria enter 
and then leave the circulatory system at a different juncture an EPTB infection can 
ensue.
189
 Bacteria that re-enter the bronchus can be coughed into the atmosphere 
allowing infection of a new host and the infection process to start all over again.
189
 
1.2.4 Diagnostic guidelines for TB 
Once an individual is infected with TB prompt and accurate diagnosis is key to the 
effective treatment of the disease and precise disease surveillance. However currently 
there is no global consensus upon a finite definition of a TB case and thus no 
standardised diagnostic guidelines. The way in which TB is diagnosed is mainly 
determined by the setting in which the diagnosis is being made and the resources 
available.
190 191
 There are numerous ways in which to diagnose a case of TB clinically 
and, or, microbiologically some common methods are outlined within Table 1. 
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Table 1: Diagnostic tests available to identify a TB case155 
Diagnostic Test 
Clinical 
Assessment 
Chest 
Radiography 
Sputum Smear Sputum Culture 
Polymerase Chain 
Reaction 
Tuberculin 
skin test 
Quantiferon 
TB test 
Mode of 
detection 
Clinician 
detection of signs, 
symptoms and 
history suggestive 
of TB 
Allows detection 
of signs of TB 
such as lobar 
infiltrates or 
cavitations 
Allows 
identification of 
acid fast bacilli 
(M.tuberculosis) if 
present within a 
sample 
Allows identification 
of M.tuberculosis if 
present within a 
sample 
Allows detection of 
M.tuberculosis 
Deoxyribonucleic 
acid (DNA) if 
present in a sample 
Detects immune 
reactivity 
indicative of 
prior exposure 
to 
mycobacterium 
Detects immune 
reactivity 
indicative of 
prior exposure 
to 
mycobacterium 
Time to obtain 
diagnosis 
Minutes Minutes Up to 24 hours 
Up to 6 weeks if 
using solid media 
Up to 2 weeks if 
using high pressure 
chromatography 
Hours Up to 72 hours Up to 24 hours 
15 
 
Global case definition and diagnostic criteria 
The WHO is the United Nations directing and coordinating health authority for global 
health. They provide leadership for; the global health research agenda, norms and 
standards for global health, evidence-based global health policy and monitor and assess 
global health trends.
192
 Their definitions for a TB case and diagnostic guidelines to 
identify cases are probably the most commonly used worldwide.  
The WHO defines a case of TB as:  
“A patient in whom TB has been bacteriologically confirmed or has been diagnosed by 
a clinician”.193  
The WHO defines an EPTB case simply as an individual with:  
“TB of organs other than the lungs”.193 
However these definitions are broad and lead to broad diagnostic guidelines. The WHO 
suggest basing a TB diagnosis upon either a single positive sputum culture, or strong 
“histological or clinical evidence suggestive of TB”.193 194  
Definition and diagnostic criteria remain broad as the WHO recognises that many 
countries still lack microbiological diagnostic capacity. 
UK case definition and diagnostic criteria 
The National Institute for Clinical Excellence (NICE) is a UK Department of Health 
‘arms length’ body which develops evidence-based guidelines on the most effective 
ways to diagnose, treat and prevent disease and ill health.
195
 
NICE has also outlined definitions and diagnostic guidelines for TB.
21
 The diagnostic 
guidelines for TB as dictated by NICE reflect the UK’s capacity to utilise complex 
laboratory based diagnostic techniques. 
In the UK when PTB is suspected due to the presence of some or all of the common TB 
signs and symptoms NICE suggest that a chest X-Ray should be taken. Then, if results 
are indicative of TB (evidence of infiltrates, consolidations and or cavitations in upper 
lobes with or without mediastinal or hilar lymphadenopathy) that three sputum samples 
should be sent for culture and microscopy.
21
  
If EPTB is suspected then NICE suggest a biopsy or needle aspiration be taken and 
culture or histological examination of either pus or a surgical sample be completed to 
confirm diagnosis. They also state that upon confirmation of EPTB that a chest X-Ray 
should also be taken (if not already done) to identify whether there is presence of co-
existing respiratory TB.
21
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If latent TB is suspected NICE suggest confirmation by Mantoux testing or, in those for 
whom Mantoux testing is likely to be unreliable, by IFN-γ testing.21 
1.2.5 TB Treatment 
TB is a curable disease however as with diagnosis, standard treatment regimens for TB 
differ by setting and resource availability.
196
 TB cases, once identified, need to be 
efficiently and effectively treated in order to reduce transmission, achieve cure and thus 
reduce preventable morbidity and mortality.
196
  
Standard treatment 
The standard treatment regimens prescribed for TB are made up of a combination of the 
following antibiotics; Ethambutol, Isoniazid, Pyrazinamide, Rifampicin and 
Streptomycin.
21 22
 
Antibiotics are given in combination and over a prolonged period of time in order to 
prevent development of drug resistance.
196
 
For PTB both the WHO and NICE advise a daily dose of Rifampicin, Isoniazid, and 
Ethambutol for two months followed by dosage with Isoniazid and Rifampicin for a 
further four months.
21 22
  
Further treatment standards in the UK  
The site of TB infection leads to specific signs and may be associated with specific 
morbidities and increased mortality. Thus, due to the nature of pericardial, meningeal, 
spinal and disseminated TB infection NICE also gives specific guidelines for their 
treatment within the UK.
21
  
In the UK, as occurs in other countries, individuals failing to comply with a treatment 
regimen can be given ‘Directly Observed Therapy’. This is when a case worker supplies 
an individual with their medication and watches whilst they take it.
21 197
 
Also, in order to monitor treatment success NICE advocates for microbiological follow 
up (using sputum smears) of all individuals after treatment for TB.
21
 It is recommended 
that sputum smears are examined two months after an individual starts on treatment 
(after completion of the initial treatment phase), after five months on treatment, and at 
the end of treatment.
21
 
1.2.6 TB rates and risk factors 
The WHO estimates that globally one in 3 people are infected with latent TB and that 5 
to 10% of these people will develop active disease at some point over their life-course.
56
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In 2010 there were an estimated 8.8 million prevalent cases of active TB globally and, 
although TB is a curable infectious disease, it was estimated that it caused 1.45 million 
deaths.
56
 The majority of deaths from TB will occur within middle to low income 
countries.
56
 
In 2010 sub-Saharan Africa saw the largest proportion of new TB cases per population 
with more than 270 cases occurring per 100,000 individuals.
56
 However, due to 
demographics, the largest number of new TB cases seen in 2010 were within Asia, the 
world’s largest and most highly populated continent.56 In 2010 60% of the incident 
global TB cases could be found spread throughout this continent.
56
 Figure 4 clearly 
depicts the areas with the highest incidence of TB. 
Looking at Figure 4 it can also clearly be seen that although disproportionately TB 
affects every part of the world with cases occurring in every single country across the 
globe.
56
  
Prevalence and incidence rates of TB in the UK are relatively low comparative to the 
rates occurring in other countries globally; however, TB incidence in the UK is similar 
to the incidence rates across other European countries (see Figure 4). 
18 
 
Figure 4: Estimated incidence rates for TB in 2010 by country56 
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UK TB Rates 
In England, Scotland, Northern Ireland (N.Ireland) and Wales TB is a notifiable 
infectious disease.
198
 This means that it is a statutory requirement for registered medical 
professionals to report cases of TB to the HPA’s Centre For Infections as part of their 
professional duties.
198
 Statistics for TB rates within the UK population are thus very 
accurate and easily identifiable. The HPA collates all data upon TB in the UK through 
an enhanced reporting system which, because of its accuracy, is where the majority of 
the data presented below have been assimilated from.
198-200
 
Historically the UK had high incident rates of TB and TB was a disease which afflicted 
the general population. Now however TB mainly affects specific sub-groups of the UK 
population who are described as being at high risk of active TB.
199
  
Although the UK has relatively low rates of TB over recent years these have been seen 
to be rising. TB incidence for all active TB has seen a slight rise within the UK between 
2005 and 2009 from 13.8 per 100,000 to 14.6 per 100,000 as is shown in Table 2.  
Within the UK pulmonary TB tends to be slightly more common than EPTB with 4,401 
cases (54%) and 3,186 cases (46%) being reported respectively in 2009.
160 198 200 201
  
Table 2: TB incidence rates by country and year, 2005-2009201 
Year 
England N.Ireland Scotland Wales Total 
Rate per 100,000 (95% CI) 
2005 15.2 (14.9-15.6) 4.3 (3.4-5.5) 7.2 (6.4-7.9) 6.4 (5.5-7.3) 13.8 (13.5-14.1) 
2006 15.2 (14.9-15.6) 3.5 (2.7-4.5) 7.4 (6.7-8.2) 6.1 (5.3-7.1) 13.8 (13.5-14.1) 
2007 14.9 (14.6-15.3) 3.9 (3.1-5.0) 8.0 (7.2-8.8) 6.7 (5.8-7.7) 13.6 (13.3-13.9) 
2008 15.4 (15.1-15.8) 3.7 (2.9-4.7) 8.6 (7.8-9.5) 5.6 (4.8-6.5) 14.0 (13.7-14.3) 
2009 16.0 (15.7-16.3) 3.1 (2.3-4.0) 9.3 (8.5-10.2) 7.1 (6.2-8.2) 14.6 (14.3-14.9) 
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Geographic variation 
When data is stratified by country a rise in incidence over time can be seen for England, 
Scotland and Wales but the reverse is seen for N.Ireland, as shown in Table 2. 
The decrease in TB incidence within N. Ireland could be due to any number of socio-
demographic factors. Perhaps exposure is lower; for example immigration from high 
risk TB countries to N. Ireland could be decreasing, or perhaps control programmes and 
contact tracing are becoming more efficient lowering the number of contacts per index 
case. 
The average incidence rate of TB within the UK is 14.6/100,000 however, when 
stratified by county, incidence rates of TB vary within England by region as shown in 
Figure 5.
201
 The highest incident rates of TB tend to be within urban conurbations such 
as London where there were 44.4 new cases per 100,000 in 2010 compared to 6.1 new 
cases per 100,000 in the rural South West of England, see Figure 5.  
As well as showing variance between regions, TB incidence shows variance within 
regions and even within cities. In 2001 in London there was a 30 fold difference 
between the borough with the highest TB incidence compared to the borough with the 
lowest TB incidence.
202
 The regions covered by the ORLS Database had an average TB 
incidence rate of 10.5/100,000 population (95% CI 8-13) between 2004 and 2009. 
21 
 
Figure 5: Number and rate of TB cases in England by region, 2010 
 
 
Non modifiable risk factors 
Within the UK TB rates are seen to be patterned according to sex. Males are seen to 
develop active TB more commonly than females. In 2010 4,808 (15.7/100,000) incident 
TB cases were amongst males comparative to 3,629 (11.5/100,000) amongst females.
201
 
That is 57% of TB occurred amongst males comparative to 43% amongst females. 
TB in childhood is relatively uncommon, see Figure 6. Incidence rates in 2010 peaked 
for those aged 15 to 40 years and a smaller peak was seen for those aged 70 to 90
287 
6.1 
887 
18.7 
843 
11.8 
778 
9.3 
481 
8.4 
486 
12.3 
648 
13.4 
3309  
44.4 
   143  
   6.5  
Key 
Number of Cases 
Rate/100,000 
 
22 
 
Figure 6: Cases of TB reported within UK by age group, 2010
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TB rates within the UK population are also ethnically patterned. Figures for incident 
cases of TB reported in 2009 (as with those reported since 1988) show TB to be much 
more common amongst individuals of Black African, and Indian Subcontinent ethnic 
origin.
203 204
 Across all ethnicities TB rates are higher amongst migrants i.e. those not 
born in the UK compared to those born within the UK as is portrayed in Table 3.
201
 
Table 3: TB incidence rate for the UK in 2009 stratified by place of birth and 
ethnic group201 
Ethnic group 
UK-born Non-UK-born 
Total including those of 
unknown birth place 
Number 
of cases 
Rate per 
(100,000) 
Number 
of cases 
Rate per 
(100,000) 
Number 
of cases 
Rate per 
(100,000) 
White 1,412 3 241 7 1,881 3 
Black - Caribbean 78 21 82 38 173 29 
Black – African 130 43 1,574 273 1,749 199 
Black – other 26 55 51 218 87 123 
Indian 171 30 1,798 235 2,058 154 
Pakistani 237 42 1,012 234 1,319 132 
Bangladeshi 50 22 252 133 323 78 
Chinese 7 11 103 59 119 50 
Mixed/other 82 9 758 59 859 39 
Total Including those 
of unknown ethnicity 
2,240 4 5,994 86 9,040 15 
 
Amongst non UK born, UK residents the risk of TB increases with time since entry to 
the UK as shown in Figure 7. However it should be noted that this trend could be a 
reflection of risk of TB increasing as these individual’s age. 
24 
 
Figure 7: Percentage of migrants developing TB by time since entry to the UK 
 
Risk Factors 
Commonly cited risk factors for the development of active TB can be broadly grouped 
into those which increase an individual’s likelihood of prolonged exposure to TB 
bacillus (such as; Socio-economic status (SES), homelessness, working or residing 
within hospitals, prisons, premises with overcrowding, nursing homes and residential 
homes)
205 206
, or those which increase likelihood of progression to active disease (such 
as; SES, drug use, alcohol use, smoking status, HIV, silicosis, bronchitis, emphysema, 
renal failure, carcinoma of the head and neck, transplantation, malnourishment, 
treatment with corticosteroids, treatment for rheumatoid arthritis or Crohn’s  
disease).
139 205 206
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1.3 DM: a brief overview  
1.3.1 Aetiology 
Unlike for TB there is no known aetiological agent which causes DM. DM is a chronic 
condition and has been defined as a group of heterogeneous disorders with a common 
underlying metabolic dysfunction.
207
 The metabolic pathway that is disrupted resulting 
in DM is shown in Figure 8.
52
 209
 210
 
Figure 8: The metabolic pathway disrupted amongst individuals with DM
208
 
 
The usual signs of DM are hyperglycaemia and glucose intolerance due to insulin 
deficiency and, or, impaired insulin action.
207 209
 Insulin is a proteinaceous hormone 
which is produced within the islets of langerhans β-cells in response to high blood 
glucose levels.
209 210
 Insulin stimulates; the uptake of blood glucose into body cells 
where ever it is needed (for example into muscle cells within muscle tissue which use 
glucose during glycolysis),
209 210
 storage of blood glucose as glycogen,
209 210
 a decrease 
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in the rate of glycogen breakdown to sugar in the liver and inhibition of the conversion 
of amino acids and glycerol from fats to sugar
209 210
 
There are 3 common sub-types of DM; type 1, type 2 and gestational DM. 
Type 1 DM 
Individuals with T1DM have evidence of pancreatic β cell destruction which has led to 
a detrimental decrease in their levels of insulin requiring them to administer insulin in 
order to prevent ketoacidosis, coma or death.
 209 211 212
 The inability to produce insulin 
can be idiopathic or due to an autoimmune response characterised by the presence of 
insulin auto-antibodies such as Islet Cell Antibodies, anti-glutamic acid decarboxylase 
antibodies, or protein tyrosine phosphatase-like protein IA-2 antibodies.
209
 Signs and 
symptoms of T1DM are normally a combination of the following: polyuria, malaise, 
constant thirst and hunger, weight loss, recurrent infections, poor healing, and blurred 
vision.
209 210
 An individual’s risk of developing T1DM is influenced by both genetic and 
environmental risk factors. Genetic risk is predominantly associated with Human 
leukocyte antigen markers and less strongly with genes from other chromosomes.
213 214
 
It is thought that environmental triggers such as viral and bacterial infection, or 
nutritional factors can elicit an autoimmune
 
process in individuals genetically 
predisposed to developing T1DM.
215
 Although the field of literature upon the aetiology 
of DM is rapidly expanding the precise cause of T1DM is unknown.
213 214
 
Type 2 DM 
Individuals with T2DM have insulin resistance and, or, a decreased level of insulin 
secretion the exact aetiology of which is unknown.
209
 It is commonly agreed that in 
individuals with T2DM there is no autoimmune degeneration of the pancreas as is seen 
in individuals with T1DM and that individuals with T2DM are not ketosis prone.
209
 
Most often individuals with T2DM can achieve hyperglycaemic control with dietary 
change and use of oral hypoglycaemic agents. However, if blood glucose control is not 
achieved by these means, insulin may be used.
209
 Weight loss can decrease an 
individual’s risk of developing T2DM and indeed in some individuals with T2DM can 
stop the need for medication usage or reverse their T2DM disease status.
216
 T2DM is 
commonly asymptomatic, although when signs and symptoms occur they are similar to 
those of T1DM, thus diagnosis of T2DM is often made incidentally or due to the 
appearance of its associated complications.
209
 The risk of developing T2DM is 
associated with: older age, ethnicity, dietary intake, a sedentary lifestyle, obesity, and 
prior history of glucose intolerance or gestational DM. As with T1DM family history of 
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DM (heritable/genetic risk factors) and environmental triggers such as viral or bacterial 
infection are thought to play a role in susceptibility.
7 209
  
Two recent seminal studies have given new and mixed insights into the aetiology of 
T2DM. A study published by Winer and colleagues has begun to more clearly define a 
B-cell led auto-immune involvement in the development of T2DM.
217
 The study 
demonstrates that inflammation (which occurs when rapidly growing fat cells apoptose 
due to an in ability of the blood supply to adapt quickly enough to fulfil their new 
nutrient demand) causes a B cell, T cell and macrophage response which inhibits the 
ability of remaining fat cells to respond to insulin and causes fatty acids to be shed into 
the blood. This release of fatty acids sets in motion a physiological cascade that causes 
further insulin resistance (as well as high blood pressure (BP) and blood lipids). A 
recently published intervention study by Lim and colleagues, although undertaken with 
low participant numbers, has shown that diet is very important in the aetiology of 
T2DM. This study shows that a reversal in impaired beta cell function and impaired 
insulin sensitivity can be achieved by major calorific restriction.
216
 Further research is 
needed to corroborate the findings of both of these studies. 
1.3.2 Criteria for the classification and diagnosis of DM 
Historically there have been many nomenclature and diagnostic criteria used to define 
DM evolving alongside the evidence base for this disease. However, unlike for TB, 
there are now universally recognised nomenclature, diagnostic criteria and definitions 
for DM. In 2006 a revolutionary consensus statement on DM was released by the 
International Diabetes Federation (IDF, an umbrella organisation of more than 200 
national DM associations with the aim of effecting policy, public awareness, health 
improvement, and knowledge exchange upon DM) and the WHO which gave updated 
definitions and diagnostic criteria for DM intended for universal use.
212
  
In production of this statement the aetiological types and clinical stages of disorders of 
glycaemia were reviewed. It was concluded that current nomenclature should be 
maintained keeping the distinctions between T1DM, T2DM and gestational DM, but 
that the fluidity of the clinical stages should be highlighted, as depicted in Figure 9.
212
 It 
was decided that for notation purposes Arabic numerals should be used universally in 
favour of Roman numerals.
212
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Figure 9 portrays how some individuals will pass from a stage of normoglycaemia with 
normal glucose tolerance to IGT with impaired fasting glucose and so forth along the 
continuum of clinical DM disease stages. 
Figure 9: Transient clinical stages of DM212 
 
 
The WHO/IDF consensus statement also gave specific diagnostic guidelines for DM.
212
  
DM should be diagnosed when clinical signs are present alongside any of the following 
four measures: 
“A random venous plasma glucose concentration of > 11.1mmol/l”, or 
“A fasting venous plasma glucose concentration of > 7.0mmol/l (whole blood venous > 
6.1mmol/l)”, or 
“A venous plasma glucose concentration > 11.1 mmol/l two hours after 75g anhydrous 
glucose in an oral glucose tolerance test”, or 
“A venous whole blood glucose concentration of > 10.0 two hours after 75g anhydrous 
glucose in an oral glucose tolerance test.”212 
UK NICE guidelines do differ slightly from this stating that DM should be confirmed 
by a single diagnostic measurement as given above in presence of classical DM 
symptoms, or, alongside a secondary diagnostic measure.  
The fasting blood glucose (FBG) cut point for a diagnosis of DM (as defined by the 
WHO) consistently decreased as new evidence and guidance was published from 1980 
29 
 
up until the most recent 2006 diagnostic guidelines were produced. In 1980 guidance 
was for a positive DM diagnosis if FBG > 8.0mmol/l, in 1985 if FBG > 7.8mmol/l, and 
in 1999 if FBG was > 7.0mmol/l.
212
 
1.3.3 DM Management 
The major purpose of DM treatment is to improve health outcomes and reduce 
associated complications. Unlike for TB there is no ‘standard care’ for an individual 
with DM. Treatment differs markedly between settings especially between low to 
middle income countries and middle to high income countries. A standard global 
treatment would need to account for the vastly differing healthcare resources and 
infrastructure found worldwide.  
The WHO have begun to set norms for DM care stating that the universal aim of DM 
treatment should be symptom relief and delay of complications however they are far 
from giving a treatment standard.
218
 For T1DM the WHO highlight that a consistent 
supply of insulin is essential although acknowledge that even this may not be achievable 
in many low income countries.
218
 They highlight the need for a holistic approach to treat 
T2DM with use of patient education, and when needed oral hypoglycaemic medications 
and insulin.
218
 The WHO also notes the importance of monitoring treatment 
effectiveness and those diagnosed for early signs of complication development.
218
 
DM management in the UK  
Within the UK individuals with T1DM and T2DM for the most part self manage any 
treatment they have been prescribed in order to normalise their glucose levels. Often 
their own treatment preferences are integrated into an appropriate care plan in order to 
create a highly adhered to management regime. Alongside this self managed care a 
multi-disciplinary team will monitor the effectiveness of blood glucose control in order 
to facilitate its optimisation and will work to identify and treat as early as possible any 
diabetic complications or co-morbidities that an individual may develop.
219
  
For individuals with T1DM, a form of insulin will almost always be used to regulate 
blood glucose levels.
220
 
Stabilisation of blood glucose amongst individuals with T2DM is usually carried out 
without pharmacological intervention by implementing lifestyle changes (tackling 
where appropriate sedentary behaviour and poor nutritional intake).
221 222
 However, 
sometimes this approach to treatment is not possible and individuals will either initially 
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begin, or progress to, controlling their blood glucose levels using a pharmacological 
regime which may or may not include insulin.
221 222
 
Lowering prevalence of complications 
Regardless of sub-type, individuals with DM often have high or cycling glucose levels 
which lead to many complications either due to the direct toxicity of the high glucose 
levels or, indirectly, because of elevated BP and lipid levels which occur due to kidney 
damage or structural and functional anomalies in the microvasculature.
209
 Commonly 
diagnosed complications of DM are cardiovascular disease, nephropathy, neuropathy, 
retinopathy, hypoglycaemia and hyperosmolar hyperglycaemic state.
209
 Large trials 
have shown that increases in levels of blood glucose, BP and lipid levels correspond to 
an increase in an individual’s risk of developing diabetic complications.223 224 
Conversely healthy lifestyle choices or optimisation of pharmacological therapy leading 
to low levels of blood glucose, BP and lipid levels can delay or prevent onset of diabetic 
complications.
225
  
NICE gives set guidelines and targets aimed at preventing, improving detection of, or 
delaying onset of early and late stage DM complications.
220-222
 These guidelines are 
aimed at improving an individual’s lifestyle choices, lowering their average blood 
glucose measure, lowering their average blood lipid levels, lowering their average BP 
and monitoring their kidney function, visual acuity, presence of neuropathy and 
psychological wellbeing.
220-222
 
1.3.4 DM rates and risk factors 
The IDF estimated that in 2011 366 million people worldwide were living with DM, 
and that 4.6 million people died as a consequence of having DM.
226
  
The prevalence of DM in the UK is middling comparative to other countries globally 
but is similar to that seen in other European countries, see Figure 10. 
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Figure 10: Relative DM prevalence by country, 2011226 
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DM rates in the UK 
Unlike for TB, there is no national surveillance system in place within the UK to 
monitor incidence and prevalence of DM however there are some regional databases 
collating this information. This means that although diagnostic criteria for DM are 
standardised
212
, the exact disease prevalence or incidence within the UK population is 
unknown and only best estimates are available.  
Methods used to collate demographic information upon individuals with DM in the UK 
are as follows; cross sectional surveys (e.g. the Health Survey for England), 
questionnaires, routine health information (e.g. Hospital Episode Statistics (HES), 
primary care database records or GP audit data) and specialist local registries.
227
 The 
majority of available DM prevalence and incidence estimates for the UK have been 
calculated using information from these sources. It is important to note that the use of 
these sources probably underestimates the number of individuals with DM and in 
particular of those with T2DM. This is because individuals with T2DM are often 
asymptomatic with infrequent interaction with healthcare systems meaning that many 
individuals with T2DM are undiagnosed and unaware of their status.
227
 
The following information upon the distribution of DM within the UK population is 
assimilated from some of the ‘best estimates’ available. 
Rate changes over time 
Temporal trends show a dramatic increase in the rates of DM within the UK, between 
1996 and 2005 Gonzalez et al document an approximate doubling of DM prevalence. 
They found that in the UK DM prevalence rose from 2.8% in 1996 to 4.3% in 2005 and 
incidence rose from 2.71 per 1,000 person years in 1996 to 4.42 per 1,000 person years 
in 2005.
228
 When these figures were broken down by sub-type it was noted that the 
incidence of T2DM had risen most dramatically from 2.60 per 1,000 person years in 
1996 to 4.31 per 1,000 person years in 2005.
228
    
Geographic variation 
Within the UK approximately 4% of adults have a clinical diagnosis of DM, stratified 
by country the prevalence of diagnosed DM is; 5.1% for England, 4.6% for Wales, 
3.9% for Scotland and 4.5% for N.Ireland.
229-235
 This equates to their being more than 
2.5 million individuals with diagnosed DM in the UK.
229 235
 It is estimated that on top of 
these individuals with diagnosed DM there are up to another 750,000 people with DM 
in the UK whom remain undiagnosed.
236
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In the areas that are covered by the ORLS database the estimated prevalence of 
diagnosed DM is 3.47% (95% CI 3.43-3.52) for Oxfordshire, 4.09% (95% CI 4.05-
4.14) for Northamptonshire and 3.59% (95% CI 3.50-3.69) for Reading.
235
 
Risk factors 
As with risk of TB, risk of DM is known to increase with a variety of biological factors 
such as sex, age and ethnicity.
237
  
Throughout the UK DM shows a male preponderance with DM prevalence 1% higher 
amongst males than females.
229
 
Incident rate of DM amongst children and adolescents (those aged 0-19) within the UK 
are between 10 and 15 cases per 100,000 population per year.
229 235
 The majority of 
these incident cases will be of T1DM as although T1DM can affect all age
 
groups its  
peak incidence occurs amongst individuals aged 4–5, and 15-20.238  
In England there are over 22,000 people under the age of 17 with DM. Of these the 
majority (97%) have T1DM, a small number have early onset T2DM (1.5%) and the 
same amount again have other uncommon forms of DM (1.5%).
229-235
 Unlike those with 
T2DM, who are mainly asymptomatic, the majority of individuals with T1DM will 
present to healthcare rapidly due to their need for insulin therapy. Thus, as these 
individuals make up the majority with childhood DM, most individuals with T1DM are 
diagnosed and rate estimates are comparatively accurate.
230
 
In England, Wales, Scotland and N.Ireland prevalence of DM is highest amongst those 
aged 65 and above.
232-235
 This is because the majority of individuals with DM have 
T2DM. Incidence of T2DM increases with age, the peak incidence trends occurring 
amongst those above the age of 40. However, temporal trends show that the age of onset 
of T2DM is falling especially amongst certain ethnic groups (those of South Asian or 
African–Caribbean origin).239  
Of all individuals (adults and children) with prevalent DM it is estimated that 85% have 
T2DM and 15% have T1DM. Of all adults in the UK with prevalent DM it is estimated 
that 90% have T2DM and 10% have T1DM. 
DM is ethnically patterned with DM prevalence almost double in those of Black 
Caribbean, Pakistani, Bangladeshi, and Indian origin when compared to the national UK 
prevalence, see Table 5.
229 235
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Table 4: Prevalence of self reported DM in the UK by ethnic group and sex 
Ethnic group Men Women 
Bangladeshi 8.2% 5.2% 
Black African 5% 2.1% 
Black Caribbean 10% 8.4% 
Chinese 3.8% 3.3% 
Indian 10.1% 5.9% 
Irish 3.6% 2.3% 
Pakistani 7.3% 8.6% 
General Population 4.3% 3.4% 
The following modifiable risk factors are associated with an increased risk of DM or if 
already diabetic of developing complications and co-morbidities; poor diet, obesity, 
physical inactivity, smoking, high alcohol intake and SES.
240 241
 The most deprived 
quintile of the UK population are more likely than the least deprived to have DM at any 
given age.
242 243
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1.4 A review of available evidence upon the association between TB and DM 
To enable the reader to place the analyses carried out by the candidate amidst the body 
of contemporary research on the magnitude of the association between TB and DM the 
following section presents a semi-systematic review of evidence published up until 
March 2012.  
This review of available evidence was rigorous and attempted to identify and assimilate 
published data no matter how disparate whilst applying the main tenets of systematic 
review methodology. However, as the review of existing evidence was completed by 
the candidate alone certain standard systematic review conventions could not be 
adhered to (such as duplicate abstract review by independent investigators) and it is for 
this reason that this review is referred to as a ‘semi-systematic’ review. 
Systematic Review 
Systematic review utilises specific techniques in order to identify and assimilate 
research evidence upon a specific topic no matter how dissimilar the publications that 
hold relevant information may be.  
Systematic review is a replicable scientific method which begins with a drafted protocol 
outlining; a research question (hypothesis), how studies that answer this question will 
be identified and obtained (search strategy), how relevant studies will be summarised 
(analysis techniques) along with any other information deemed pertinent to the review 
process.
244 245
 Next, pre-outlined search strategies are completed and abstracts of 
returned citations are reviewed in order to identify relevant literature for full review. 
Full review of potentially relevant papers is then completed and relevant data is 
extracted ready for narrative and if appropriate statistical synthesis.
244 245
  
The Cochrane Collaboration and the Centre for Review and Research Dissemination 
based at York University have comprehensively outlined protocols and guidelines to 
facilitate researchers at each stage of the systematic review process. 
244 245
  Open access 
documents giving further detail upon generic systematic review method can be found 
upon either organisation’s website.244-247 
1.4.1 Semi-systematic review 
There have been two previously published systematic reviews of studies upon the 
magnitude of the association between DM and TB.
25 28
 These reviews present a précis 
and statistical analysis of research published up until the end of March 2007, the review 
of literature presented here aims to expand upon and update this work.  
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Search Strategy 
The intention of the initial search and abstract review was to identify and systematically 
critique primary epidemiological publications reporting a risk estimation of the 
association between TB of any site amongst individuals with any type of DM, or the 
converse.  
The search strategy developed was purposefully broad and sensitive in order to try and 
identify any relevant, published papers. The search strings outlined in Table 7 were used 
to comprehensively search literature catalogued within the two largest biomedical 
databases MEDLINE® and EMBASE® between 1948 and March 2012 utilising the 
OvidSP search interface (Ovid MEDLINE®1948 to MARCH 2012 and Ovid 
EMBASE® 1974 to MARCH 2012).  
The search strategy used contains both medical subject heading (MESH) terms (terms 
assigned to studies by a librarian to represent the topics it covers in Major or Minor 
detail) and text word terms (.tw. which identify studies with any mention of the 
searched term in the title or abstract) in order to identify all relevant studies whether 
catalogued under relevant terms or not. Special characters, search functions and 
Boolean Operators were used to produce a succinct but thorough search strategy.  
The “exp” and the back slash within search strings 1 and 2 indicate that these strings 
used the explode command; an exploded search string will select articles indexed with 
that search term plus articles indexed with related narrower terms. In search strings 3 
and 4 the truncation wildcard symbol (*) indicates that articles were returned which 
contained any elongated derivative of the original search term (for example; diabet* 
will return articles containing the words diabetes, diabetic, diabetologist etc). Strings 8, 
9 and 10 were completed using automated OvidSP limits and ENDNOTEX4 functions.  
Due to restricted availability of translation resources only English language papers were 
reviewed for relevance. Initial search returns were limited to those in English language 
using the integral OvidSP search interface. Any duplicated references were removed 
from the listed search results using the integral OvidSP search interface. Duplicated 
references were also checked for and removed after citations were downloaded in to 
ENDNOTEX4 using the duplicate function in this programme.  
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Table 5: Search strategy used to identify papers reporting upon TB and DM   
Abstract review 
For this semi-systematic review of background literature abstract review was completed 
only by Fiona Pearson (FP) and not independently by two investigators.  
In order to expand upon as well as update the two prior reviews upon the magnitude of 
the association the inclusion and exclusion criteria as set out by Jeon et al and 
Stevenson et al were not wholly utilised.
25 28
  
Inclusion and exclusion criteria 
Publications that cited any analytical estimate of the association between TB and DM 
(or sub-types of these diseases) with measures of uncertainty surrounding the estimate 
were included, as well as the converse.
25 28 
  
Studies were excluded if they: were case studies or reviews, did not adjust for age, 
assessed TB, or where relevant DM, differently amongst study population sub-groups, 
or, were duplicate reports of the same results.
25 28
  
Due to amendments to the inclusion and exclusion criteria of previous systematic 
reviews searching was completed from the first year of each database rather than simply 
from March 2007 onwards.
25 28
  
After abstract review 2,639 citations were deemed entirely irrelevant i.e. during abstract 
sifting were not found to present any quantitative discussion upon the magnitude of the 
association between TB and DM or the converse and did not fit within the pre-specified 
inclusion and exclusion criteria.  
Search String MEDLINE Hits EMBASE Hits 
1 Exp diabetes mellitus/ 275,732 481,334 
2 Exp tuberculosis/ 142,480 174,384 
3 Diabet*.tw. 329,092 448,985 
4 Tuberculo*.tw. 136,781 163,076 
5 1 or 3 377,261 560,989 
6 2 or 4 173,451 211,137 
7 5 and 6 2,173 3,927 
8 English Language (OvidSP) 1,148 2,553 
9 
Remove duplicates preference to keep EMBASE 
references over MEDLINE (OvidSP) 
202 2,523 
10 Remove duplicates (ENDNOTE) 2,690 
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Forty seven remaining publications were identified as likely to contain risk estimations 
for an association between active TB amongst individuals with DM, or the converse.
25-
28 90 95 205 248-286 295
 These publications were retrieved in full in order to verify relevance 
and allow extraction of data if relevant.  
During full review 24 publications were deemed relevant for data extraction, one of 
which is a paper including work presented in this thesis.
26 27 90 95 205 264-273 276-283 295 
 The 
publication of analyses presented in this thesis (Young et al) has been included in Table 
6 and Figure 11 but findings are not discussed further in this chapter.
283
 References of 
papers identified as being relevant were reviewed in case of further as yet unidentified 
pertinent publications (grey literature) however no further publications were found. 
Case reports and reviews 
Amongst the excluded citations there were 44 case reports or small case series (less than 
10 cases) describing unusual manifestations of co-morbid TB and DM.
287-331
 It is 
interesting to note the number of case reports published as to a certain extent 
publication reflects the initial implicit recognition of the importance or at least unusual 
presenting nature of these co-morbid cases. However, as publication of case reports are 
spontaneous and contain predominantly anecdotal comment along with minimal 
descriptive data rather than analytical findings these publications are discussed no 
further. 
Somewhat surprisingly 57 reviews were also identified from the initial search either 
entirely focussed upon the relationship between DM and TB or that noted the 
association within an alternately focussed review.
25 28 116 332-363
 Again although these 
publications are not presenting primary data analysis it is interesting to note their 
number. A large number of reviews would imply that the plausibility of an association 
is generally accepted by researchers working within the field. It is notable that over 60% 
of these reviews were published after 2008 (the year this body of work was initiated and 
the year after 2 systematic reviews of evidence upon the association were published).
25 
28 116 351-363
 This suggests that it is only very recently that researchers within the field 
have begun to recognise the importance of a potential association between DM and 
TB.
25 28 116 351-363
 As non-systematic reviews contain anecdotal comment upon a field of 
research rather than primary analytical findings these publications are also discussed no 
further. 
Five of the identified reviews were full systematic reviews two of which are those that 
are being updated and expanded upon. These systematic reviews appraised the literature 
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upon the magnitude of the association between DM and TB up until March 2007.
25 28
 A 
third review which has also been previously mentioned appraises the literature upon TB 
outcomes amongst individuals with co-morbid TB and DM comparative to those with 
TB in isolation.
121
 A fourth review appraised literature upon bidirectional screening for 
TB and DM
128
, and a fifth reviewed literature upon the epidemiology and public health 
issues related to DM in sub-Saharan Africa giving only a brief mention of the 
association.
361
  
Amidst the systematic reviews there is some primary analysis of secondary data 
however most of this is not of relevance to the magnitude and directionality of the 
association between TB and DM. Thus, only the two systematic reviews being updated 
that give a synopsis (and one a meta-analysis) of primary publications upon the 
magnitude of the association between DM and TB are discussed any further.
25 28
   
Full review and data extraction 
Data extraction was completed for the 24 studies containing relevant information 
(Alisjahbana 2006
264
, Baker 2012
265
, Brassard 2006
266
, Buskin 1994
267
, Chen 2006
27
 
Coker 2006
268
, Dobler 2012
269
, Dyck 2007
270
, Farhoult-Jepsen 2011
271
, Goldhaber-
Fiebert 2011
90
, Jick 2005
205
, John 2001
26
, Kim 1995
272
, Leegaard 2011
273
, Leung 
2008
295
, Marks 2011
95
, Mori  1992
276
, Pablo-Mendez 1997
277
, Perez 2006
278
, 
Ponce de Leon 2004
279
, Rosenman 1996
280
, Shetty 2006
281
, Wu 2007
282
 and Young 
2010
283
). 
This included nine more studies (Baker 2012
265
, Dobler 2012
269
, Farhoult-Jepsen 
2011
271
, Goldhaber-Fiebert 2011
90
, Leegaard 2011
273
, Leung 2008
295
, Marks 2011
95
, 
Wu 2007
282
 and Young 2010
283
) than those précised within previous systematic 
reviews, a study by Alisjahbana et al
264
 and one completed by Shetty et al
281
 having 
been included in the systematic review by Stevenson et al
28
 but not identified by Jeon et 
al
25
 in their review.  
Extracted data on the population studied, study design, exposure and outcome 
definitions (ascertainment method for cases of DM and TB) and confounders that were 
adjusted for from all of the identified published studies is presented within Table 6.  
With no universally accepted standard protocols for quality assessment of observational 
studies the studies identified were assessed by the following pre-specified ‘quality’ 
criteria deemed by the candidate likely to affect study rigour; study design, setting, 
method of case ascertainment and confounders adjusted for. Based upon these criteria 
each study was graded as being either of ‘high quality’, ‘unclear quality’ or ‘low 
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quality’ as would be done within a Cochrane systematic review. However, as only a 
small number of studies were identified many of which were not specifically designed 
to look at the association between TB and DM the attributed quality grades seemed 
somewhat naïve. Whether each study was subjectively deemed of poor or high quality 
would negate the fact that due to the limited body of knowledge each study is of great 
importance. It was thus decided that rather than present individual grades an overall 
evidence grade for quality would be given (see last row of Table 6). This overall 
evidence grade gives the percentage of all studies graded as ‘low quality’, ‘unclear 
quality’ and ‘high quality’ in an attempt to outline the shortcomings of the entire body 
of evidence. 
The main risk estimation reported within each paper is presented pictorially within a 
forest plot (Figure 11).
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Table 6: Summary of studies giving a quantitative estimate of the association between DM and TB 
First Author Setting & Study Date Study Design Study Population 
DM Sub-type & 
Definition Used 
TB Sub-type & Definition 
Used 
Adjustments 
Alisjahbana 
2006
264
 
Indonesia, 2001-05 Case Control 
TB patients from a 
hospital and inpatient 
clinic. Neighbourhood 
controls matched for age 
& sex. 
DM: FBG> 126 mg/dl 
PTB: Clinical suspicion, chest 
x-ray and confirmed by acid 
fast bacilli (AFB) presence in 
sputum 
Age, sex, body mass index (BMI), overcrowding, 
income, TB contact in family 
Baker 2012
265 Taiwan, 2001-04 Cohort 
Participants in the 
Taiwanese National 
Health Interview Survey 
DM: Self report and 
medical record review 
(MRR) 
TB: MRR 
Age, sex, BMI, overcrowding, smoking, alcohol, 
household income, employment, receipt of 
government subsidy, marital status, education 
residence in an indigenous community, lung 
disease, hypertension, & heart disease 
Brassard 
2006
266 
United States of 
America (USA), 1998-
2003 
Case Control 
Patients with anti-
rheumatic prescription 
on pharmetrics database 
DM: Medical records 
coded using International 
Classification of Diseases 
(ICD) 9; 250.0-250.9 
TB: Medical records coded as 
ICD 9; 010-018 
Age, sex, silicosis, renal failure, haemodialysis, 
solid organ transplant, head and neck cancer, 
Non-steroidal anti-inflammatory medications, 
steroids, cox-2 inhibitors 
Buskin 
1994
267 
USA, 1988-90 Case Control 
Patients from a 
Washington TB clinic 
DM: Self report 
TB: As defined by the Centre 
for disease control and 
prevention (CDC) 
Age 
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Chen 2006
27 Taiwan, 1983-2003 Cohort 
Renal transplant patients 
from Taichung 
DM: Medical notes 
TB: Positive culture, 
granuloma presence upon 
biopsy, or, chest X-ray or 
clinical findings consistent 
with TB which clear after 
treatment 
Age, sex, dialysis duration, Hepatitis B or C, 
immunosuppressive medication, graft rejection>3 
months 
Coker 
2006
268 
Russia, January(Jan)-
Dec 2003 
Case Control Residents of Samara DM: Self report 
TB: Diagnosed by culture 
positivity 
Age, sex, smoking, alcohol, illicit drugs, 
imprisonment, number of co-habiting individuals, 
assets, employment, financial security, relative 
with TB, drinking raw milk 
Dobler 
2012
269 
Australia, 2001-06 Cohort 
Patients on the national 
DM services scheme 
database and TB 
notification databases 
All DM and T1DM: Self 
report with clinical 
confirmation 
TB: Notification scheme 
Age, sex, indigenous status and TB incidence in 
country of birth 
Dyck 2007
270 
Canada, Jan 1986- Dec 
2001  
Aboriginals and non-
aboriginals from 
Saskatchewan 
DM: Medical records 
coded as ICD 9; 250 
TB: Cases reported to health 
department 
Age, sex, ethnicity 
Farhoult-
Jepsen 
2011
271 
Tanzania, April 2006- 
Jan 09 
Case Control Residents of Mwanza 
DM: FBG >6 mmol/L or 
a 2hBG>11 mmol/L 
PTB: Sputum smear and 
culture 
Age, sex, socio-demography, HIV and AGP 
Goldhaber-
Fiebert 
2011
90 
“Global”, 2002-03 Case Control 
124,545 adults from 46 
countries 
DM: Self report PTB: Self report 
Age, sex, BMI, crowding, education, housing 
quality and health insurance 
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Jick 2005
205
 UK, 1990-2001 Case Control GP registered 
DM: Primary care data 
medication record 
TB: First diagnosis of TB and 
6 months of 3 types of TB 
medication record 
Age, sex, smoking, BMI, index date, amount of 
history, pulmonary disease, anti-rheumatic, 
glucocorticoid, immunosuppressive medication 
John 2001
26 India, 1986-99 Cohort Renal transplant patients 
DM: FBG>126 mg/dl or 
post prandial blood 
glucose > 200 mg/dL 
PTB: X-ray, AFB in gastric 
juice or culture 
Age, chronic liver disease, co-infections, 
immuno-suppresive medication 
Kim 1995
272 Korea, 1988-90 Cohort 
Korean civil servants. 
7,705 individuals with & 
782,440 without DM. 
DM: Screening blood 
glucose ≥119mg/dl, FBG 
of ≥150mg/dl or 
postprandial blood 
glucose of ≥180mg/dl 
PTB: Chest X-ray and 2 
positive sputum smears 
Age and sex 
Leegaard 
2011
273 
Denmark, 1980-2008 Case Control 
Danish Civil 
Registration System 
 
T1DM & T2DM: Episode 
of care and medication 
use 
TB: Hospital diagnosis of TB 
Age, sex, place and length of residence in 
Denmark, and country of emigration alcoholism, 
immunosuppressive medications, and 
socioeconomic markers 
Leung 
2008
295 
Hong Kong, Jan-Dec 
2000 
Cohort 
Population of the elderly 
(>65) 
DM: FBG>7mmol/L 
PTB & EPTB: 
Bacteriologically proven, X-
ray, histology or favourable 
treatment response 
Age, sex, BMI, weight loss, smoking, alcohol, 
SES, marital status, education, housing, 
employment, language, Cardiovascular disease, 
hypertension, Chronic Obstructive Pulmonary 
Disease, asthma, malignancy, hospitalisation, 
activity and daily living score 
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Marks 2011
95 USA, 2000-05 Cohort 
US National Health 
Interview Survey 
respondents 
DM: Self Report TB: Self Report 
Age, sex, ethnicity, foreign birth, high school 
drop-out, history of homelessness or 
incarceration, cancer, smoking, alcohol, no health 
insurance and HIV 
Mori  1992
276
 USA, 1986 Case Control 
Oglala Sioux Indians 
from South Dakota 
DM: Record of DM 
medication, Screening 
Blood Glucose 
>11.1mmol/L or FBG 
>7.8mmol/L 
TB: Clinical diagnosis Age, sex, alcohol, Isoniazid therapy, residence 
Pablo-
Mendez 
1997
277 
USA, 1991 Case Control Residents of California 
DM: Medical records 
coded as ICD 9; 250.0-
250.9 
TB: Medical records coded as 
ICD 9; 010-018 
Age, sex, ethnicity, alcohol, drug use, education, 
income, health insurance, HIV related conditions, 
renal insufficiency, two way interactions 
Perez 2006
278
 USA, 1999-2001 Case Control 
Residents of 
Mexico/Texas border 
countries 
DM: Medical records 
coded as ICD 9; 250.0-
250.9 
TB: Medical records coded as 
ICD 9; 010-018 
Age, sex, ethnicity, malnutrition, income, 
education, insurance, renal failure 
Ponce de 
Leon 2004
279
 
Mexico, March 1995-
2005 
 Residents of Veracruz 
DM: Clinical diagnosis or 
FBG>126mg/dl or 
random blood 
glucose>200mg/dl 
TB: DNA fingerprinting Age, sex 
Rosenman 
1996
280 
US, 1985-87 Case Control 
New Jersey health 
department reported TB 
cases 
DM: Self Report 
PTB: Clinical diagnosis, 
positive culture or effective 
treatment 
Age, sex, ethnicity 
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Shetty 
2006
281 
India 2001-2003 Case Control 
Outpatients from St 
John's Medical College 
Hospital in Bangalore 
DM: DM diagnosis with 
or without hypertension 
or CVD 
PTB: Smear positive or chest 
X-ray 
Age sex, alcohol, smoking, overcrowding, 
income, education, separate kitchen, cooking fuel 
Wu 
2007
282 
Taiwan, Jan 2002 to 
Dec 2004 
Case Control 
TB cases and controls 
with non TB lower lung 
infection OR TB 
contacts 
DM: Medical records PTB: Culture confirmed 
Age, sex, pneumoconiosis, prochiectasis, liver 
cirrhosis, haemodialysis and lung cancer 
Young 
2010
283* 
UK, 1963-2005 Cohort 
Patients from the oxford 
healthcare region 
DM, T1DM and T2DM: 
MRR using ICD codes 
TB, PTB and EPTB: MRR 
using ICD codes 
Age, sex 
Overall Quality of Evidence
364     
 *Publication of partial findings from this thesis 
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Previous reviews of evidence 
In a systematic review of evidence on the association between DM and TB by 
Stevenson and colleagues 9 studies (2 cohort studies and 7 case control studies) were 
found in which having DM was estimated to increase the risk of TB infection amongst 
individuals between 1.5 and 7.8 fold.
28
 Heterogeneity was deemed too great by the 
authors to carry out statistical pooling of risk measures identified. Thus narrative 
synthesis of studies was given. 
Jeon and colleagues also completed a systematic review of publications identifying 13 
studies (3 cohort studies, 8 Case control and 2 ‘other’) which did not include 2 of the 
studies identified by Stevenson et al (Alisjahbana 2006
264 
 and Shetty 2006
281
) but 
reported upon a further 6 (Brassard 2006
266
, Buskin 1994
267
, Chen 2006
27
, John 2001
26
 
Mori 1992
276
 and Rosenman 1996
280
). 
The Begg and Egger test were used by Jeon et al to show that there was no indication of 
publication bias amongst the literature they identified.
25
 
Jeon et al completed a meta-analysis of identified effect measures which showed having 
DM was associated with an overall RR of  3.11 for contracting TB.
25
 However, as 
previously mentioned, this analysis was heavily weighted by a single study (Kim 
1995
272
) and the 2 other studies (John 2001
26
 and Chen2006
27
)from which results were 
pooled were completed amongst populations of individuals with renal failure (renal 
failure itself being a risk factor for TB). Thus, the external validity and improved 
precision of this pooled estimate is perhaps questionable. 
Jeon et al used meta-regression to explore the impact of age upon estimates of the 
association.
25
 They found that as age increased risk estimate decreased this trend was 
significant in work reported by Kim et al
272
 and Ponce de Leon et al
279
 but not of that 
reported by Dyck et al.
270
  
Jeon at al also used meta-regression to explore any impact upon the association due to 
study design, case ascertainment and adjustments made. They identified that studies 
which; did not establish the temporal order of TB and DM, where DM or TB status was 
not identified in an empirical manner, that did not adjust for smoking and which did 
adjust for SES saw an attenuation in the reported effect measure.
25
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Overview of studies identified in the semi-systematic review 
Risk of DM amongst individuals with TB 
Although the temporal nature of disease is not clear in cross sectional case control 
studies; no studies were identified by this semi-systematic review that expressly stated 
measuring the risk of DM amongst individuals who have had TB. 
Due to the plausible bi-directional nature of an association between DM and TB and 
lack of available evidence this is something that will be addressed in the candidate’s 
analyses.  
Risk of TB amongst individuals with DM 
All 24 studies identified by the semi-systematic review gave an estimation of TB risk 
amongst individuals with DM adjusted for, at least, by age and sex (inclusion criteria). 
Risk estimations in the newly identified studies did not affect the overall variance in 
risk seen within the previous reviews.
25 28
 Figure 11 gives a visual overview of the 
‘main’ reported risk estimations published in all of the identified studies.  
Study Design 
The additional publications identified within this review give a new total of 14 case 
control studies (Alisjahbana 2006
264
, Brassard 2006
266
, Buskin 1994
267
, Coker 2006
268
, 
Farhoult-Jepsen 2011
271
, Goldhaber-Fiebert 2011
90
, Jick 2005
205
, Leegaard 2011
273
, 
Mori  1992
276
, Pablo-Mendez 1997
277
, Perez 2006
278
, Ponce de Leon 2004
279
, Shetty 
2006
281
 and Wu 2007
282
), seven cohort studies (Baker 2012
265
, Chen 2006
27
, Dobler 
2012
269
, Dyck 2007
270
, John 2001
26
, Kim 1995
272
 and Leung 2008
295
) and two further 
studies (Ponce de Leon 2004
279
 and Dyck 2007
270
) which accrued cases prospectively 
and then determined the distribution of DM during a different time period. 
Study design, due to biases inherent with methods used, may affect the measure of a 
risk estimate either amplifying away from or attenuating towards the null. Jeon et al 
used meta-regression to assess the effect of study design on the measures of association 
found in their 13 identified studies. They found estimates of TB risk amongst those with 
DM to be weaker in studies which did not establish the temporal order of TB and DM.
25
 
Amongst the studies identified by this semi-systematic review the finding of an increase 
in TB risk amongst those with DM comparative to those without seems robust across 
study designs (as assessed visually, see Figure 11). Five studies (Buskin 1994
267
, 
Dyck
270
, Leegaard 2011
273
, Marks 2011
95 
and Rosenman 1996
280
) show no significant 
change in risk of TB amongst those with DM comparative to those without DM, 
however three of these studies present figures tending towards statistical significance 
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(Dyck
270
, Leegaard 2011
273
 and Marks 2011
95
). The remaining 19 identified studies 
show a statistically significant increase in TB risk for those with DM comparative to 
those without (Alisjahbana 2006
264
, Baker 2012
265
, Brassard 2006
266
, Chen 2006
27
, 
Coker 2006
268
, Dobler 2012
269
, Dyck 2007
270
, Farhoult-Jepsen 2011
271
, Goldhaber-
Fiebert 2011
90
, Jick 2005
205
, John 2001
26
, Kim 1995
272
, Leung 2008
295
, Mori  1992
276
, 
Pablo-Mendez 1997
277
, Perez 2006
278
, Ponce de Leon 2004
279
, Shetty 2006
281
 and Wu 
2007
282
).  
Setting 
As was found in the review completed by Jeon et al this review finds geographic setting 
not to affect the increase in TB risk seen amidst those with DM. One study completed 
by Goldhaber-Fiebert and colleagues looked at the effect of region upon the association 
finding that stratified risk estimates stayed relatively stable Europe 2.38 (95%CI 1.08-
5.24), Africa 1.96 (95%CI 1.23-3.12), Asia 1.74 (95%CI 0.82 3.72) and Latin America 
1.99 (95%CI 1.44-2.75).
90
 
It is of note that the majority of the studies 17 were completed within high income 
countries (Baker 2012
265
, Brassard 2006
266
, Buskin 1994
267
, Chen 2006
27
, Dobler 
2012
269
, Dyck 2007
270
, Goldhaber-Fiebert 2011
90
, Jick 2005
205
, John 2001
26
, Leegaard 
2011
273
, Leung 2008
295
, Marks 2011
95
, Mori  1992
276
, Pablo-Mendez 1997
277
, Perez 
2006
278
, Rosenman 1996
280
 and Wu 2007
282
), five within middle income countries 
(Alisjahbana 2006
264
, Coker 2006
268
, Kim 1995
272
, Ponce de Leon 2004
279
 and Shetty 
2006
281
), only one within a low income country (Farhoult-Jepsen 2011
271
) as specified 
by the world bank.
413
 One study utilised a global dataset (Goldhaber-Fiebert 2011
90
). 
The impact of any association is likely to be most adverse in low income countries due 
to inherent issues with healthcare provision.
366
 Further research is needed into the 
magnitude and impact of the association within these settings. 
It is also of note that only four studies have assessed the association in areas with high 
TB incidence two in India (John 2001
26
 and Shetty2006
281
), one in Russia (Coker 
2006
268
) and one in Tanzania, sub Saharan African (Farhoult-Jepsen 2011
271
), see 
Figure 4. Given the high background prevalence of TB in these areas
367
 and the 
projected increases in DM
54
 even a moderate increase in risk within these regions is 
likely to have a dramatic public health impact over the coming years.
58
 Again further 
research is needed to identify the magnitude and impact of the association within 
settings with high TB incidence. 
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Alisjahbana
Brassard
Buskin
Coker
Farhoult-Jepsen
Goldhaber-Fiebert
Jick
Leegarrd
Leung
Marks
Mori
Pablo-Mendez
Perez
Rosenman
Shetty
Wu
Chen
Dobler
Dyck
Kim
Ponce de Leon
Baker
John
Leung
Young
Author
2006
2006
1994
2006
2011
2011
2005
2011
2008
2011
1992
1997
2006
1996
2006
2007
2006
2012
2007
1995
2004
2012
2001
2008
2010
Year
4.20 (1.50, 11.70)
2.09 (1.10, 3.95)
1.70 (0.70, 4.30)
7.83 (2.37, 25.89)
4.23 (1.54, 11.57)
1.81 (1.37, 2.39)
3.80 (2.30, 6.10)
1.18 (0.96, 1.45)
1.77 (1.41, 2.24)
1.40 (1.00, 2.00)
5.20 (1.22, 22.10)
7.84 (4.71, 13.02)
1.53 (1.37, 1.70)
1.16 (0.58, 2.32)
2.44 (1.17, 5.09)
3.43 (2.16, 5.46)
3.07 (1.14, 8.26)
1.48 (1.04, 2.10)
0.99 (0.80, 1.23)
3.60 (3.10, 5.20)
6.80 (5.70, 8.20)
2.09 (1.10, 3.95)
2.31 (1.42, 3.76)
1.77 (1.41, 2.24)
3.11 (1.17, 7.03)
ES (95% CI)
  
.5 2 8 32
Although undoubtedly impact of an association will be most detrimental in these 
countries, it is not to say that an effect within middle to high income countries such as 
the UK would be negligible.
130
 Only a single study of those identified gave an estimate 
of the association within a UK setting (Jick 2005
205
), and this was within a study which 
was not specifically designed to look at the association.  
Figure 11: Pictorial summary of effect estimations with studies ordered 
alphabetically 
 
  
ffect Size (95% CI) 
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Methods of case ascertainment utilised in identified studies 
Accurate exposure and case identification is fundamental when estimating a measure of 
association. Misclassification describes the ‘mislabeling’ of a study subject as; exposed 
when they are unexposed, as having an outcome of interest when they do not, or, the 
converse of either of these described situations. Over or underestimation of those 
exposed or with an outcome of interest can lead to an over or under estimation of effect 
estimate calculations.
368-370
 
The effect that misclassification has upon an effect estimate is dependent upon what 
variable is misclassified, if it is dichotomous and the type of misclassification that is 
occurring. Misclassification can be either differential or non-differential (random). Non-
differential misclassification can be a random misclassification of an individual’s 
exposure status, outcome status or both that is independent of their status for any other 
of these variables. Differential misclassification is a non-random misclassification of an 
individual’s exposure status, outcome status or both which is dependent upon an 
individual's status for at least one other of these variables.
368-370
 
If non differential misclassification exists amongst a study with a dichotomous exposure 
(DM/no DM) and outcome (has had TB/never had TB), as is the case in most of the 
studies identified, it will cause an attenuation of the risk estimate towards the null. It is 
only in rare circumstances that non-differential misclassification will cause an inflation 
of risk estimates. However, if there is a systematic over estimation of those exposed 
amongst cases or a systematic underestimate of exposure amongst non-cases i.e. 
misclassification is dependent upon another variable the subsequently calculated risk 
estimate will be inflated. A systematic under estimate of cases exposed or a systematic 
over estimate of exposure in non-cases will give a deflated risk estimate.
368-370
 
Within studies of the association between DM and TB the most accurate method of case 
identification for both diseases (any sub-type) would be utilising the following standard 
diagnostic techniques; for DM a measure of FBG and for TB through microbiological 
sputum smear or culture. This is how five of the identified studies ascertained both DM 
and TB status (Alisjahbana 2006
264
, Farhoult-Jepsen 2011
271
, Kim 1995
272
, Leung 
2008
295 
and Ponce de Leon 2004
279
). 
If diagnostic testing for everyone within an identified population at risk is unfeasible 
then medical records can be used to identify those who have been clinically diagnosed 
with either disease. However it should be noted that case ascertainment using medical 
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records will only identify those diagnosed with TB or DM and would exclude people 
who have disease but are, as yet, clinically undiagnosed. 
The number with undiagnosed TB is likely to be negligible due to the acute nature of 
the active disease. However, as previously discussed, there are likely to be a number of 
individuals with DM who are clinically undiagnosed. If individuals with DM are 
identified in a study as non-cases estimates of an association may be biased towards the 
null (no association). Seven studies were identified that used medical records to identify 
cases of DM and TB (Baker 2012
281
, Brassard 2006
265
, Dobler 2012
269
, Dyck 2007
270
, 
Jick 2006
90
, Leegaard 2011
273
, Pablos-Mendez 1997
276
, Perez 2006
277
).  
Self report of status through interview or questionnaire could also be used to identify 
those with either disease although case identification in this manner is likely to be 
affected by both an individual’s ability to identify their own status and whether or not 
they have been clinically diagnosed (given that status cannot be reported if accurately 
unknown). In theory, any errors made to recall status should occur non-systematically 
and equally across those recalling their TB or DM status and thus no attenuation of the 
measured association should be seen. However, as with using medical records you 
might expect to miss count a number of individuals with DM as free from disease which 
would lead to an under estimate of any association seen between DM and TB. 
Of the studies identified, only 2 utilised self-report to ascertain cases of DM and cases 
of TB (Goldhaber-Fiebert 2011
90 
and Marks 2011
95
). However seven of the studies used 
self-report to identify DM status alongside standard diagnostic procedures to identify 
TB status (Buskin1994
267
, Coker 2006
268
, Chen 2006
27
, John 2001
26
, Rosenman 
1996
280
, Shetty 2006
281
 and Wu 2007
282
).  
Jeon et al found, for the 13 studies that they identified, that risk of TB amongst those 
with DM was weaker in studies which did not establish the temporal order of TB and 
DM and studies where DM or TB status were not identified in an empirical manner.
25
 
From visual assessment of the studies identified within this review (see Figure 11) no 
change in direction or significance of effect measure due to study type or method of 
case ascertainment was seen. 
Measures of association between sub-types of TB and DM 
Of the studies identified ten did not specify if they were assessing the association 
between specific sub-types of DM or TB and were assumed to be assessing the 
association between all types of DM and all types of TB (Baker 2012
265
, Brassard 
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2006
266
, Buskin 1994
267
, Dyck 2007
270
, Jick 2005
205
, Marks 2011
95
, Pablo-Mendez 
1997
277
, Perez 2006
278
, Ponce de Leon 2004
279
 and Rosenman 1996
280
).  
Seven studies specified that they were assessing an association between PTB and DM 
(Alisjahbana 2006
264
, Coker 2006
268
, Farhoult-Jepsen 2011
271
, Goldhaber-Fiebert 
2011
90
, Shetty 2006
281
, Kim 1995
272
 and Wu 2007
282
). Two studies assessed the 
association between post-transplant TB and DM (Chen 2006
27
 and John 2001
205
). Two 
between both T1DM, T2DM and TB (Dobler 2012
269 
and Leegaard 2011
 273
) and a 
single study between DM and both PTB and EPTB (Leung 2008
295
). Both papers which 
included a measure of TB risk amongst individuals with T1DM identified an increase in 
risk although only one estimate showed significance (RR 2.27 (95%CI 1.19-3.66))
269
 
and (Odds Ratio (OR) 2.59 (95%CI 0.44-15.29)).
273
 For T2DM the risk estimates 
reported were (RR 1.48 (95%CI 1.04 – 2.10))269 and (OR 1.17 (95%CI 0.95-1.44)).273 
Again both studies showed an increase in risk with only one being statistically 
significant. Both papers showed an increased risk estimate for TB amongst those with 
T1DM comparative to without T1DM, it has been suggested that this is because the risk 
is mediated through levels of hyperglycaemia seen amidst people with DM and those 
with T1DM tend to have poorer hyperglycaemic control. 
The only publication to include measures of both PTB and EPTB risk amongst 
individuals with DM comparative to those without found risk of PTB to be significantly 
increased amongst individuals with DM and risk of EPTB to be non-significantly 
increased although numbers for the later sub-analysis were small (RR 1.42 (95%CI 
1.12-1.80)) and (OR 1.05 (95%CI 0.49-2.31)).  
From a public health perspective the association between T2DM and PTB is of most 
interest as approximately 90% of individuals with DM have T2DM and PTB is the most 
prevalent infectious form of TB. However in thinking about disease aetiology and the 
close link between sub-types of DM then it is of interest to explore the relationships 
between the sub-types of each disease further. This is something that will be addressed 
within the candidates work. 
Risk modification  
Few of the studies identified were of sufficient size to give estimates of TB risk 
amongst individuals with DM by any suspected effect modifiers. Those publications 
that presented stratified estimates of risk are discussed below. 
Only three studies presented stratified risk estimates by gender; two found an increased 
risk of TB amongst females with DM (Dyck 2007
270
 and Leegaard 2011
273
) and one the 
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converse (Perez 2006
278
). Giving the mixed findings it is fair to say the true impact of 
gender upon the association between DM and TB is unknown. 
This semi-systematic review found only four studies which assessed the impact of age 
upon the association. Three showed that the estimates of association decrease as age 
increases (Kim 1995
272
, Leegaard 2011
273 
and Ponce de Leon 2004
279
), however, one 
study found no clear effect of age (Dyck 2007
270
). It is possible that the later study was 
underpowered to detect any effect. 
As has already been discussed, Jeon et al report that risk estimations for contracting TB 
amongst individuals with DM vary by age being highest amongst the young and 
attenuating as age increases.
25
 
These findings as with those for gender need further examination. They could be due to 
a decrease in baseline glucose tolerance amongst those of older age without DM, which 
would reduce the apparent effect of DM. Or, if we take note of findings upon disease 
sub-type specificity of the association, trends seen could be due to those of younger age 
having a more severe form of DM and hyperglycaemia. As most studies did not 
distinguish between T1DM and T2DM we cannot conclude satisfactorily whether the 
effect modification by age would have been due to differences in types of DM. Dyck et 
al who found a negative association amongst the elderly suggest that this may be caused 
by differential mortality occurring amongst those with DM of older age comparative to 
the elderly without DM.
270
 
Evidence for variance in the association from a single study which stratified by specific 
ethnic groups has shown there to be higher risk amongst ‘Whites’ and Hispanics with 
DM for developing TB compared to those without DM than the risk amongst African 
American’s with DM for developing TB compared to those without DM.277 278 Again, 
due to the effect of ethnicity on risk of Developing DM and risk of developing TB alone 
this is something which needs further study.  
A single study showed that homelessness and imprisonment is more common amongst 
those with TB and DM (Perez 1996
278
), and another study found that those with DM 
and TB were more likely to live in crowded households (Ponce de Leon 2004
279
). 
Although HIV is an important modifier of TB risk only one study (Farhoult-Jepsen 
2011
271
) was able to look at the impact of HIV upon the measure of association between 
DM and TB finding that the risk of TB amongst those with DM became attenuated 
amongst individuals who also had HIV. Due to the importance of HIV as a risk factor 
for TB and thus as a strong competing factor it’s affect upon the association between 
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TB and DM is also in need of further research. It was interesting to note that anti-
retroviral use (known to cause metabolic syndrome) seemed to bare no relevance to the 
association between DM and TB.
271
  
Four studies (Alisjahbana 2006
264
, Baker 2012
265
, Leegaard 2011
273
 and Pablos-Mendez 
1997
276
) looked at glucose control and how this modified estimates of TB risk amongst 
individuals with DM. All four studies identified an increase in TB risk for those with 
poor hyperglycaemic control either as judged by HbA1c measure or by number of 
existing DM complications although no testing for trend was completed. 
1.4.2 Further findings from the semi-systematic review 
As the search string for the completed semi-systematic review was purposefully broad 
many articles were incidentally returned that presented research upon the association 
between TB and DM but did not focus upon identifying the magnitude or directionality 
of the association. Further narrative discussion of these publications is given to place 
the analyses presented within this thesis in to the broader context of published research 
upon the association between DM and TB.  
Numbers presenting with co-morbid TB and DM 
The semi-systematic review identified three studies which focused upon estimating the 
impact of an association between DM and TB upon TB incidence (Ruslami 2010
58
, 
Stevenson 2007
57
 and Walker 2010
47
). In order to do this all three studies calculated the 
population attributable fraction  (PAF) of TB due to DM utilising best estimates of; the 
association size, DM prevalence and TB incidence for specific regions. 
Stevenson et al used data from India to make PAF calculations. These showed that up to 
20.2% of smear-positive TB can be attributed to DM.
57
  
Walker et al calculated PAF for the UK showing that the effects of an association 
between DM and TB would not be negligible in this setting especially amongst those 
already at an increased risk of TB due to their ethnicity.
47
 Risk estimates for all ages 
varied showing that from 6.9% of incident TB (amongst white British) to 19.6%
 
of 
incident TB (amongst those of asian ethnicity) could be attributed to DM.
47
 
A publication by Ruslami et al outlined the estimated proportion of TB incidence 
attributable to DM in the ten countries with the highest incidence of TB; India (12.9%), 
China (7.8%), Indonesia (9.5%), Nigeria (7.6%), South Africa (8.7%), Bangladesh 
(11.2%), Ethiopia (4%), Pakistan (14.4%), the Philippines (12.9%) and the Democratic 
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Republic of Congo (5.2%) noting that these estimates would be expected to rise as DM 
prevalence increases.
58
 
The semi-systematic review also identified a number of papers focusing upon the 
surrounding context of the association between TB and DM; these studies highlight the 
possible impact of the association given the numbers expected to present co-morbidly 
with TB and DM. 
Unusual radiographic presentation amongst co-morbid individuals 
There are a number of studies which have assessed the radiological presentation of TB 
amongst individuals with DM. As has been discussed, radiographic techniques are 
normally the initial diagnostic tool and sometimes the only tool used to diagnose active 
TB disease. If radiographic presentation is atypical amongst this group of individuals 
(those with co-morbid TB and DM) it is likely that they will go undiagnosed for longer 
periods of time than those with TB alone and perhaps suffer clinically as a consequence. 
PTB is normally found predominantly in the lung apices, however, amongst individuals 
with DM this is thought not to be the case. There is a review published by Sosman et al 
which found that multilobular cavitary TB is more common in people with DM.
371
 The 
semi-systematic review highlighted numerous studies which suggested that in 
individuals with co-morbid DM TB occurs predominantly in the lower lobes, with an 
increased number of multi-lobular cavities and increased prevalence of effusion.
30 253 371-
379
 However, there were also a number of publications identified that presented evidence 
contradictory to this. Studies carried out by Nissapatorn et al and Prasad et al 
discovered no difference in radiological findings between PTB patients with and 
without DM.
255 380
 A study by Perez-Guzman et al, one of the largest studies identified 
with highest statistical power to detect differences in presentation between patient sub-
groups, also finding no differences in the localisation of TB lesions in those with and 
without DM.
381
  
It is of note that the majority of identified studies looking at the difference in 
radiographic presentation of TB amongst individuals with DM were completed within 
low to middle income countries where incidence rates of other co-morbidities which 
may affect presentation of TB are high (such as HIV). Within a westernised setting 
Wilcke et al show that only 8% of individuals with TB have ‘unusual radiographic 
findings’. This perhaps suggests that if there is any impact from co-morbid DM on 
presentation of TB it is unlikely to be of importance within a setting such as the UK.
382
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As data published on the lung pathology of co-infected DM and TB patients is 
contradictory any evidence should be considered cautiously.
30
 It would perhaps be of 
merit to consolidate the disparate studies on the presentation of TB amongst individuals 
with DM using systematic review techniques in order to more confidently assess 
whether there is a difference in TB presentation amongst those with and without TB. 
Unusual presenting population, with unusual signs and symptoms  
The semi-systematic review completed by the candidate also identified a number of 
studies which assessed the characteristics, signs and symptoms of TB amongst 
individuals with DM comparative to those without. As with atypical radiographic 
presentation, atypical presenting signs and symptoms amongst this unusual group of co-
morbid individuals would probably mean increased chances of going undiagnosed for 
longer periods of time than those with TB alone. Again, this could perhaps lead to poor 
clinical consequences. Late TB diagnosis may also pose a public health problem as it 
could increase the risk of TB infection for others. As TB disease progresses 
undiagnosed the index case will have contact with an increased number of new 
individuals as well as increased repeat contact with a core group of people increasing 
chance of infection spread. 
This semi-systematic review identified published evidence which suggested that the 
demographic characteristics of those presenting with TB differ significantly for those 
with and without co-morbidities.
96 109 110 383 
Individuals with DM are thought to present 
with TB at an older age (normal peak incidence is in early adulthood)
30 96
, are more 
likely to be female (TB is normally predominant in males) 
30 378 383
, have a higher BMI 
before and after treatment
59 384
 and are less likely to present with EPTB.  
Another study showed that TB symptoms and signs may differ amongst those with 
compared to without DM. A retrospective study by Wang et al found that patients with 
TB and DM showed higher frequencies of fever and haemoptysis, although findings 
were based upon self report of symptoms.
110
 Alladin et al found symptoms suggestive 
of DM were not appreciably different between patients with PTB comparative to those 
without, with the exception of polyuria.
385
 There seems to be relatively few studies that 
look at the symptoms of co-infected DM and TB patients, and with sparse data and 
contradictory findings further research upon whether TB symptoms and signs differ 
amongst those with and without DM is needed. 
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Effect of co-morbidity on TB management 
The semi-systematic review also identified studies upon the decreased effectiveness of 
TB treatment amongst individuals with DM.  
DM patients are thought to have impaired gastrointestinal drug absorption due to 
gastroparesis which may affect uptake and absorption of medication. A study by Nijland 
et al reported that Rifampicin is not absorbed as effectively in individuals with co-
morbid TB and DM. Exposure to Rifampicin was 53% lower in Indonesian patients 
with TB and DM, compared with patients with TB only.
386
 This could indeed be due to 
poor gastrointestinal uptake, or, to differences in metabolism, excretion and body 
weight amongst those with DM.
386
 However it has also been highlighted within one 
study that individuals with DM and TB are less likely to adhere to their TB 
medication.
89
 However, this finding is inconsistent with other work that demonstrates a 
lower proportion of co-morbid individuals defaulting on their TB treatment comparative 
to those with TB alone.
255
 Whether these findings are of clinical relevance is debateable 
with a full evaluation of the efficacy of the Indian category 1 treatment regimen 
(recommended for all new smear positive TB cases) of the Revised National 
Tuberculosis Control Programme having been tested for use specifically amongst those 
with co-morbid DM and being found wholly appropriate.
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Effect of co-morbidity on DM management 
It is known that certain TB drugs lead to intermittent hyperglycaemia. It is plausible that 
amongst those being treated for TB hyperglycaemia is occurring as a side effect of 
treatment with Rifampicin and Isoniazid
39-41
, or, that the hyperglycaemia being 
observed is ‘stress  hyperglycaemia’42 43 rather than being a true indication of metabolic 
dysfunction. Due to the known contra-indications of treatment for TB those with DM 
being treated for TB may need increased clinical surveillance to ensure tight blood 
glucose control. 
DM and TB outcomes amongst individuals with co-morbid disease 
A large number of studies were identified by the semi-systematic review that assessed 
TB outcomes amongst those with and without DM.  
Specifically these studies seemed to have assessed risk of mortality, bacteriological 
clearance and radiographic clearance amongst co-morbid individuals compared to those 
with TB alone.
100 109 110 115 388
  
Given the plausibility of a large proportion of new TB cases being amongst individuals 
with DM and of this group of individuals growing as DM incidence increases, any 
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adverse impact of having DM and TB (comparative to those with no DM) upon TB 
outcomes would be of serious concern.
57 58 
Again however, publications upon this topic 
were sparse with contradictory findings.  
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1.5 Aims, hypotheses and objectives 
1.5.1 Aims 
The aims of this body of work were to:  
Further elucidate the association between TB and DM within a UK context.  
In particular, given evidence gaps within published literature, to assess the direction of 
the association and whether there is an association between all sub-types of DM and 
TB.  
Given the incidental findings of the semi-systematic literature review a secondary aim 
became to assess and analyse available evidence on the potential impact of DM upon 
TB outcomes in comparison to outcomes amongst those with TB alone. 
1.5.2 Hypotheses  
Given the aims of this work the following hypotheses were addressed: 
1)  DM is associated with an increased risk of developing TB, PTB and, or, EPTB  
2)  T1DM is associated with an increased risk of developing TB, PTB and, or, EPTB 
3)  T2DM is associated with an increased risk of developing TB, PTB and, or, EPTB  
4)  TB is associated with an increased risk of developing DM, T1DM and, or, T2DM 
5)  PTB is associated with an increased risk of developing DM, T1DM and, or, T2DM 
6)  EPTB is associated with an increased risk of developing DM, T1DM and, or, T2DM 
7)  It is consistently documented that when TB and DM present concomitantly TB 
disease outcomes are significantly poorer 
1.5.3 Objectives 
In order to address these hypotheses the specific objectives of this thesis were to: 
Use the ORLS database to elucidate the association between DM and TB within a 
subset of the UK national population by carrying out a set of retrospective cohort 
studies. 
Use THIN database to elucidate the association between DM and TB within a nationally 
representative dataset by carrying out a set of retrospective cohort studies. 
Produce a systematic review of the outcomes of TB amongst DM patients. 
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Chapter 2. Methods  
2.1 Introduction to study design and data sources (testing hypotheses 1 to 6) 
2.1.1 Retrospective (Historical) Cohort Studies 
Retrospective (historical) cohort studies are a type of longitudinal research method 
where historical data upon individuals in a population both exposed and unexposed to a 
specific variable are followed over time to determine whether and in whom an outcome 
of interest occurs. Observations from such studies allow for statistical assessment of 
outcome occurrence in the exposed group compared to the unexposed group and thus 
measure of an association, if present, between the exposure and outcome.
389
 
390
 The 
effect of other key variables upon the measure of association can also be accounted for 
by utilising specific statistical techniques. 
Key reasons for choosing to use this study design for the completion of work presented 
as part of this thesis were the methods ability to demonstrate the temporality and thus 
direction of an association and to allow for analyses upon relatively rare outcomes with 
limited resources.
389 390 
 
2.1.2 Routine health data 
The availability of data and adequacy for use testing specific hypotheses is integral to 
the validity of a retrospective cohort study. Both data sources used for work presented 
within this thesis are derived from routine health data. 
Routine health data are datum derived from established data collection systems and are 
not normally collected with the aim of answering specific questions.
391
 However, 
routine data can be utilised to produce health information for administrative, statutory, 
surveillance, or epidemiological purposes if suitable variables of interest have been 
collated in a non-biased manner.
391
  
There is a wealth of routine data sources collated within the UK. The following 
examples highlight the breadth of data available: census and population registers, cancer 
registrations, health information systems, medical and hospital records, vital statistics, 
disease registry data, hospital episode data, primary care data, national immunization 
records, statutory notifications of infectious diseases, and communicable disease 
surveillance data.
391 392
  
Not all routine data sources would be suitable to test the hypotheses made; 
1) DM is associated with an increased risk of developing TB, PTB and, or, EPTB  
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2)  T1DM is associated with an increased risk of developing TB, PTB and, or, EPTB 
3)  T2DM is associated with an increased risk of developing TB, PTB and, or, EPTB  
4)  TB is associated with an increased risk of developing DM, T1DM and, or, T2DM 
5)  PTB is associated with an increased risk of developing DM, T1DM and, or, T2DM 
6)  EPTB is associated with an increased risk of developing DM, T1DM and, or, T2DM 
7)  It is consistently documented that when TB and DM present concomitantly TB 
disease outcomes are significantly poorer 
Data sources needed to either individually contain or contain once linked with other 
data sources longitudinally collated data at an individual level upon TB and DM status 
as well as information on an individual’s demographic details and lifestyle 
characteristics. 
For the retrospective cohort analyses presented in this thesis data from the ORLS 
database
393  394
 and THIN database,
395
 has been utilised. A short overview of the routine 
data compiled in these databases and of the databases themselves has been given to 
contextualise the research methods chosen. 
2.1.3 HES and the ORLS database 
Routinely available data on secondary care in the UK is databased by Northgate 
Information Services on behalf of the National Health Services (NHS) Information 
Centre for Health and Social Care. This UK health data is known as Hospital Episode 
Statistics and came into being in 1987.
396
  
HES are collected within all NHS secondary care facilities in England; acute hospitals, 
primary care trusts and mental health trusts. The HES database includes inpatient data 
from 1989 onwards and outpatient data from 2003 onwards. Also included is data upon 
care provided to NHS patients by the independent sector, including that taking place in 
treatment centres, and data upon care given to private patients in NHS hospitals.
396
  
HES data is stored as a large collection of separate records for each period of care 
(financial year) and can be collated to give individual level longitudinal records of 
episodic secondary care.
396
  
Each record contains information about; an individual patient such as age, gender and 
ethnicity, any clinical events they have such as diagnoses and operations, administrative 
information such as time waited and date of admission and geographical information 
such as treatment area and habiting area.
396
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As is perhaps somewhat obvious individuals often have more than one clinical event 
occurring upon a single hospital admission. These multiple clinical events are captured 
upon the single clinical event record by using duplicate fields in which to record event 
codes. There is a primary ‘diagnosis’ field in which the main reason for hospitalisation 
is coded alongside multiple secondary ‘diagnoses’ fields in which up to 13, six before 
2002, other diagnoses relevant to the episode of care can be coded. These records are 
finalised by coding clerks, rather than the attending clinician, who review patient case 
notes in order to identify relevant codes for use.
396
 
HES data is then centrally collated and undergoes comprehensive processing and 
validation before its release in order to maintain data quality.
396
 
The ORLS Database 
The ORLS database contains statistical records of all births, NHS hospital admissions, 
cancer registrations and all deaths occurring within defined populations in the former 
Oxford NHS region of England. It comprises two datasets, one for patient admissions 
between 1963 and 1998 (‘ORLS1’) and the second for patient admissions between 1999 
and 2005 (‘ORLS2’) these datasets hold information for over 2 million people.2 397  
Data for each patient was linked together routinely as it accrued within the region’s 
health information systems and historic records are now anonymous and archived.
398
  
Unfortunately due to changes in the NHS information system between 1998 and 1999 
data in ORLS 1 cannot be linked with data in ORLS 2.
399
 
The data within both ORLS databases has been assembled from routine NHS admission 
statistics (data similar to HES from 1963-87, and the actual HES system from 1988), 
and includes episodes of both day case and inpatient care. As with HES any individual 
with a record of hospital attendance has a coded reason for admission which has been 
assigned by a trained clinical coder utilising a structured hospital case note discharge 
abstract with diagnoses recorded by clinicians.
398
 Relevant birth and death registration 
data have been linked to the ORLS databases from records in vital statistics registries 
regardless of where events occurred.
400
 
The ORLS database does exclude private sector admissions although for the UK these 
admissions amount to a negligible proportion of delivered secondary care.
2 397
  
Given the information present within the ORLS database (upon exposures, outcomes 
and basic confounders of interest for this work) and the individual level longitudinal 
nature of the health records created through data linkage it is suitable to use for 
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completion of a retrospective cohort study to elucidate the association between TB and 
DM. Of course the data sources suitability is not withstanding limitations and these are 
discussed later in this thesis. 
2.1.4 GP data and THIN database 
Within the UK a GP acts as the major frontline access point for patients to the NHS. 
They take the initial steps required to provide care for health problems an individual 
may have irrespective of disease type or personal and social characteristics. If needed, 
they will refer a patient to a specialist in the prevention, diagnosis, cure, care, and 
palliation of specific diseases.
401
  
In the UK electronic recording of primary care data, information generated when a 
patient interacts with a GP during an appointment, occurred in the early 1980’s long 
before the computerised recording of secondary care data. GP’s maintain a complete 
longitudinal medical history of their registered patients and it is data from these records 
that makes up the entries within THIN database.
395
 
THIN database 
THIN database contains the electronic medical records of 6.9 million patients collated 
from the clinical systems of over 385 GP practices in the UK, covering approximately 
5.7% of the total population in a representative manner.
395
 
These routine health data are collected directly and at regular intervals from the 
management software of GP practices using a modem arrangement which does not 
interrupt the programmes running and requires no human intervention.
395 402
 The data 
are then processed to provide coded longitudinal records of demographic details, 
lifestyle characteristics, medical events, prescriptions, specialist referrals, and any 
diagnostic or laboratory results occurring at an individual patient level. These records 
also contain information upon socio-economic markers such as Townsend scores, ethnic 
and environmental variables such as urban classification which have been derived from 
the 2001 census results and are linked to individuals via their home postcodes to output 
areas for these measures.
402
  
THIN data are organised in relational database files. Data are separated by contributing 
GP and are shared with researchers arranged in four standardised and one linked file per 
practice.
402
 The coded data are interpreted using ancillary look up tables and 
dictionaries in which medical events are coded using the Read system and prescriptions 
are coded using a Multi-lexical code alongside a British National formulary code. The 
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majority of codes assigned to an individual’s records within primary care are done so by 
the consulting physician or healthcare professional, some data will be input by 
administrative staff such as GP managers.
402
 
The information present in THIN database upon exposures, outcomes and basic 
confounders of interest for this work and the individual level longitudinal nature of the 
health records means it is also a suitable data source to use for completion of a 
retrospective cohort study to elucidate the association between TB and DM. Again 
however the suitability of THIN is not withstanding limitations and these are discussed 
later on in this thesis. 
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2.2 Methods used for analyses utilising ORLS data 
This work was completed in collaboration with MG and CW as detailed in the theses 
acknowledgements section (pages iii-iv). To reiterate work completed was initiated and 
conceived by the candidate with guidance from MG. Initial analyses were carried out by 
CW and were re-ran when the candidate visited Oxford Universities Unit of Health Care 
Epidemiology. Interpretation of results was carried out by the candidate with guidance 
from MG and CW. 
2.2.1 Objectives 
Work carried out within the ORLS aimed to establish whether individuals with DM (of 
any sub-type) have an increased subsequent risk of developing TB (of any sub-type) and 
the magnitude of any such associations. Analyses were also completed to establish 
whether the converse of this is true. In doing so analyses completed with datasets from 
the ORLS database will test hypotheses 1-6 as outlined in section 1.5.2. 
2.2.2 Ethical approval 
Ethical approval for this work was covered by that granted for the full program of work 
which has been completed utilising the ORLS database. This was originally provided by 
the Central and South Bristol Multi-Centre Research Ethics Committee 
(04/Q2006/176). 
2.2.3 Definition of key variables 
Within the ORLS database health events are presently and historically coded for using 
the ICD coding system contemporaneous for the time the health record was made. The 
ICD is a standard diagnostic classification system used worldwide for epidemiological, 
health management and clinical purposes. In particular, in the UK, ICD is used for 
disease classification on vital records including death certificates and health records 
which as discussed previously are the origin of the linked data within the ORLS 
database. 
Individuals with records in the ORLS database were selected as having an exposure or 
outcome of interest if they had an event record containing a coding or proximate 
measure for a key variable as described. 
DM: ICD7 260, ICD8 250, ICD9 250, ICD10 E10-E14.  
T1DM is not distinguishable from T2DM in the codes presented within ICD7, 8 and 9. 
In order to be able to select for T1DM and T2DM as outcomes or exposures of interest 
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throughout the ORLS database age was used as a proximate variable for disease sub-
type. 
T1DM: People 30 years of age and below at the time of first recorded hospital care for 
DM (as identified by the pre-outlined DM codes).  
T2DM: People over 30 years of age at the time of their first recorded hospital care for 
DM (as identified by the pre-outlined DM codes).  
TB: ICD7 001-019, ICD8 010-019, ICD9 010-018, 137, ICD10 A15-A19, B90 
Classification of TB codes by the candidate as either pulmonary or extra pulmonary was 
validated by a consultant physician in respiratory medicine.  
PTB: ICD7 001-002, 003, 005-008, 019.1, ICD8 011-012, 018.1, 019.0, ICD9 011, 
012, 018.0, 137.0, ICD10 A15, A16, A19, B90.9. 
EPTB: ICD7 004, 010-018, 019.0, 019.2, ICD8 010, 013-017, 018.0, 018.9, 019.1-
019.9, ICD9 010, 013-017, 018.8-018.9, 137.1-137.4, ICD10 A17, A18, B90.0-B90.8. 
Individuals to be included in the reference cohort (made up of individuals with a diverse 
range of pre-specified minor disorders) were selected for using the Office of Population, 
Censuses and Surveys (OPCS) code edition 3 for operations alongside ICD9 codes 
(again with the equivalent contemporaneous ICD codes used for earlier and later time 
periods). Reference Conditions: OPCS Appendectomy 441, tonsillectomy 230, knee 
arthroplasty 812, hip arthroplasty 810, 811, ICD squint 378, otitis externa & otitis 
media 380-382, varicose veins 454, haemorrhoids 455, upper respiratory tract infections 
460, deflected septum & nasal polyp 470-471, impacted tooth & other disorders of teeth 
520-521, inguinal hernia 550, in growing toenail and other diseases of nail 703, 
sebaceous cyst 706.2, internal derangement of knee 717, bunion 727.1, selected 
fractures 810-816, 823-826, dislocations, sprains and strains 830-839, 840-848, 
superficial injury and contusion 910-919, 920-924. 
2.2.4 Cohort construction 
The overall study size was fixed by the size of the ORLS population and the number 
within meeting the inclusion criteria and the number of years for which data were 
available.  
Cohorts were then constructed using the definitions for key variables as outlined in 
section 2.2.3. A reference cohort and six exposure cohorts (TB, PTB, EPTB, DM, 
T1DM and T2DM) were created to allow for outcome rate calculation. 
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Construction methods were comparative for each exposure cohort (DM, T1DM, T2DM, 
TB, PTB and EPTB). Cohorts were dynamic, with individuals being selected into an 
exposure cohort from the date of their first record on file for said exposure. First record 
of an exposure is representative of an individual’s first admission, or episode of day 
care, for the condition in an NHS hospital. 
A reference cohort was constructed by identifying the first admission for individuals 
with a diverse range of minor medical and surgical, conditions (using key variable 
codes as outlined 2.2.3). The use of a diverse range of conditions rather than a narrow 
range is standard epidemiological practice when using hospital data in case individuals 
selected into a non-exposed comparison group, here the reference cohort, are atypical in 
their risk of any outcome of interest. The reference cohort used is based on a 'reference' 
group of conditions that has been used in other similar studies of disease associations 
and dissociations within the ORLS database.
399 400 403 
  
To validate the use of the selected conditions within the reference cohort for this study 
the risk of each outcome amongst each reference condition was studied to ensure they 
did not have atypically high or low rates of studied outcomes.  
Individuals who had a record for both an exposure condition and a reference condition 
were assigned to the exposure cohort and not the reference cohort.  
Descriptive statistics were calculated for the main cohorts created although not for 
subgroups. The age and sex distribution for those with T1DM, due to the proximate 
measures used to identify them, would be equivalent to those within the DM cohort 
under the age of 30. For those with T2DM the same would be true although their age 
and sex distribution would match those within the DM cohort over the age of 30. 
2.2.5 Outcome rate and rate ratio calculation 
In order to estimate measures of association utilising data from the ORLS database a 
non-model, stratification based approach was used as has been previously utilised with 
ORLS data.
399 400 403 
 
The same methods were used for each set of analyses completed and thus to save 
repetition are outlined in the remainder of this section in a generic format where the 
terms outcome and exposure could be substituted with terms as relevant for any of the 
separate analysis completed in order to obtain the specific methods used. For example 
for the analyses assessing the risk of subsequent TB amongst those with DM the term 
outcome could be replaced with TB and the term exposure with DM. 
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The statistical software package Stata was used for all analyses. 
Calculating standardised outcome rates amongst the exposure cohort and the 
reference cohort (unexposed) 
In order to calculate an overall estimate of association using the ORLS data an estimate 
of outcome rates amongst the exposure cohort members and reference (unexposed) 
cohort members as they occurred over the study period was first calculated.  
To calculate the standardised outcome rate in the exposure and reference cohorts based 
on person years at risk, entry date into each cohort was taken as the date of first 
admission for exposure or reference condition and the exit date for each individual was 
taken as either the date of subsequent admission for outcome, death, or 31st March 1999 
(ORLS 1) or 31st March 2005 (ORLS2), whichever occurred first. 
Rates were standardised by sex, age (in five year bands), calendar year of first recorded 
admission (in single years), and district of residence. This was done to ensure that the 
exposure and reference populations under comparison were equivalent by these 
variables. The combined exposure and reference cohorts were used as the standard 
population (internal standardisation).  
Where records had missing values for any one of the stratification variables (age, sex, 
place of residence, or year of admission) they were excluded from the analysis however, 
data on each variable was missing from less than 1% of the records so less than 1% 
were excluded. 
Standardisation was completed by calculating, within each age, sex, year, and district 
stratum, the rate of outcome per person years at risk in the standard population; and by 
applying this rate to the person years at risk in each equivalent stratum in each 
individual exposure and reference cohort. This gave an expected number of outcome 
events for each stratum in each cohort.  
For each cohort the expected numbers of outcome events across all the strata were then 
summed and the summed expected figures were compared with the summed observed 
number. These were then expressed as an overall, standardised rate for each cohort by 
adjusting the ratio of the observed to the expected outcome event numbers by the crude 
rate of outcome events in the standard population.  
Outcome rates in the reference cohort should approximate those in the general 
population of the region while allowing for migration in and out of it as data upon 
actual migration is not available.  
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Calculating rate ratios and statistical inferences 
The ratio of the standardised rate of occurrence of outcome in the exposure cohort 
relative to that in the reference (unexposed) cohort was then calculated.  
Each five year age group of exposed individuals was compared with all of the people 
within the reference cohort on file for that age group. This was done to increase 
statistical power and the precision of calculated estimates.  
Calculated in this way, the RR provides a measure of relative risk of outcome in the 
exposure cohort, compared with the reference cohort.  
The methods used to calculate RRs and statistical inferences were based upon methods 
which have been previously used for analyses within the ORLS
400 403
 and were first 
outlined by Breslow and Day.
404
 For further information on the Breslow and Day 
methodology please refer to appendix A.  
P-values of less than 0.05 were taken as being statistically significance. However, as 
multiple comparisons have been made, exact p-values have been given so that the 
reader may assess the level of significance of each comparison.  
Sensitivity analysis 
Sensitivity analyses were completed in which people with an outcome within a year of a 
first admission for exposure were excluded from the dataset. This was done to assess 
whether Berksonian bias or surveillance bias were unduly affecting calculated risk 
estimates. Berksonian bias is a type of selection bias; a potential problem in hospital-
based studies causing identification of spurious associations between diseases or 
characteristics due to differing probabilities of admission for those with the exposure, 
without the exposure and with an outcome of interest.  
Sensitivity analyses were also completed to assess whether utilising exposure and 
outcome admissions recorded only within the primary position on a HES record 
comparative to those recorded within the secondary position or regardless of where 
recorded affected any association effects identified. 
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2.3 Methods used for analyses utilising THIN data 
2.3.1 Objectives 
Work carried out using data from THIN aimed to establish if individuals with DM (any 
sub-type) have an increased subsequent risk of developing TB (any sub-type) and the 
magnitude of any such associations. Analyses were also completed to establish if the 
converse of this is true. In doing so analyses completed with datasets from THIN 
database will re-test hypotheses 1-6 as outlined in section 1.5.2. 
2.3.2 Ethical approval  
Ethical approval for the study carried out using data from THIN database was granted 
by THIN Scientific Review Committee on the 15/10/2010 (see appendix B). 
2.3.3 Definition of key variables 
Key Variables for TB, PTB, EPTB, DM, T1DM and T2DM were defined using a 
combination of Read codes within multiple relevant fields within relational dataset files 
provided to the candidate by CSD-EPIC. There was a total of 265 codes relevant to a 
TB diagnosis, 479 codes relevant to a DM diagnosis (see appendices C and F). These 
codes were then subcategorised into ones which were indicative of disease sub-types. 
When the candidate was uncertain whether a code was representative of disease of a 
specific sub-type, or not, they were checked by either a consultant physician in 
respiratory medicine or by a diabetologist (see appendices D, E, G and H).  
2.3.4 Data provision 
Datasheets containing study denominator data were provided to the candidates 
specification and contained the standard THIN denominator data; the numbers of active 
individuals within THIN (with a patient flag of A or C, meaning their data was adequate 
for research use as deemed by CSD-EPIC) by each year between 2003 and 2009 
aggregated by sex, five year age bands along with additional data upon smoking status 
(current smoker, previous smoker and non-smoker) and Townsend Quintile. The 
denominator data provided was essentially equivocal to count data. 
As has been stated data upon individuals with DM and, or, TB was provided in 
relational database files. These were grouped by contributing GP and then arranged in 
four standardised and one linked file per practice. 
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2.3.5 Cohort construction  
Our study population, the population at risk, was made up of all individuals in THIN 
database with active records between 2003 and 2009 that met THIN minimum data 
acceptability standards, that is, those within the database who had a patient flag of A or 
C showing their data as complete and acceptable for use in research as validated by the 
CSD-EPIC team.  
When generating exposure cohorts for disease sub-types (DM, T1DM, T2DM, TB, 
PTB, EPTB) the populations were generated to include individuals within the 
population at risk with an appropriate Read code indicating an exposure event in either 
one of two medical code fields, within a relational medical record file (MRF) and an 
additional health data file (AHDF).  
Other potential confounders of interest that it was possible to attain data upon and thus 
adjust for in THIN datasets were; age, sex, Townsend Quintile and smoking status 
(current smoker, past smoker, non-smoker). Data upon SES for each individual was 
taken from the appropriate fields within a relational postcode variable indicators file 
(PVIF). The PVIF records contain a value indicating into which quintile of postcodes 
with ascending levels of deprivation as measured by Townsend Index an individual’s 
local area falls. Data upon smoking status was, as with exposure and outcome status, 
identified from Read codes in either of 2 medical code fields within the relational MRF 
and AHDF. The Read codes used to ascertain status as a current smoker, a past smoker 
or a non-smoker are outlined in appendix I. 
Individuals with missing data for main variables of interest were excluded from datasets 
as (given the random pattern of missingness) it was deemed that this would not 
introduce any inherent biases to the analyses. The total number with missing data was 
negligible (<1%) except foe Townsend score where those with missing data were coded 
as 9 and included in statistical models.  
Multiple recoding and collapsing of the original datasets was completed in order to 
produce numerator data comparable to the format in which denominator data had been 
supplied. 
Cohort construction methods were comparative for each exposure cohort (DM, T1DM, 
T2DM, TB, PTB, and EPTB) and are described in a generic manner. Cohorts were 
dynamic, with individuals being selected into an exposure cohort from the date of their 
first record on file for said exposure between the years 2003 and 2009 as identified 
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using Read codes (as listed for each disease in appendices B, C D, E, G and H). In 
THIN data, first record of an exposure is representative of an individual’s first diagnosis 
of a disease by a GP.  
Files were then searched for a subsequent record of an outcome of interest. Unexposed 
cohorts were constructed from the provided denominator data files. 
To account for Berksonian bias and surveillance bias anyone with; less than 1 year of 
follow up after their first exposure record, with a record of an outcome of interest 
recorded at the same time as their exposure record, or with a record of an outcome of 
interest within the first year following their exposure record was excluded in a 
sensitivity analysis. 
Subjects entered the analysis period at their date of diagnosis and exited at the earliest 
of either date of death, de-registration with their GP or at the end of 31/12/2009 
whichever was the last date of available data within the dataset.  
The statistical software package Stata was used for all analyses.  
Descriptive statistics for each cohort were calculated.  
2.3.6 Choosing an appropriate regression technique 
In order to estimate measures of association adjusted for multiple variables utilising 
data from THIN database it was decided that a model based approach to calculate effect 
estimates would be more appropriate than calculating RRs using a non-model based 
approach.  
The most appropriate regression technique for analysing count data is Poisson 
regression.
405
 However the Poisson model holds a rather strong assumption that the 
mean and variance are equal.
406
 Overdispersion within THIN datasets would be the 
presence of greater variability (dispersion) than would be expected based on the 
assumptions of a Poisson model.
406
 If overdispersion was present within THIN datasets 
it would be inappropriate to analyse them using Poisson regression.
406
 
Checking for overdispersion 
Thus, this assumption was checked by producing a histogram of outcome counts 
amongst all created THIN datasets, a histogram allows for a visual summary of the 
skewness and kurtosis of a dataset. The exact figures for each datasets skewness and 
kurtosis were calculated alongside the mean and variance using the statistical software 
package Stata and are also given. Skewness is a measure of symmetry which indicates 
statistically if the variance of a dataset is indeed equivocal to the mean.
407
 Kurtosis is a 
74 
 
measure of whether a datasets peak is flat or relative to a normal distribution also 
assessing whether the dataset fits the expected properties of a normal distribution and 
whether it would thus be appropriately analysed using Poisson regression.
407
 The 
expected values of skewness and kurtosis for a normally distributed dataset are 0 and 3 
respectively.
407
 
THIN datasets were identified as being highly skewed with many true zero counts (see 
section 3.2.3); as being overdispersed. 
Given this, the data could undergo transformation in order to try and meet the normality 
assumption, but it may not be possible to normalise the data in this way and doing so 
would make the interpretation of any regression coefficients calculated difficult as they 
would no longer be estimated on their original scale.
408
  
The modelling approach that would produce the most conceptually easy to interpret 
outcomes and be able to accommodate an increased frequency of true zero counts and 
overdispersion is the negative binomial regression.
409
 
Negative binomial regression 
Negative binomial regression is a generalisation of Poisson regression that accounts for 
overdispersion by including a ‘disturbance’ or ‘error term’.406 The functional form for 
the negative binomial regression model is given in equation 1.
406
 Where λi is the 
expected value of the outcome variable yi for subject i, xi are the independent variables 
with corresponding regression coefficients βn, and σεi is the disturbance term.
406
 
Equation 1  
    λi = β0 + β1χi1 + β2 χi2 + …. + βkχik + σϵi 
All univariate and multivariate analyses were carried out using the negative binomial 
regression function, nbreg.  
Univariate analysis was completed to see which of the variables being modelled, age 
sex, smoking and townsend quintile, were independently associated with TB in the 
largest dataset with data upon TB as an outcome. Univariate analysis was also 
completed to see which of the variables being modelled, age, sex, smoking and 
Townsend quintile, were independently associated with DM within the largest THIN 
dataset containing data upon DM as an outcome. Results were calculated as IRRs and 
the following statistical inferences are reported; the 95% CI and the P-value. P-values of 
less than 0.05 were taken as being statistically significance. However, as multiple 
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comparisons have been made, exact p-values have been given so that the reader may 
assess the level of significance of each comparison.  
Multivariate analyses were completed to see whether DM and any sub-types of DM 
were associated with TB and any sub-types of TB, or the converse. The Stata nbreg 
command was used with relevant counts of disease set as the dependent variable and 
contributed person years set as the offset. Results were calculated as IRRs and the R
2
 
was taken as an indicator of model fit. If indicative of the wrong model having been fit 
the likelihood ratio test that alpha equals zero with its associated chi-squared value were 
reported (compares the use of the Negative binomial model to a Poisson model). 
Interaction effects were also tested for in case any of the variables in the multivariate 
models were representing either or all of the association found between the exposure 
and outcome variables. 
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2.4 Methods used for systematic review (testing hypothesis 7) 
2.4.1 Overview 
This systematic review aimed to exhaustively identify and synthesise data in a 
quantitative manner (as appropriate) from publications which reported a comparison of 
clinically relevant TB outcomes amongst individuals with and without co-morbid DM 
between Jan 1976 and September 2009.  
2.4.2 Search strategy 
More specifically the objectives of this review were to identify all literature reporting 
upon the following clinically relevant TB outcomes; culture or sputum conversion after 
initial treatment phase (2-3 months), sputum or culture conversion after treatment 
completion (>6 months), TB recurrence or relapse and all cause mortality amongst 
individuals with DM and TB comparative to those with TB.  
Literature was comprehensively searched between 1976 and September 2009 within the 
2 largest electronic biomedical databases MEDLINE® and EMBASE®. Searches were 
completed using the OvidSP search interface (Ovid MEDLINE® 1976- SEPTEMBER 
2009 and EMBASE® 1976-SEPTEMBER 2009).  
The search strategy used (see Table 7) contains both MESH terms and text word terms, 
(with the subfix .mp.) which identify studies with any mention of the searched term in 
the title or abstract or MESH terms, in order to identify all relevant studies whether 
catalogued under relevant terms or not. Special characters, search functions and 
Boolean Operators were used as in the semi-systematic review in chapter 1 in order to 
produce a succinct but thorough search strategy. The exp and the back slash within 
search strings 1 and 2 indicate that these strings used the explode command. In search 
strings 3 and 4 the truncation wildcard symbol * was utilised to minimise search strings 
needed. Strings 8 and 9 were completed using automated OvidSP limits and 
ENDNOTEXI functions.  
Due to limited resources only English language publications were identified and 
retrieved. 
Citations, including abstracts, returned from the completed searches were downloaded 
into ENDNOTEXI. Duplicated references were removed from the returned citations 
using the duplicate removal function in the ENDNOTE programme alongside hand 
search techniques.  
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Table 7: Equivalent search terms used within Medline and Embase 
Search String 
1 Exp diabetes mellitus/ 
2 Exp tuberculosis/ 
3 Diabet*.tw. 
4 Tuberculo*.tw. 
5 1 or 3 
6 2 or 4 
7 5 and 6 
8 Limit to English language (OvidSP) 
9 Remove duplicates (ENDNOTE) 
 
In an attempt to identify grey literature of relevance to the review the references lists of 
pertinent articles identified during abstract and full review were also searched.  
2.4.3 Abstract review 
Abstract review of all citations returned by the search was completed utilising a pre-
specified abstract review form (see appendix J) and was completed by two independent 
investigators; FP and NU.  
2.4.4 Inclusion and exclusion Criteria  
The PICO (patient population, intervention, comparator, outcome) framework was used 
to guide development of inclusion and exclusion criteria which were used to screen 
articles for inclusion within the review.
410
  
Inclusion 
All studies reporting upon an outcome of interest as follows amongst those with and 
without TB, where both the denominator and numerator data was available for data 
extraction:  
1) Sputum or culture clearance at 2-3 months after treatment initiation 
2) Sputum or culture clearance more than 6 months after treatment initiation 
3) Relapse or recurrence of TB and  
4) All cause mortality  
Studies including all adult participants (>18 years old) will be included, regardless of 
other biological and social characteristics.  
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Exclusion 
Studies were excluded if they: were case studies or reviews, if they included individuals 
with HIV but did not make any adjustment to findings, if they assessed TB differently 
amongst those with and without DM, or, were re-reports of the same work.  
2.4.5 Full review and data extraction 
FP obtained full articles published on potentially relevant studies. At least two 
investigators (JC, NU, or FP) re-assessed study eligibility. Where disagreement on 
study inclusion occurred this was resolved by discussion between the investigators and 
where necessary authors were contacted in order to clarify any moot points. FP and 
either JC or NU extracted relevant data from included papers using a pre-specified data 
extraction form (appendix K). If data extraction forms for included studies showed 
disagreements these were resolved by discussion, or by contacting authors for 
clarification.  
Data sections on the extraction form were completed detailing relevant descriptive 
information upon included studies such as: study date, setting, and design, how DM and 
TB were defined, numbers with TB and with co-morbid TB and DM included in the 
analyses. Data sections on the extraction form were also completed in order to 
assimilate data reported upon any relevant outcomes of interest. 
2.4.6 Pre-specified analysis techniques 
It was decided that descriptive data upon studies included in the review would be 
summarised using a standard summary of findings table as was used for the semi-
systematic review in chapter 1.  
Extracted quantitative outcome data was input into and analysed using the statistical 
software package Stata. This meant that any between study heterogeneity could be 
calculated as an I
2 
value (where an I
2 
of more than 0 indicates the level of heterogeneity 
present). Heterogeneity is when individual estimates of effect vary more than would be 
expected by chance alone.
244
 Due to the likely disparate nature of the studies being 
searched for and the likely diversity in study quality it was decided a-priori that all 
analysis would be completed using a Mantel-Haenszel random effects meta-analysis 
(with 95% CI) weighting studies more equally relative to one another than a fixed 
effects analysis would.
244
  
As with the semi-systematic review each paper was given a quality grade of ‘low 
quality’, ‘unclear quality’ or high quality’ based upon the following criteria; study 
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design, setting, method of case ascertainment and confounders adjusted for. This grade 
was then used to produce an overall evidence quality grade, which gives the percentage 
of all studies graded as ‘low quality’, ‘unclear quality’ and ‘high quality’ to clearly 
outline the shortcomings of the entire body of evidence (see last row of Table 17).
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Chapter 3. Results 
3.1 ORLS analyses 
3.1.1 Descriptive statistics 
In the ORLS1 dataset there were 19,244 patients in the DM cohort, 6,997 in the TB 
cohort and 572,131 in the reference cohort. The mean age of entry to the DM cohort 
was 52 years, with an average follow up of 7.1 years. In the TB cohort the mean age at 
entry was 49 years and the average follow up was 11.2 years. In the reference cohort, 
the mean age at entry was 31 years, with an average period of follow up of 11.6 years. 
In the ORLS2 dataset there were 7,943 patients in the DM cohort, 999 in the TB cohort 
and 230,085 in the reference cohort. The mean age of entry into the DM cohort was 51 
years, with an average follow up of 3.2 years. In the TB cohort the mean age at entry 
was 46 years and the average follow up was 2.4 years. In the reference cohort, the mean 
age at entry was 39 years, with an average period of follow up of 3.5 years.  
Age distributions for the ORLS1 and ORLS2 cohorts are given in Table 8.  
Table 8: Age distributions at entry for the sub-populations in ORLS1 and ORLS2 
with DM and TB  
Age group 
distribution 
(yrs) 
ORLS1 ORLS2 
DM TB DM TB 
Number 
% of 
total 
Number 
of total 
% of 
total 
Number 
% of 
total 
Number 
% of 
total 
0-4 454 2.4 174 2.5 147 1.9 24 2.4 
5-9 707 3.7 106 1.5 311 3.9 11 1.1 
10-14 1,038 5.4 129 1.8 543 6.8 12 1.2 
15-19 753 3.9 207 3.0 310 3.9 43 4.3 
20-24 765 4.0 406 5.8 262 3.3 95 9.5 
25-29 687 3.6 516 7.4 308 3.9 145 14.5 
30-34 701 3.6 428 6.1 381 4.8 112 11.2 
35-39 603 3.1 425 6.1 386 4.9 79 7.9 
40-44 674 3.5 442 6.3 393 4.9 59 5.9 
45-49 766 4.0 462 6.6 372 4.7 47 4.7 
50-54 1,084 5.6 482 6.9 482 6.0 45 4.5 
55-59 1,303 6.7 601 8.6 536 6.7 55 5.5 
60-64 1,618 8.4 597 8.5 680 8.6 45 4.5 
65-69 1,945 10.1 577 8.2 728 9.2 59 5.9 
70-74 2,132 11.1 529 7.6 701 8.8 58 5.8 
75-79 1,855 9.6 437 6.2 627 7.9 38 3.8 
80+ 2,159 11.2 479 6.8 776 9.8 72 7.2 
Total 19,244  6,997  7,943  999  
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The numbers of individuals with DM was much greater in both ORLS datasets for those 
aged 30 upwards comparative to those under the age of 30.  
It can be seen within Table 8 that, for both the ORLS 1 and ORLS 2 dataset, numbers of 
individuals with TB are lower during childhood than adulthood.  
3.1.2 Inferential Statistics 
Risk of TB amongst those with DM 
The risk of TB (all sub-types) was significantly greater amongst individuals with DM 
(all sub-types) than amongst those without DM in both the ORLS1 dataset (1963-98) 
and in the ORLS2 dataset (1999-05). The RRs were, respectively, 1.77 (95% CI 1.45-
2.15, P-value <0.001) and 2.56 (95% CI 1.78-3.69, P-value <0.001), refer to Table 9.  
The risk of PTB was significantly increased amongst individuals with DM (all sub-
types) compared to those without DM (all sub-types) in both the ORLS1 and ORLS2. 
RRs 1.72 (95% CI 1.22-2.37, P-value <0.001) and 3.33 (95% CI 1.51-6.62, P-value 
0.001) respectively, see Table 9. 
In ORLS1 and ORLS2 there was no statistically significant association between DM 
(all sub-types) and subsequent risk of EPTB, refer to Table 9. It should be noted that the 
numbers in these analysis were very small and therefore may be affected by type II 
errors. 
In ORLS1 there was no statistically significant association between T1DM and 
subsequent risk of TB, with a RR of 2.24 (95% CI 0.45-6.76, P-value 0.33). However, 
there was a statistically significant elevation of risk for TB after T2DM compared to no 
T2DM, with a RR of 1.58 (95%CI1.15-2.14, P-value 0.003). 
In ORLS2 it was not possible to compare the rates of TB amongst those with and 
without T1DM due to the low numbers of individuals within this smaller dataset with 
T1DM. In the ORLS2, as in the ORLS1, there was a statistically significant increase in 
the risk of TB after T2DM compared to no T2DM (RR 3.60 (95% CI 1.76-6.76, P-value 
<0.001). 
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Table 9: RRs, 95%CI and P-values for the occurrence of TB amongst people with 
DM and the converse 
Exposure 
condition
 
Outcome 
condition 
Observed 
number in 
exposure 
cohort 
Expected 
number 
in 
exposure 
cohort 
Adjusted rate 
ratio (95% CI)
1
 
P-value 
ORLS1 (1963-1998) 
TB risk amongst individuals with DM 
DM TB 131 81.0 1.77 (1.45-2.15) <0.001 
T1DM (<30) TB 3 1.4 2.24 (0.45-6.76) 0.33 
T2DM (30+) TB 48 31.4 1.58 (1.15-2.14) 0.003 
DM PTB 42 25.4 1.72 (1.22-2.37) 0.001 
DM EPTB 10 8 1.27 (0.59-2.39) 0.59 
DM risk amongst individuals with TB 
TB DM 34 30.8 1.11 (0.76-1.55) 0.62 
TB T1DM (<30) 3 3.5 0.86 (0.18-2.54) 0.99 
TB T2DM (30+) 31 27.3 1.14 (0.77-1.63) 0.54 
PTB DM 21 23.3 0.90 (0.55-1.38) 0.70 
EPTB DM 13 8.6 1.51 (0.80-2.60) 0.18 
ORLS2 (1999-2005) 
TB risk amongst individuals with DM 
DM TB 59 32.1 2.56 (1.78-3.69) <0.001 
T1DM (<30) TB Numbers too small for meaningful analyses 
T2DM (30+) TB 12 3.8 3.60 (1.76-6.76) <0.001 
DM PTB 10 3.4 3.33 (1.51-6.62) 0.001 
DM EPTB 2 0.6 3.68 (0.41-15.4) 0.23 
DM risk amongst individuals with TB 
TB DM 18 13.0 1.39 (0.82-2.19) 0.21 
TB DM (<30) Numbers too small for meaningful analyses 
TB DM (30+) 2 0.7 3.00 (0.36-11.0) 0.31 
PTB DM 
Numbers too small for analyses 
EPTB DM 
1Adjusted for sex, age in 5-year bands, time-period in single calendar years and district of residence 
Risk of DM amongst those with TB 
There was no significant association between TB (all sub-types) and subsequent risk of 
DM (all sub-types), T1DM or T2DM in ORLS1 or ORLS2; see Table 9 for RRs, 95% 
CI, and P-values. 
There was no statistically significant association between PTB or EPTB and subsequent 
DM risk in ORLS1 (see Table 9 for detail). Numbers in ORLS2 only allowed for 
meaningful analysis of risk of DM and risk of T2DM after TB, refer to Table 9.  
84 
 
Sensitivity Analyses 
Conditions selected into the reference cohorts were checked in case they themselves had 
atypical risk of TB or DM. As grouped by condition, no individuals selected into the 
referent population upon examination had an atypical risk of TB, PTB, EPTB, DM, 
T1DM or T2DM. 
Cases were also excluded dependent on the position of exposure health events on their 
HES records in order to ascertain whether having an exposure as a primary or secondary 
diagnosis changed the risk of developing an outcome of interest. No difference in effect 
estimates was found.  
To account for potential Berksonian or surveillance biases cases with a diagnosis of an 
exposure of interest within a year of diagnosis of any outcome of interest were 
excluded. This did not affect most trends seen (see table 10), but did effect risk 
estimates calculated due to decreases in the overall numbers included in analyses. 
Table 10: RRs, 95% CI and P-values for occurrence of TB in people with DM and 
the converse after excluding people who present with both diseases within a year 
Exposure 
condition
 
Outcome 
condition 
Observed number 
in exposure cohort 
Expected number 
in exposure cohort 
Adjusted rate 
ratio (95% CI)
3
 
P-
value 
ORLS1 (1963-1998) 
TB risk amongst individuals with DM 
DM TB 81 46.3 1.91 (1.48-2.44) <0.001 
T1DM (<30) TB 
Numbers too small for meaningful analyses 
T2DM (30+) TB 
DM PTB 27 15.6 1.80 (1.16-2.67) 0.005 
DM EPTB 9 4.8 1.98 (0.88-3.92) 0.008 
DM risk amongst individuals with TB 
TB DM 105 140.7 1.00 (0.82-1.22) 0.99 
TB T1DM (<30) 
Numbers too small for meaningful analyses 
TB T2DM (30+) 
PTB DM 19 20.7 0.92 (0.55-1.43) 0.79 
EPTB DM 12 8.1 1.49 (0.77-2.60) 0.23 
ORLS2 (1999-2005) 
TB risk amongst individuals with DM 
DM TB 25 15.9 1.93 (1.12-3.27) 0.013 
DM (<30) TB 
Numbers too small for meaningful analyses 
DM (30+) TB 
DM PTB 6 2.5 2.63 (0.91-6.30) 0.05 
DM EPTB Numbers too small for analyses 
DM risk amongst individuals with TB 
TB DM 9 5.10 1.77 (0.81-3.37) 0.13 
TB DM (<30) 
Numbers too small for meaningful analyses 
TB DM (30+) 
PTB DM 
EPTB DM 
1Adjusted for sex, age in 5-year bands, time-period in single calendar years and district of residence 
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After excluding cases that had an outcome of interest within a year of being diagnosed 
with an exposure of interest within both the ORLS1 and ORLS 2 datasets statistically 
significant increases in risk of TB and PTB after DM in ORLS1 and ORLS2 still 
remained although point estimates were reduced, see Table 10. However, now a 
statistically significant increase in the risk of EPTB compared to no EPTB after DM 
was seen within ORLS 1 (RRs 1.98 (95% CI 0.88-3.92, P-value 0.008)). It should be 
noted that due to the exclusion of cases this sensitivity analysis contained very small 
numbers and therefore may show type I errors. Risk of DM after TB compared to no TB 
in both ORLS1 and ORLS2 remained to show no statistically significant association as 
did risk of DM after PTB and EPTB within ORLS1. 
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3.2 THIN analyses 
3.2.1 Descriptive statistics 
Within THIN dataset there were 224,508 individuals in the DM cohort, in the T1DM 
cohort 44,874, in the T2DM cohort 193,929, in the TB cohort 5,470, in the PTB cohort 
1,589 and in the EPTB cohort 1,006. The mean age of entry into the DM cohort was 60 
years, T1DM cohort 51 years, T2DM cohort 62 years, TB cohort 48 years, PTB cohort 
53 years and EPTB cohort 47 years respectively. Average follow up for each cohort was 
4.1 years, 4.8 years, 4.2 years, 3.7 years, 3.7 years, and 4 years respectively. 
Sex, age, SES and Smoking distribution for the DM cohorts are given in Table 11 and 
for the TB cohorts are given in Table 12.  
Table 11: Sex, Age, SES and Smoking distribution within the DM, T1DM and 
T2DM cohort 
Cohort DM T1DM T2DM 
Variable Categories N (224,508) % of total N (44,874) % of total N (193,929) % of total 
Sex 
Male 123,264 54.9 24,771 55.2 106,760 55.1 
Female 101,244 45.1 20,103 44.8 87,169 44.9 
Age Group 
0-15 3,045 1.3 2,739 6.1 201 0.1 
16-30 8,696 3.9 5,686 12.6 2,975 1.5 
31-45 29,576 13.1 9,027 20.1 22,241 11.5 
46-60 63,977 28.5 10,716 23.9 57,921 29.9 
61-75 80,235 35.7 11,995 26.7 74,999 38.7 
76+ 38,979 17.4 4,751 10.6 35,592 18.3 
Towensend Quintile 
1 45,608 20.3 9,150 20.4 39,012 20.1 
2 44,518 19.8 8,697 19.4 38,553 19.9 
3 45,121 20.1 9,095 20.3 39,120 20.2 
4 43,283 19.3 8,724 19.4 37,702 19.4 
5 32,502 14.5 6,500 14.5 28,238 14.6 
Smoker 
Yes 62,288 27.7 13,231 29.5 54,514 28.1 
Past 119,619 53.3 21,430 47.8 106,377 54.9 
No 42,601 19.0 10,213 22.8 33,038 17.0 
The prevalence of DM in THIN dataset is highest amongst males. The prevalence of TB 
and of DM increases with age, however, there is no spike in DM prevalence at age 14 
years within THIN dataset as there is in the ORLS dataset.  
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Table 12: Sex, Age, SES and Smoking distribution within the TB, PTB and EPTB 
cohort 
Cohort TB PTB EPTB 
Variable Categories N (5,470) % of total N (1,589) % of total N (1,006) % of total 
Sex 
Male 2,698 49.3 856 53.9 440 43.7 
Female 2,772 50.7 733 46.1 566 56.3 
Age Group 
0-15 394 7.2 68 4.2 67 6.7 
16-30 1,035 19 236 14.9 174 17.4 
31-45 375 19.3 78 16.4 239 23.8 
46-60 1,109 20.3 328 20.7 211 21.1 
61-75 1,268 23.2 473 29.8 226 22.6 
76+ 584 10.7 219 13.8 85 8.5 
Towensend Quintile 
1 774 14.1 210 13.2 152 15.1 
2 800 14.6 234 14.7 136 13.5 
3 1,017 18.6 280 17.6 216 21.5 
4 1,193 21.8 376 23.7 221 22.0 
5 1,252 22.9 364 22.9 212 21.1 
Smoker 
Yes 1,449 26.5 420 26.4 254 25.2 
Past 2,236 40.9 781 49.2 410 40.8 
No 1,785 32.6 388 24.4 342 34.0 
3.2.3 Testing for over-dispersion 
Poisson models are the standard regression method used to model count response data 
however as previously discussed they have a very strong theoretical assumption; that the 
conditional variance of the outcome variable is equal to the conditional mean. Due to 
the nature of the data being analysed over-dispersion was suspected amongst every 
single compiled dataset from THIN database; testing to see if this Poisson assumption 
held was completed. For all analyses graphing of outcome counts showed that data was 
skewed and does not approximate a normal distribution as outlined by a plotted normal 
distribution curve (see Appendix L). Summary statistics for each analyses completed 
showed that the mean was not equivalent to the variance with Skewness figures far from 
zero and Kurtosis figures far from 3 indicative of over-dispersion within each dataset 
(see Table 13). 
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Table 13: Tests for over-dispersion within THIN cohorts 
Exposure Outcome Mean Variance Skewness Kurtosis Over-dispersion Present 
DM TB 1.047 9.66 4.9 33.91 Yes 
T2DM TB 0.61 3.71 5.96 54.05 Yes 
T1DM TB 0.59 3.66 6.01 55.08 Yes 
DM PTB 0.15 0.31 6.11 61.30 Yes 
T2DM PTB 0.16 0.33 5.95 58.13 Yes 
T1DM PTB 0.15 0.32 6.16 61.25 Yes 
DM EPTB 0.10 0.20 6.25 55.08 Yes 
T2DM EPTB 0.10 0.20 6.25 55.08 Yes 
T1DM EPTB 0.11 0.21 6.23 54.34 Yes 
TB DM 28.18 7,005.99 6.05 51.11 Yes 
PTB DM 32.14 7,919.02 5.65 44.90 Yes 
EPTB DM 33.71 8,273.25 5.51 42.86 Yes 
TB T1DM 13.18 1,049.72 4.06 23.48 Yes 
PTB T1DM 15.06 1,172.09 3.77 20.69 Yes 
EPTB T1DM 5.34 172.461 4.56 30.44 Yes 
TB T2DM 26.21 6,635.80 6.12 51.80 Yes 
PTB T2DM 29.86 7,501.93 5.71 45.49 Yes 
EPTB T2DM 31.30 7,835.97 5.58 43.43 Yes 
3.2.2 Inferential Statistics 
Univariate analyses were completed using negative binomial regression to ascertain 
which of the independent variables had a direct relationship with the dependent variable 
amongst the datasets created within THIN database.   
There were no significant associations between TB risk and sex.  
Risk of TB was significantly higher amongst those aged 21-40 years comparative to 
those under the age of 20 years (IRR 1.38 (95% CI 1.12-1.69, P-value 0.002)), see 
Table 14.  
TB risk decreased with Townsend score i.e. was lowest for those of highest SES. 
Comparative to a Townsend score of 1 a Townsend score of 2 (IRR 0.29 (95% CI 0.24-
0.36, P-value <0.001)), 3 (IRR 0.35 (95% CI 0.29-0.43, P-value <0.001)), 4 (IRR 0.44 
(95% CI 0.36-0.52, P-value <0.001) and 5 (IRR 0.58 (95% CI 0.48-0.69, P-value 
<0.001)) was significantly associated with lower risk of developing TB, see Table 14.  
Risk of TB was also significantly increased for past smokers (IRR 2.37 (95% CI 2.06-
2.72, P-value <0.001)) and current smokers (IRR 1.70 (95% CI 1.47-1.98, P-value 
<0.001)) in comparison to non-smokers. 
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Table 14: Baseline characteristics associated with TB risk within THIN 
Individual’s baseline 
characteristics 
Categories Outcome IRR (95% CI)
1
 
P-
value 
Risk of TB following DM 
Sex 
Male 
TB 
1  
Female 0.95 (0.84-1.08) 0.445 
Age 
0-20 
TB 
1  
21-40 1.38 (1.12-1.69) 0.002 
41-60 0.96 (0.78-1.18) 0.685 
61-80 1.18 (0.96-1.46) 0.114 
81+ 0.95 (0.68-1.32) 0.741 
Townsend 
1 (Most Deprivation) 
TB 
1  
2 0.29 (0.24-0.36) <0.001 
3 0.35 (0.29-0.43) <0.001 
4 0.44 (0.36-0.52) <0.001 
5 (Least Deprivation) 0.58 (0.48-0.69) <0.001 
Smoking 
Non-Smoker 
TB 
1  
Past Smoker 2.37 (2.06-2.72) <0.001 
Current Smoker 1.70 (1.47-1.98) <0.001 
There was a significant decrease in DM risk amongst women compared to men (IRR 
0.87 (95% CI 0.77-0.98, P-value 0.024)), see Table 15.  
DM risk increased with age. Comparative to those under the age of 20 years those aged 
41-60 years (IRR 4.77 (95% CI 3.92-5.80, P-value <0.01)), 61-80 years (IRR 8.06 (95% 
CI 6.63-9.80, P-value <0.01)) and 81 years and over (IRR 3.94 (95% CI 3.03-5.13, P-
value <0.01)) were at a significantly higher risk of developing DM, see Table 15.  
DM risk was not significantly associated with Townsend score, all IRRs reported were 
near to 1 and P-values were above 5%. 
Risk of DM significantly increased for past smokers (IRR 4.47 (95% CI 4.00-5.00, P-
value <0.001) and current smokers (IRR 8.59 (95% CI 7.70-9.57, P-value <0.001)) in 
comparison to non-smokers.   
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Table 15: Baseline characteristics associated with DM risk within THIN 
Individual’s baseline 
characteristics 
Categories Outcome IRR (95% CI)
1
 
P-
value 
Risk of DM following TB 
Sex 
Male 
DM 
1  
Female 0.87 (0.77-0.98) 0.024 
Age 
0-20 
DM 
 
1  
21-40 0.98 (0.80-1.20) 0.873 
41-60 4.77 (3.92-5.80) <0.01 
61-80 8.06 (6.63-9.80) <0.01 
81+ 3.94 (3.03-5.13) <0.01 
Townsend 
1 (Most Deprivation) 
DM 
1  
2 1.01(0.82-1.25) 0.900 
3 1.10 (0. 90-1.36) 0.360 
4 1.15 (0.93-1.42) 0.190 
5 (Least Deprivation) 1.09 (0.89-1.35) 0.370 
Smoker 
Non Smoker 
DM 
1  
Past Smoker 4.47 (4.00-5.00) <0.001 
Current Smoker 8.59 (7.70-9.57) <0.001 
In order to sufficiently model the association between TB and DM, and the converse, 
multivariate analysis was performed to take into account the effect of multiple predictor 
variables simultaneously upon outcomes of interest. Specifically, multivariate negative 
binomial regression was conducted. 
In THIN dataset the risk of TB (all sub-types) was found to be significantly increased 
amongst individuals with DM (all sub-types), T1DM and T2DM when compared to 
those without. The IRR of TB (all sub-types) was significantly increased amongst 
individuals with DM (all sub-types) (IRR 1.50 (95%CI 1.27-1.76) P-value <0.001), 
T1DM (IRR 1.46 (95%CI 1.10-1.92) P-value 0.008) and T2DM (IRR 1.54 (95%CI 
1.30-1.82) P-value < 0.001) compared to those without DM. 
The rate of PTB amongst individuals with DM (all sub-types) (IRR 1.237 (95%CI 0.93-
1.64), P-value = 0.137), T1DM (IRR 1.30 (95% CI 0.79-2.16), P-value = 0.303), or 
T2DM (IRR 1.24 (95% CI 0.92-1.67), P-value = 0.152), compared to those without DM 
were not significantly raised.  
The rate of EPTB was raised significantly amongst those with T1DM (IRR 2.09 
(95%CI 1.19-3.66), P-value 0.010) but was not significantly raised amongst those with 
DM (all sub-types) (IRR 1.43 (95% CI 0.99-2.07), P-value 0.055) or those with T2DM 
(IRR 1.39 (95%CI 0.93-2.06), P-value 0.11) when compared to those without DM. 
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However, it should be noted that the P-value for EPTB amongst those with DM tended 
towards significance and may be being affected by type II errors. 
Table 16: IRRs, 95%CI and P-values for the occurrence of TB amongst people 
with DM 
Exposure 
condition
 
Outcome 
condition 
Unadjusted 
IRR (95% CI) 
P-value 
Adjusted IRR 
(95% CI)
1
 
P-value PseudoR
2
 
Risk of TB following DM 
DM TB 
1.619 (1.367-
1.917) 
< 0.001 
1.50 (1.27-
1.76) 
<0.001 0.08 
T1DM TB 
1.692 (1.275-
2.245) 
<0.001 
1.455 (1.104-
1.917) 
0.008      0.09 
T2DM TB 
1.654 (1.384-
1.975) 
<0.001 
1.536 (1.296-
1.822) 
<0.001 0.08 
DM PTB 
1.735 (1.299-
2.316)  
<0.001 
1.237 (0.934-
1.638)  
0.137 0.10 
T1DM PTB 
1.844 (1.106-
3.074) 
0.019 
1.304 (0.787-
2.160) 
0.303 0.11 
T2DM PTB 
1.747 (1.288-
2.368) 
<0.001 
1.243 (0.923-
1.673) 
0.152 0.10 
DM EPTB 
1.561 (1.088-    
2.240)  
0.016 
1.434 (0.993-
2.071) 
0.055 0.05 
T1DM EPTB 
2.428 (1.385-
4.256) 
0.002      
2.088 (1.190-
3.664)  
0.010      0.06 
T2DM EPTB 
1.514 (1.028-
2.230) 
0.036 
1.388 (0.934-
2.062) 
0.105      0.05 
1Adjusted for age, sex, region, Townsend score and smoking status  
In THIN dataset the rates of DM (all sub-types), T1DM and T2DM were found to be 
significantly raised amongst those who have had TB (all sub-types), PTB and EPTB 
when compared to those who have not had TB (all sub-types), PTB and EPTB.  
The rate of DM (all sub-types) was significantly increased amongst those who had had 
TB (all sub-types) (IRR 5.65 (95% CI 5.19-6.16) P-value <0.001), amongst those who 
had had PTB (IRR 5.74 (95% CI 5.08-6.50) P-value <0.001) and amongst those who 
had had EPTB (IRR 4.66 (95% CI 3.94-5.51) P-value <0.001) when compared to those 
who had not had TB.  
The rate of T1DM was significantly increased amongst those who had had TB (all sub-
types) (IRR 5.49 (95% CI 5.02-6.02) P-value <0.001), amongst those who had had 
EPTB (IRR 0.84 (95% CI 0.35-2.03) P-value <0.001) but was not significantly raised 
amongst those who had had PTB (IRR 1.09 (95% CI 0.62-1.93) P-value 0.77) when 
compared to those who had not had TB. 
The rate of T2DM was significantly increased amongst those who had had TB (all sub-
types) (IRR 2.21 (95% CI 1.68-2.91) P-value <0.001), amongst those who had had PTB 
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(IRR 5.38 (95% CI 4.73-6.12) P-value <0.001) and amongst those who have had EPTB 
(IRR 4.36 (95% CI 3.65-5.22) P-value <0.001) when compared to those who have not 
had EPTB. 
Table 17: IRRs, 95%CI and P-values for the occurrence of DM amongst people 
with TB 
Risk of DM following TB 
Exposure 
condition
 
Outcome 
condition 
Unadjusted 
IRR (CI) 
P-value 
Adjusted IRR 
(CI)
1
 
P-value PseudoR
2
 
TB DM 
6.384 (5.693-
7.159) 
<0.001 
5.651 (5.185-
6.159) 
<0.001 0.16 
TB T1DM 
6.668 (5.876-
7.566) 
<0.001 
5.491(5.019-
6.020) 
<0.001 0.19 
TB T2DM 
2.103 (1.582-
2.797) 
<0.001 
2.212 (1.684-
2.906) 
<0.001 0.12 
PTB DM 
8.026 (6.896-    
9.342) 
<0.001 
5.740 (5.077-
6.490) 
<0.001 0.16 
PTB T1DM 
1.591 (0.893-
2.835) 
0.115 
1.088 (0.616-
1.930) 
0.772 0.13 
PTB T2DM 
8.130 (6.880-
9.608) 
<0.001 
5.382 (4.730-
6.124) 
<0.001 0.19 
EPTB DM 
5.416 (4.460-
6.577) 
<0.001 
4.659 (3.940-
5.509) 
<0.001 0.15 
EPTB T1DM 
1.025 (0.423-
2.483) 
0.956 
0.843 (0.349-
2.034) 
<0.001 0.13 
EPTB T2DM 
5.427 (4.385-
6.716) 
<0.001 
4.364 (3.649-
5.218) 
<0.001 0.18 
1Adjusted for age, sex, region, Townsend score and smoking status  
Adjusted results 
Testing for interaction effects: TB to DM 
Upon testing for interaction effects whilst exploring the relationship seen between risk 
of DM following TB a large, statistically significant interaction was seen between age 
and TB as displayed within Table 18. 
Table 18: Test of the interaction effect between age and TB, IRR (95% CI) and P-
values 
Exposure Outcome Interaction Effect IRR (95% CI) P-value 
TB DM Age 
0-20 1  
21-40 11.54 (1.58-84.17) 0.016 
41-60 20.27 (2.82-145.49) 0.003 
61-80 21.14 (2.95-151.57) 0.002 
80+ 17.89 (2.43-131.59) 0.005 
R
2
 0.17 
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3.3 Systematic review findings 
3.3.1 Summary of studies identified and included in full review 
Table 19 displays the number of citations returned by each search string carried out as 
part of the full search strategy.  
Table 19: Search strategy used to identify papers reporting upon TB and DM with 
a view to identifying papers including data on TB outcomes 
 
After abstract review 116 papers were identified as likely to contain data upon TB 
outcomes amongst those with and without DM. These papers were retrieved in full by 
the candidate and searched for relevance with a decision being made on inclusion in the 
full review by 2 independent investigators (FP and either NU or JC).  
Upon full review twenty five studies were identified as including relevant data for 
extraction. These were then searched for specific information using a pre-specified data 
extraction form (Appendix L). 
Specifically data on the following was extracted: 
1) All cause mortality  
2) Bacterial clearance at 2-3 months (culture results included preferentially to 
sputum smear) 
3) Bacterial clearance at >6 months (again with culture results included 
preferentially to sputum smear) 
4) Re-occurrence of TB 
 
Search MEDLINE Hits EMBASE Hits 
Exp diabetes mellitus/ 229,502 379,224 
Exp tuberculosis/ 129,184 165,413 
Diabet*.mp. 308,584 402,511 
Tuberculo*.mp. 134,652 143,762 
1 or 3 368,086 502,113 
2 or 4 164,236 198,365 
5 and 6 985 2,101 
English Language (OvidSP) 879 1,986 
Remove duplicates (ENDNOTE) 1,  868 
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Table 20 summarises the detail of the 25 studies including most notably the study 
design, the way in which case ascertainment was made and the outcomes of interest 
upon which each paper reported.  
In this review 7 studies described as prospective cohort studies (Alisjahbana 2007
59
, 
Ambrosetti 1999 (1995)
411
, Ambrosetti 1999 (1996)
412
, Ambrosetti 1999 (1997)
413
, 
Centis 2000
414
, Centis 2002
415
 and Ponce de Leon 2004
279
) were identified, 16 
described as retrospective cohort studies (Banu-Rekha 2007
416
, Chiang 2009
115
, Dooley 
2009
60
, Fielder 2002
417
, Fischer Hoch 2008
252
, Guler 2007
418
, Hasibi 2008
419
, Matthew 
2006
420
, Oursler 2002
421
, Singla 2003
62
, Singla 2006
422
, Subhash 2003
423
, Tatar 2009
111
,  
Vasankari 2009
424
, Wang 2001
425
 and Wang 2009
110
) and two (Bashar 2001
251
 and 
Kourbatova 2006
426
) as retrospective case control studies.  
Only three studies identified both TB and DM status using standard diagnostic testing 
(Alisjahbana 2007
59
, Singla 2003
62
 and Singla 2006
422 
), the rest utilised a mix of self 
report or MRR.  
The majority of the studies were completed within high income countries (13; 
Ambrosetti 1999 (1995)
411
, Ambrosetti 1999 (1996)
412
, Ambrosetti 1999 (1997)
413
, 
Bashar 2001
251
, Centis 2000
414
, Centis 2002
415
, Chiang 2009
115
, Dooley 2009
60
, Fielder 
2002
417
, Fischer Hoch 2008
252
, Oursler 2002
421
, Singla 2003
62
, Singla 2006
422
, 
Vasankari 2009
424
, Wang 2001
425
 and Wang 2009
110
) with 9 completed in middle to low 
income countries (Alisjahbana 2007
59
,  Banu-Rekha 2007
416
,  Guler 2007
418
, Hasibi 
2008
419
, Kourbatova 2006
426
 Matthew 2006
420
, Ponce de Leon 2004
279
, Subhash 2003
423
 
and Tatar 2009
111
 ).  
Only four of the studies were completed in countries with a high incidence of TB 
(Banu-Rekha 2007
416
, Kourbatova 2006
426
, Subhash 2003
423
 and Matthew 2006
420
). 
Twenty of the studies reported upon all cause mortality, six gave numbers with sputum 
conversion at 2-3 months, only 1 at 6 months and four studies reported upon recurrence 
or relapse of TB, as indicated in Table 20. The majority of the studies identified, as 
graded by the pre-specified criteria, were of a ‘poor’ quality (see Table 20). 
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Table 20: Summary of findings table showing the characteristics of identified studies 
First Author & 
Year Published 
Setting & Study 
Date 
Study Design DM Definition Used TB Definition Used 
Outcomes of 
Interest Reported 
Alishjahbana 2007
59
 
Indonesia, 1998-
2002 
Prospective cohort  
FBG>126 mg/dl at 2 
different time points 
PTB: Clinical & radiological symptoms & a 
positive smear 
1, 2 and 3 
Ambrosetti 1999 
(1995)
411
 
Italy, 1995 Prospective cohort MRR 
TB: histological findings of AFB, or positive 
culture or smear 
1 
Ambrosetti 1999 
(1996)
412
 
Italy, 1996 Prospective cohort MRR 
TB: histological findings of AFB, or positive 
culture or smear 
1 
Ambrosetti 1999 
(1997)
413
 
Italy, 1997 Prospective cohort MRR 
TB: histological findings of AFB, or positive 
culture or smear 
1 
Banu-Rekha 2007
416
 India, 1998-2002 
Retrospective 
analyses 
MRR and FBG 
PTB: Radiological symptoms and positive 
culture or smear 
2 
Bashar 2001
251
 USA, 1987-1997 
Retrospective case 
control 
Previously diagnosed DM, 
MRR 
TB: Record review for culture results 1 
Centis 2000
414
 Italy, 1998 Prospective cohort MRR TB: Positive culture or smear 1 
Centis 2002
415
 Italy, 1999 Prospective cohort MRR TB: Positive culture or smear 1 
Chiang 2009
115
 Taiwan, 2003 
Retrospective 
cohort 
MRR PTB: Positive culture or smear 1 
Dooley 2009
60
 USA, 2004-2005 
Retrospective 
cohort 
MRR & taking DM 
medication or non-FBG> 
200g/dl 
TB: Positive culture 1 and 2 
Fielder 2002
417
 USA, 1993-1998 
Retrospective 
cohort 
MRR PTB: Positive smear 1 
Fischer Hoch 
2008
252
 
USA-Mexico 
border, 1996-2002 
Retrospective 
cohort 
Self Report TB: Positive culture or smear 1 and 4 
Guler 2007
418
 Turkey, 2000-2005 
Retrospective 
cohort 
MRR PTB: Positive smear 2 
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Hasibi 2008
419
 Iran, 1999-2006 
Retrospective 
cohort 
MRR 
Disseminated TB, clinically & 
microbiologically diagnosed 
1 
Kourbatova 2006
426
 Russia, 1995-2001 
Retrospective case 
control 
MRR 
TB: clinical symptoms, chest x-ray or 
positive culture or smear 
1 
Matthew 2006
420
 Russia, 2002-2003 
Retrospective 
cohort 
MRR 
PTB: clinical, radiological or microbiological 
evidence 
1 
Oursler 2002
421
 USA 1994-1996 
Retrospective 
cohort 
MRR 
TB: Fingerprinting with Restriction Fragment 
Length Polymorphism  
1 
Ponce de Leon 
2004
279
 
Mexico, 1995-
2003 
Cohort  
MRR 
Non-FBG> 200g/dl or 
FBG>126 mg/dl 
TB: Positive culture or fingerprinting with 
Restriction Fragment Length Polymorphism 
1 
Singla 2003
62
 
Saudi Arabia, 
1998-1999  
Retrospective 
cohort 
Fasting Plasma Glucose 
>140mg/dl at 2 time points 
PTB: Positive smear or culture 2* 
Singla 2006
422
 
Saudi Arabia, 
1998-1999 
Retrospective 
cohort 
Fasting Plasma Glucose 
>140mg/dl at 2 time points 
PTB: Positive smear or culture 1, 2 and 4 
Subhash 2003
423
 India, 1997-1999 
Retrospective 
chort 
MRR and medication 
review or 
Non-FBG> 140mg/dl 
TB: Positive culture 4 
Tatar 2009
111
 Turkey, 1997-2003 
Retrospective 
cohort 
MRR TB: Positive Smear or Culture  1 and 2 
Vasankari 2009
424
 
Finland, 1995-
1996 
Retrospective 
cohort 
DM medication use PTB: Positive culture 1 
Wang 2001
425
 
Taiwan, 1996-
1999 
Retrospective 
cohort 
MRR 
PTB: Radiological findings, clinical 
suspicion or microbiological evidence 
4 
Wang 2009
110
 
Taiwan, 2003-
2006 
Retrospective 
cohort 
Medical history and 
treatment 
PTB: Culture or smear positive 1 
Overall Quality of Evidence
364      
*Findings re-published alongside further data in Singla 2006422 
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3.3.2 Statistical synthesis of extracted data 
Data upon mortality, bacterial clearance at 2-3 months, 6 months and relapse or 
recurrence was extracted from each paper in its most basic format; as numbers with an 
outcome of interest amongst the non-exposed (TB alone) and the exposed (Co-morbid 
TB and DM). This information is given below in Table 21. 
Table 21: Data extracted from identified studies upon TB outcomes of interest 
First Author & 
Year Published 
All Cause 
Mortality 
No Bacterial Clearance at Relapse or 
Recurrence 2-3 months > 6months 
 TB 
TB & 
DM 
TB 
TB & 
DM 
TB 
TB & 
DM 
TB 
TB & 
DM 
Alishjahbana 
2007
59
 
0/540 2/94 68/372 7/41 32/333 6/27 - - 
Ambrosetti 1999 
(1995)
411
 
29/737 3/32 - - - - - - 
Ambrosetti 1999 
(1996)
412
 
19/773 4/50 - - - - - - 
Ambrosetti 1999 
(1997)
413
 
1/40 43/667 - - - - - - 
Banu-Rekha 
2007
416
 
- - 10/68 8/69 - - - - 
Bashar 2001
251
 1/105 7/50 - - - - - - 
Centis 2000
414
 49/1059 5/41 - - - - - - 
Centis 2002
415
 26/852 2/40 - - - - - - 
Chiang 2009
115
 137/886 52/241 - - - - - - 
Dooley 2009
60
 20/255 6/42 9/30 50/163 - - - - 
Fielder 2002
417
 29/152 13/22 - - - - - - 
Fischer Hoch 
2008
252
 
112/1022 46/391 - - - - 20/115 14/47 
Guler 2007
418
 - - 88/262 32/44 - - - - 
Hasibi 2008
419
 3/6 6/44 - - - - - - 
Kourbatova 
2006
426
 
87/440 5/20 - - - - - - 
Matthew 2006
420
 75/1872 8/44 - - - - - - 
Oursler 2002
421
 14/108 8/18 - - - - - - 
Ponce de Leon 
2004
279
 
61/409 34/172 - - - - - - 
Singla 2006
422
 3/505 1/187 45/486 30/185 - - 3/505 2/187 
Subhash 2003
423
 - - - - - - 106/145 20/28 
Tatar 2009
111
 0/78 2/78 8/53 11/55 - - - - 
Vasankari 2009
424
 86/537 22/92 - - - - - - 
Wang 2001
425
 - - - - - - 3/25 27/173 
Wang 2009
110
 11/143 13/74 - - - - - - 
 
All Cause Mortality 
Data extracted from all studies reporting upon all cause mortality was pooled using a 
random effects analysis due to the high statistical heterogeneity present (I-squared 
59.9%). Of the studies pooled, 9 showed no statistically significant findings, the 
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remainder showed a significant increase in risk of death amongst individuals with co-
morbid disease compared to those with TB alone.  
The pooled results showed a statistically significant increase in all cause mortality 
amongst those with concomitant TB and DM compared to those with TB alone (12,128 
participants, 18 trials, RR 1.97 (95% CI 1.53-2.55)).  
Figure 12: Forest plot showing the individual and pooled risk of mortality amongst 
those with TB compared to those with concomitant TB and DM 
 
Sputum and culture clearance at 2-3 months an over 
Data extracted from all studies reporting upon sputum clearance at 2-3 months was 
pooled using a random effects analysis due to the high statistical heterogeneity present 
(I-squared 60.3%). Four of the studies pooled showed no statistically significant 
findings, the remainder showed an increased risk of remaining sputum or culture 
positive amongst individuals with co-morbid disease at 2-3 months after treatment 
initiation when compared to those with TB alone. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 59.9%, p = 0.001)
Centis
Ambrosetti
Ambrosetti
Author
Centis
Oursler
Hasibi
Vasankari
Fischer Hoch
Ponce de Leon
Singla
Chiang
Kourbatova
Wang
Fielder
Dooley
Ambrosetti
Matthew
Bashar
2002
1999
1999
Year
2000
2002
2008
2009
2008
2004
2006
2000
2006
2009
2002
2009
1999
2006
2001
1998
1997
1996
DataCollection
1999
1995
1.97 (1.53, 2.55)
2.64 (1.11, 6.26)
0.39 (0.05, 2.74)
3.25 (1.15, 9.20)
RR (95% CI)
1.64 (0.40, 6.66)
3.43 (1.68, 6.98)
3.67 (1.23, 10.93)
1.49 (0.99, 2.26)
1.07 (0.78, 1.48)
1.33 (0.91, 1.94)
0.90 (0.09, 8.60)
1.40 (1.05, 1.86)
1.26 (0.58, 2.76)
2.28 (1.08, 4.85)
3.10 (1.92, 4.99)
1.82 (0.78, 4.27)
2.38 (0.77, 7.41)
4.54 (2.33, 8.82)
14.70 (1.86, 116.27)
100.00
5.05
1.50
4.02
Weight
2.60
6.22
3.76
9.12
10.04
9.46
1.16
10.40
5.65
5.88
8.44
5.14
3.57
6.62
1.36
%
  
1.05.1 .5 2 8 1632
 
Higher amongst exposed (TB DM) Higher amongst unexposed (TB) 
% 
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The pooled results showed no statistically significant findings (1,675 participants, 6 
trials RR 1.38 (95% CI 0.97-1.97)), although the results tended towards significance 
meaning type II statistical error may be occurring.  
Figure 13: Forest plot showing the individual and pooled risk of failure to clear 
bacteria amongst those with TB compared to those with concomitant TB and DM 
 
Sputum and culture clearance at 6 months 
Only a single study by Alisjahbana et al measured failure to clear bacteria by 6 months 
(treatment completion) they found 28% with DM had not achieved cure at 6 months 
compared to 11% with TB alone not achieving cure. 
Recurrence or relapse 
Data extracted from all studies reporting upon TB recurrence or relapse was pooled 
using a fixed effects analysis as statistical heterogeneity was low (I-squared = 26.2%). 
Of the studies pooled, none identified any statistically significant findings. 
The pooled results also showed no statistically significant findings (1,225 participants, 4 
trials RR 1.20 (95% CI 0.93-1.54)), although the results tended towards significance 
meaning type II statistical error may be occurring.  
NOTE: Weights are from random effects analysis
Overall  (I-squared = 60.3%, p = 0.028)
Author
Singla
Banu-Rekha
Dooley
Tatar
Alisjahbana
Guler
Year
2006
2007
2009
2009
1999 (1997)
2007
1.38 (0.97, 1.97)
RR (95% CI)
1.75 (1.14, 2.69)
0.79 (0.33, 1.88)
1.02 (0.56, 1.85)
1.33 (0.58, 3.04)
0.93 (0.46, 1.90)
2.17 (1.69, 2.78)
100.00
Weight
21.08
10.75
16.43
%
11.39
13.72
26.63
  
1.3 .5 2 4
 
Higher amongst exposed (TB DM) Higher amongst unexposed (TB) 
% 
100 
 
Figure 14: Forest plot showing the individual and pooled risk of TB relapse or 
recurrence amongst those with TB compared to those with concomitant TB and 
DM 
 
 
Overall  (I-squared = 26.2%, p = 0.254)
Fisher Hoch
Subhash
Wang
Author
Singla
2008
2003
2001
Year
2006
1.20 (0.93, 1.54)
1.71 (0.95, 3.10)
1.80 (0.30, 10.69)
1.30 (0.43, 3.97)
RR (95% CI)
0.98 (0.76, 1.26)
100.00
21.99
3.07
9.93
Weight
65.01
%
  
1.2 .3.4 .6 2 4 8 16
Higher amongst exposed (TB DM) Higher amongst unexposed (TB) 
% 
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Chapter 4. Discussion 
4.1 Brief synopsis of research aims and methods 
Diseases can co-occur within populations at either an increased or decreased rate than 
would be expected due to chance given the background frequency of each disease.
2 
Identifying disease associations and dissociations is important as it may lead to the 
advancement of knowledge upon disease sequalae, aetiology and upon differences in 
disease outcome. This in turn can give insights into methods for disease prevention, 
control or management.
2
 
This body of work was initiated to elucidate the association between DM and TB. The 
presence, direction, specificity, and magnitude of any such associations were 
investigated as well as the impact of having co-morbid DM and TB upon TB outcomes. 
The following hypotheses, as previously listed in section 1.5, were addressed utilising a 
quantitative approach: 
 1)  DM is associated with an increased risk of developing TB, PTB and, or, EPTB  
2)  T1DM is associated with an increased risk of developing TB, PTB and, or, EPTB 
3)  T2DM is associated with an increased risk of developing TB, PTB and, or, EPTB  
4)  TB is associated with an increased risk of developing DM, T1DM and, or, T2DM 
5)  PTB is associated with an increased risk of developing DM, T1DM and, or, T2DM 
6)  EPTB is associated with an increased risk of developing DM, T1DM and, or, T2DM 
7)  It is consistently documented that when TB and DM present concomitantly TB 
disease outcomes are significantly poorer 
Secondary data from the ORLS, a regional dataset, and THIN, a national dataset, were 
used to inform retrospective cohort studies which addressed hypotheses 1 to 6. 
Quantitative systematic review techniques were used to address hypothesis 7.  
The Oxford Record Linkage Study (ORLS) is a database containing records of all 
hospital admissions and all deaths (regardless of where they occurred), in defined 
populations within the former Oxford National Health Service Region. It consists of 2 
separate datasets which are not linkable; ORLS1 which covers the years 1963 to 1998 
and ORLS2 which covers the years 1999 to 2008. The Health Improvement Network 
(THIN) is a database containing electronic medical records collected at GP clinics 
throughout the UK. Data was used from the years 2003-2009. 
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Within both databases all patients were classified as exposed to (having had) or 
unexposed to (not having had) TB (all sub-types, PTB or EPTB) and exposed or 
unexposed to DM (all sub-types, T1DM or T2DM).  
In the ORLS1 and ORLS2 datasets, standardised RRs and corresponding 95% CIs were 
calculated and compared for DM (all sub-types, T1DM and T2DM) in individuals who 
have had and have not had TB (all sub-types, PTB or EPTB). Also, the converse, RR 
and 95% CIs were calculated and compared for TB (all sub-types, PTB or EPTB) in 
patients with and without DM (all sub-types, T1DM and T2DM). 
Within THIN datasets, IRRs and 95% CIs of DM (all sub-types, T1DM and T2DM) 
were calculated using negative binomial regression, with TB (all sub-types, PTB or 
EPTB) as an explanatory variable. Also, the converse, IRRs and 95% CIs for TB (all 
sub-types, PTB or EPTB) were calculated using negative binomial regression with DM 
(all sub-types, T1DM or T2DM) as an explanatory variable. 
Systematic searches were completed within Medline and Embase to identify studies 
comparing TB outcomes amongst those with and without DM. Data from these studies 
were utilised to inform meta-analyses that assessed all cause mortality, bacterial 
clearance rate and TB relapse or recurrence rate amongst individuals with DM and co-
morbid TB comparative to those with TB alone. 
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4.2 Discussion of findings 
4.2.1 Analysis of ORLS and THIN data 
Summary of descriptive and univariate statistics 
ORLS1 and ORLS2 
The mean patient age at entry into the exposed cohorts generated in ORLS1 and ORLS2 
was greater than the mean patient age at entry into the unexposed cohorts. Mean age at 
entry into the: DM cohorts was 52 years (ORLS1) and 51 years (ORLS2), TB cohorts 
was 49 years (ORLS1) and 46 years (ORLS2) and into the unexposed, reference cohorts 
was 31 years (ORLS1) and 39 years (ORLS2). As the analyses were standardised by 
age this will have had no bearing upon any of the RR’s calculated however it does 
highlight the association between both the exposure and outcome diseases under study 
and older age. 
In both ORLS datasets the follow-up time in the exposed and unexposed cohorts was 
similar; however, it was much shorter for all cohorts generated within ORLS2 when 
compared to all cohorts generated within ORLS 1. This is due to the substantially 
shorter time period covered by ORLS2 (9 years, 1999 to 2008) compared to that 
covered by ORLS1 (35 years, 1963 to 1998). If the lag time between our exposure and 
outcomes of interest is long, this could potentially affect estimates of risk within the 
ORLS 2 dataset biasing towards the null. 
The number of individuals within the DM cohorts (all subtypes) generated in ORLS1 
and ORLS2 identified as having T2DM (over 30 years old) were much greater than the 
numbers identified as having T1DM (under 30 years old). This is reflective of the rates 
of T1DM comparative to T2DM within the background population. In the UK the 
prevalence of T1DM is 15% whereas the prevalence of T2DM is much higher at 
85%.
229-235
 Within both the ORLS 1 and ORLS 2 datasets, TB prevalence was greatest 
amongst those over 25 years old and was lowest during childhood. This is again 
reflective of the background population rates of TB. In the UK TB incidence is very low 
during childhood with only around 4 cases per 100,000 individuals under the age of 15 
years old being diagnosed each year.
200
  
THIN 
The mean patient ages at entry into the exposed, TB and DM, cohorts generated within 
THIN dataset were comparable to those for the exposed cohorts generated in ORLS1 
and ORLS2. Mean age at entry into the DM cohort was 60 years old and into the TB 
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cohort was 48 years old. Due to the aggregated format of the referent data it was not 
possible to calculate the mean age at entry into the unexposed cohorts generated within 
THIN.  
Mean follow up time for all cohorts generated within THIN database were similar 
ranging from 3.7 to 4.1 years. THIN database covers a 6 year time period from 2003 to 
2009. The mean follow up times in cohorts generated in THIN were similar to those for 
cohorts generated in ORLS2 which covers a comparable time period (9 years, from 
1999 to 2008) but were much shorter than the mean follow up times for cohorts 
generated in ORLS1 which covers a much longer, and more historic time period (35 
years, 1963 to 1998).  
The number of individuals within the constructed THIN T1DM cohort (n=44,874) was 
much smaller than the number of individuals within the T2DM cohort (n=193,929). 
This is most likely due to the higher prevalence of T2DM (85%) comparative to T1DM 
(15%) in the background population and is as would be expected within a sample 
population representative of the UK. The prevalence of DM amongst those under the 
age of 14 years old in THIN dataset (1%) is also representative of the prevalence of DM 
in the UK which is 1% amongst those under the age of 16 years old.
229
 
Within THIN datasets it was found that risk of DM is significantly raised amongst 
males comparative to females, amongst current or past smokers comparative to non-
smokers, and amongst those above the age of 20 years comparative to those aged 20 
years and below. This is representative of DM rates in the general UK population which 
show a male preponderance
229
 and have been found to be associated with older age and 
smoking.
240 241
 
Within THIN datasets it was found that the risk of TB is significantly increased 
amongst current or past smokers comparative to non-smokers and those aged 21-40 
years comparative to those under the age of 20 years old. This is again representative of 
TB rates in the general UK population. In the UK the incidence rates of TB peak 
amongst those aged 20 to 40 years201 and the risk of TB is increased amongst individuals 
who are current or past smokers.
139 205 206
 In the THIN dataset, as elsewhere, it was 
found that the risk of TB is greater amongst those of low SES when compared to those 
of high SES.
229
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Discussion of risk estimates calculated 
DM risk amongst individuals with TB 
The analyses completed in ORLS1 and ORLS2 found no statistically significant 
increases in risk of developing DM (any sub-type, T1DM or T2DM) amongst 
individuals who have had TB (any sub-type, PTB or EPTB) when compared to those 
who have not. This, alongside results for the converse analyses, suggests that the 
association between TB and DM is uni-directional.  
However, within THIN risk of DM was found to be significantly increased amongst 
individuals who have had; TB (IRR 5.651 (95% CI 5.185-6.159, P-value <0.001)), PTB 
(IRR 5.740 (95% CI 5.077-6.490, P-value <0.001)) and EPTB (IRR 4.659 (95% CI 
3.940-5.509, P-value <0.001)) compared to those who have not. Risk of T1DM was 
found to be significantly increased amongst individuals who have had TB (IRR 5.491 
(95% CI 5.019-6.020, P-value <0.001)) and EPTB (IRR 0.843 (95% CI 0.349-2.034, P-
value <0.001)) compared to those who have not. And, risk of T2DM was found to be 
significantly increased amongst individuals who have had; TB (IRR 2.212 (95% CI 
1.684-2.906, P-value <0.001)), PTB (IRR 5.382 (95% CI 4.730-6.124), P-value 
<0.001)) and EPTB (IRR 4.364 (95% CI 3.649-5.218, P-value <0.001)) when compared 
to those who have not.  
No other studies identified in the semi-systematic review have specifically assessed the 
risk of DM amongst those with TB comparative to those without so it is not possible to 
compare findings presented in this thesis directly with the work of others. To put these 
findings in context; it is biologically plausible that the risk of developing DM is 
increased amongst those who have had TB when compared to those who have not. As 
discussed in chapter 1, there are numerous cross sectional studies which have found a 
high prevalence of glucose intolerance amongst individuals with TB.
32 427
  Studies have 
shown induced hyperglycaemia and, or, impaired glucose tolerance occurring during the 
early phases of active TB disease
29-32
 and these metabolic states themselves are linked 
with progression to overt DM amongst 20-50% of individuals after 3 to 5 years.
33-36
 
However, these findings do need to be interpreted cautiously as some studies have noted 
that the hyperglycaemia observed amongst populations of individuals with TB is 
intermittent reversing after the early, acute phase of TB infection.
30 32 37 38
 It could be 
that these observations of hyperglycaemia are due to short term side effects of treatment 
with Rifampicin and Isoniazid
39-41
, or, to stress  hyperglycaemia
42 43
 rather than being 
signs of true metabolic dysfunction and DM. 
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As has been previously outlined Berksonian bias is a type of selection bias; a potential 
problem particularly in hospital-based studies causing identification of spurious 
associations or inflation of risk estimates between diseases or characteristics due to 
differing probabilities of admission for those with the exposure, without the exposure 
and with an outcome of interest. In the work presented within this thesis, to account for 
Berksonian bias and surveillance bias, sensitivity analyses were completed in which 
anyone with; less than 1 year of follow up after their first exposure record, with a record 
of an outcome of interest recorded at the same time as their exposure record, or with a 
record of an outcome of interest within the first year following their exposure record 
was excluded in a case-wise fashion. In THIN these analyses attenuated risk estimates 
slightly but did not alter the statistical significance of the findings. This primarily 
indicates that the increase in risk identified is not an artefact due to different 
probabilities of attendance at a GP’s for those with the outcome, without the outcome 
and with the exposure of interest. However, it also suggests that the cause of the DM 
seen amongst those with TB is unlikely to be due to TB treatment as there would have 
been enough time for treatment ‘wash out’ within the first year of diagnosis. If the DM 
diagnosed amongst those who have had TB was due to a side effect of treatment the 
case exclusion analyses would be expected to show dramatically attenuated risk 
estimates. 
Further exclusion analyses were also completed within the ORLS datasets to assess 
whether utilising exposure and outcome admissions recorded only within the primary 
position on a HES record comparative to those recorded within the secondary position 
or regardless of where recorded had an impact upon effect estimates identified. No 
significant changes were found. 
It is of importance to note that Pseudo R
2
 figures for the models fitted to assess the risk 
of DM amongst those with TB comparative to those without in THIN dataset were very 
low. This suggests that the variables modelled accounted only for a minimal amount of 
the association seen between the variables. This could mean that the increased risk of 
DM amongst those with TB comparative to those without is not truly positive and rather 
is due to unmeasured confounding. If this were the case it would mean that the apparent 
TB to DM association was being overestimated when in truth the exposure has no 
causal effect on the outcome.  
In order to try and further understand these risk estimates, tests for interaction between 
variables included within the THIN models were carried out. The interaction between 
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TB and age was seen to be highly significant. An interaction shows that the combined 
effect of two risk factors in increasing the risk of an outcome of interest is higher than 
the effect of either single factor. An interaction between TB and age could be 
amplifying the effect estimates calculated. Those who have TB and are of an older age 
could be at an increased risk of DM comparative to those with TB and of a younger age. 
This could be because baseline DM risk being higher amongst individuals of an older 
age or because those of an older age have a higher overall risk of developing DM due to 
their greater additive life time risk. 
TB risk amongst individuals with DM 
Within ORLS 1, ORLS2 and THIN a significant increase in TB risk was found amongst 
individuals with DM comparative to those without; (ORLS1 RR 1.77 (95% CI 1.45-
2.15, P-value <0.001)), (ORLS2 RR 2.56 (95% CI 1.78-3.69, P-value <0.001)) and 
(THIN IRR 1.50 (95% CI 1.27-1.76, P-value <0.001)). Effect estimates calculated in 
ORLS1 and THIN are comparable, however, the effect estimate calculated in ORLS2 is 
almost double those. 
Positive findings are in line with the majority of results presented amongst other studies 
which have assessed this association and that were identified in the semi-systematic 
literature review (see section 1.4). An increase in risk of TB amongst those with DM 
comparative to those without was identified in 11 studies (Baker 2012
265
, Brassard 
2006
266
, Chen 2006
27
, Coker 2006
268
, Dobler 2012
269
, Jick 2005
205
, Leung 2008
295
, Mori  
1992
276
, Pablo-Mendez 1997
277
, Perez 2006
278
 and Ponce de Leon 2004
279
). Five of the 
studies identified by the semi-systematic review (Buskin 1994
267
, Dyck
270
, Leegaard 
2011
273
, Marks 2011
95 
and Rosenman 1996
280
) showed no significant change in risk of 
TB amongst those with DM. It is of interest that three of these five studies presented 
positive effect estimates tending towards statistical significance (Dyck
270
, Leegaard 
2011
273
 and Marks 2011
95
), perhaps these studies are suffering from type II statistical 
error. However, all five studies are fairly heterogeneous and it is thus unlikely that they 
are all showing null effect estimates due to a specific anomaly in study design causing 
statistical error and bias.  
Seven studies (Alisjahbana 2006
264
, Farhoult-Jepsen 2011
271
, Goldhaber-Fiebert 2011
90
, 
John 2001
26
, Kim 1995
272
, Shetty 2006
281
 and Wu 2007
282
) found an increase in PTB 
risk amongst those with DM  when compared to those without. A significant increase in 
PTB risk amongst those with DM compared to those without was also found in analyses 
within ORLS1 (RR 1.72 (95% CI 1.22-2.37, P-value = 0.001) and ORLS2 (RR 3.33 
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(95% CI 1.51-6.62, P-value = 0.001). This finding was not replicated within the 
analyses completed in THIN dataset. It should be noted that again the effect estimate 
calculated in ORLS2 is almost double that in ORLS1. 
In ORLS1 the RR of acquiring TB (any sub-type) and PTB amongst individuals with 
DM (any sub-type) compared to those without DM is very similar, (TB RR 1.77 
(95%CI 1.45-2.15, P-value <0.001)) and (PTB RR 1.72 (95% CI 1.22-2.37, P-value = 
0.001)). This is perhaps unsurprising as the majority of TB cases within the UK (over 
80%) will be of PTB
201
 and thus make up the vast majority of people amongst the ‘all’ 
TB group with ‘their’ risk heavily affecting that of the whole group.  
The only study (Leung 2008
295
) identified during semi-systematic review to assess risk 
of EPTB following DM found an increase in risk of EPTB amongst those with 
comparative to those without DM. No significant association between DM status and 
EPTB was found in ORLS1, ORLS2, or THIN. However, in THIN the risk of EPTB 
amongst those with DM comparative to those without tended towards statistical 
significance (IRR 1.434 (95% CI 0.993-2.071, P-value = 0.055)). It should be noted that 
the numbers for these analyses in all datasets were small and thus null findings could 
conceivably be due to bias or type II statistical error.  
Just two studies identified within the semi-systematic literature review specifically 
looked at risk of TB amongst individuals with Type 1 DM comparative to those with no 
DM (Dobler 2012
269
 and Leegaard 2011
273
). These studies showed an increased risk of 
TB amongst those with T1DM comparative to those without, as was found in THIN 
(IRR 1.455 (95% CI 1.104-1.917, P-value = 0.008)). However, in ORLS1 risk of TB 
was not found to be raised amongst those with T1DM comparative to those without. 
The ORLS2 dataset was too small to complete these analyses. Again, it should be noted 
that the numbers for these analyses were very small and null findings could conceivably 
be due to type II statistical error. 
The risk of TB amongst those with T2DM compared to those without was raised in 
ORLS1 (RR 1.58 (95% CI 1.15-2.14, P-value = 0.003)), ORLS2 (RR 3.60 (95% CI 
1.76-6.76, P-value <0.001)) and THIN (IRR 1.536 (95% CI 1.296-1.822, P-value 
<0.001)). Again, the risk estimates in THIN and ORLS1 were comparable whereas the 
estimates calculated in ORLS2 were almost double those.  
Four studies (Alisjahbana 2006
264
, Baker 2012
265
, Leegaard 2011
273
 and Pablos-Mendez 
1997
276
) identified in the semi-systematic review looked at glucose control and how this 
modified estimates of TB risk amongst individuals with DM. All four studies identified 
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an increase in TB risk for those with poor hyperglycaemic control, as judged by HbA1c 
measure or by the number of DM complications an individual had, although no tests for 
trend were completed. Analyses completed within ORLS1, ORLS2 and THIN did not 
directly address this. However, if somewhat naively subtype of DM is taken as a proxy 
for glycaemic control, findings in this thesis do not support the hypotheses that TB is 
more common amongst those with poorer control given that risk estimates for TB are 
fairly stable amongst those with T1DM and T2DM. 
From a public health perspective the association between T2DM and PTB is of most 
interest as approximately 80% of individuals with DM have T2DM and PTB is the most 
prevalent infectious form of TB. In THIN risk of PTB was not raised amongst those 
with T1DM or T2DM when compared to those without. This is to be expected given 
that risk of PTB was not raised amongst those with DM (any sub-type). These analyses 
could not be completed in ORLS1 or ORLS2 due to the datasets relatively small sizes. 
In THIN risk of EPTB was raised amongst those with T1DM comparative to those 
without DM (IRR 2.088 (95% CI 1.190-3.664, P-value = 0.010)) but not amongst those 
with T2DM comparative to without DM. These analyses could not be completed in 
ORLS1 or ORLS2 due to the datasets relatively small sizes. 
Case exclusion, sensitivity analyses were again completed to assess whether effect 
estimates were being altered by either Berksonian or surveillance bias. There was no 
alteration in overall trends identified; however, the exact effect estimates calculated did 
alter slightly. Further exclusion analyses were again completed in the ORLS datasets to 
assess whether utilising exposure and outcome admissions recorded only within the 
primary position on a HES record comparative to those recorded within the secondary 
position or regardless of where recorded had an impact upon effect estimates identified. 
No significant changes were found. Again, due to the exclusion of cases these 
sensitivity analyses contained very small numbers and therefore may be prone to type II 
statistical errors. 
The R-squared values indicative of the relative predictive power of estimating TB risk 
following DM were low for all models constructed in both ORLS and THIN datasets. 
This is likely to be due to the inability to control for potential confounders of the 
association between DM and TB, such as ethnicity, in these analyses.  
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Further comments 
It is interesting to note that the risk of developing TB amongst individuals with DM 
compared to those without was increased both within a ‘historic’ era when TB incidence 
in the UK was high (ORLS1) and within recent times when TB incidence has been 
relatively low (ORLS2 and THIN). This suggests that other risk factors for TB, 
historically present in the UK, do not mask the effect of DM on TB risk.  
Seventeen previously published studies looking at the association between DM and TB 
were completed in high income countries (Baker 2012
265
, Brassard 2006
266
, Buskin 
1994
267
, Chen 2006
27
, Dobler 2012
269
, Dyck 2007
270
, Goldhaber-Fiebert 2011
90
, Jick 
2005
205
, John 2001
26
, Leegaard 2011
273
, Leung 2008
295
, Marks 2011
95
, Mori  1992
276
, 
Pablo-Mendez 1997
277
, Perez 2006
278
, Rosenman 1996
280
 and Wu 2007
282
), five within 
middle income countries (Alisjahbana 2006
264
, Coker 2006
268
, Kim 1995
272
, Ponce de 
Leon 2004
279
 and Shetty 2006
281
), and only one within a low income country (Farhoult-
Jepsen 2011
271
); as specified by the world bank.
413
 Estimations of increased TB risk 
amongst those with comparative to without DM were not systematically effected by a 
countries wealth. However, the impact of the association between DM and TB is likely 
to be most adverse in low income countries due to inherent issues with healthcare 
provision.
366
 Only four of these 23 studies assessed the association between DM and TB 
in areas with high TB incidence and high TB transmission rates; two in India (John 
2001
26
 and Shetty2006
281
), one in Russia (Coker 2006
268
) and one in Tanzania, sub 
Saharan African (Farhoult-Jepsen 2011
271
). These four studies also found an increase in 
TB rate amongst individuals with DM. Given the high TB transmission rates in these 
areas and the projected increases in DM
54
 even a moderate increase in risk of TB 
amongst those with DM compared to those without will have a dramatic public health 
impact over the coming years.
58
 In areas where TB is endemic, TB screening amongst 
those with DM and, or, TB prophylaxis may be needed to reduce or stabilise numbers 
developing active TB. 
HIV, a well-known risk factor for TB, attenuated but did not mask the effect of DM on 
TB risk.
271
 This means that in areas like Tanzania where the prevalence of active TB 
infection is already high in part due to a high HIV prevalence; rising DM rates will 
further exacerbate TB prevalence.
90 
The effects of the association between DM and TB 
will also undoubtedly be further impacted upon in low and middle income countries by 
intertwining risk factors such as high internal migration rates and rapidly increasing 
chronic disease rates whilst some countries still undergo epidemiological transition. 
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Internal migration from rural to urban areas can lead to an increase in DM risk
428
 and 
bring people from an area where TB transmission rates are relatively low to an area 
where they are high, this may confound the association seen between DM and TB.
429
 
The increases in TB rates are likely to be especially pronounced amidst specific 
population sub-groups whose baseline risk of TB and, or, DM is already high such as 
those of Asian ethnicity.
430 431
 Those who have a high baseline risk of both diseases may 
confound the association between DM and TB.  
Strengths and limitations 
Research is often a more pragmatic, iterative process than perhaps would be wished for 
with all bodies of work having inherent strengths and limitations. Some limitations may 
cause undue bias and affect study findings whilst some will have a much more modest 
impact. The key strengths, limitations and plausible affects upon results presented in 
this thesis calculated in analyses utilising ORLS and THIN datasets are now discussed. 
A key strength of the analyses completed using the ORLS and THIN datasets was the 
cohort design which allowed a temporal order between the exposures of interest and the 
outcomes to be established.
389
 This allowed for assessment of the direction of the 
association between TB and DM something which semi-systematic review revealed had 
not been carried out explicitly in prior studies. 
The availability of data and adequacy for use testing specific hypotheses is integral to 
the validity of a retrospective cohort study. Data sources used for work presented within 
this thesis are derived from routine health-care data. Health-care datum are derived from 
established data collection systems and are not normally collected with the aim of 
answering specific questions.
391
 However, this data can be utilised to produce health 
information for administrative, statutory, surveillance, or epidemiological purposes if 
suitable variables of interest have been collated in a non-biased manner.
391
  
Due to the dataset size, and the combination of data available in THIN and the ORLS it 
was possible to investigate the risk associations between DM and TB and, in cases, 
between the sub-types of each disease. As study populations were fixed by the 
population size of each database and the numbers within meeting inclusion criteria 
analysis of the risk associations between the different subtypes of DM and TB was not 
always possible in the smaller ORLS datasets. 
As has been discussed in section 1.4.1 the accurate identification of those who have an 
exposure or outcome of interest is fundamental to making a valid effect size calculation. 
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To re-iterate misclassification is when a study subject is identified as; exposed when 
they are unexposed, as having an outcome of interest when they do not, or, the converse 
of either of these situations.
368-370
 Over or underestimation of those exposed or with an 
outcome of interest can lead to an over or under estimation of effect size dependent 
upon the variable that is misclassified, whether it is dichotomous and the type of 
misclassification that is occurring.
368-370
 Non-differential misclassification is a random 
misclassification of an individual’s exposure status, outcome status or both that is 
independent of their status for any other of these variables. Differential misclassification 
is a non-random misclassification of an individual’s exposure status, outcome status or 
both which is dependent upon an individual's status for at least one other of these 
variables.
368-370
 
In THIN, key variables for TB, PTB, EPTB, DM, T1DM and T2DM were defined using 
a combination of Read codes that were input in to specific fields within relational 
dataset files by GP staff. Inaccuracies in these codes allocated by GP staff due to human 
error may lead to incorrect identification of an individual’s exposure or outcome status 
within the presented analyses. In the ORLS database key variables for TB, PTB, EPTB, 
DM, T1DM and T2DM were defined using ICD codes. In a similar fashion, 
inaccuracies in codes allocated by hospital staff due to human error may lead to issues 
in correctly identifying an individual’s exposure or outcome status within ORLS. 
However, human error whilst coding is likely to occur randomly across all records for 
both exposures and outcomes of interest in a way which does not impact upon 
calculated risk estimates. 
Within THIN, a primary care database, the number of individual’s with a record for DM 
is likely to be accurate due to these individual’s increased interaction with primary 
healthcare. However, it is suspected that codes for TB in THIN may slightly 
underestimate the true incidence of TB as care will mainly be instigated and completed 
by secondary providers and relevant information may not be fed back to primary care 
bodies. This ‘misclassification’ is likely to be occurring in a non-differential manner; 
that is, randomly and irrespective of DM status. If this is the case whether TB is being 
examined as the exposure of interest or the outcome of interest risk estimates may be 
biased towards the null. The ‘worst case scenario’ of this being that findings presented 
in this thesis could have been attenuated so far from the ‘true’ effect size that true 
positive associations have become negative, non-significant and gone undetected. 
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However, rates of TB identified in THIN are comparative to UK rates meaning it is 
unlikely that misclassification is occurring to a great extent. 
Within ORLS, a secondary care database, the number of individual’s with a record for 
TB is likely to be accurate due to the acute nature of the disease and thus their likely 
presentation to secondary care. However, it is suspected that codes for DM may slightly 
underestimate the true incidence. Care for DM will mainly be instigated and completed 
by primary care providers and relevant information on an individual’s health status may 
not be recorded on their secondary care records. This ‘misclassification’ is likely to be 
occurring in a non-differential manner; randomly and irrespective of TB status. If this is 
the case whether DM is being examined as the exposure of interest or the outcome of 
interest risk estimates may be biased towards the null. Findings presented in this thesis 
could have been attenuated so far from the ‘true’ effect size that true positive 
associations have gone undetected. However, rates of DM identified in both ORLS 
databases are comparative to those for the UK population meaning it is unlikely that 
misclassification is occurring to a great extent. Also, no matter where on an individual’s 
health record DM was listed (primary diagnosis code or secondary diagnosis code) 
calculated risk estimates remained fairly stable. 
As previously discussed in section 1.4.1 the ideal way to assess DM and TB status 
amongst study participants would be through the utilisation of standard diagnostic tests 
such as a sputum smear for TB and a FBG measure for DM. Within the ORLS and 
THIN datasets medical records are compiled to give longitudinal data on the health 
events of individuals within specific populations. These longitudinal health event 
records are used in the analyses presented within this thesis to identify those who have 
been clinically diagnosed with either TB or DM. The use of medical records only allows 
for the identification of individuals with disease who have been actively diagnosed and 
will exclude those who have the disease but are, as yet, clinically undiagnosed. Those 
with active TB are unlikely to be undiagnosed due to the acute nature of the disease. 
However, there are likely to be a number of individuals with DM who have the disease 
but are clinically undiagnosed. These individuals are also likely to be misclassified in 
the analyses completed using ORLS and THIN data in a non-differential fashion; 
unlinked to their TB status. In analyses where DM is the exposure of interest, if 
individuals with DM have been misclassified and identified as non-exposed when they 
are indeed exposed the calculated risk estimates may be biased towards the null. In 
analyses where DM is the outcome of interest, if individuals with DM have been 
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misclassified and identified as not having developed the outcome of interest when they 
actually have, as long as misclassification is truly occurring in a non-differential 
manner, risk estimates will also be biased towards the null. In the worst case scenario 
risk estimates may have been attenuated so far that true positive associations are now 
negative or non-significant and go undetected. It is impossible to identify those who are 
undiagnosed but have DM without carrying out prospective diagnostic tests.  
Over time the standard diagnostic guidelines for DM have become more sensitive.
212
 In 
1980 WHO guidance was for a positive DM diagnosis if FBG was equal to or above 
8.0mmol/l, in 1985 if FBG was equal to or over 7.8mmol/l, and in 1999 if FBG was 
equal to or above 7.0mmol/l.
212
 THIN and the ORLS2 datasets only hold health records 
documented after the most recent change (in 1999) to clinical diagnostic cut-points for 
DM. However, ORLS1 contains health records documented throughout a period 
(January 1st 1963 to December 31st 1999) during which clinical diagnostic cut-points 
for the identification of individuals with DM changed twice. This means that the 
incidence of DM codes in the ORLS1 database from 1963 to 1980 and from 1981 to 
1998, which were allocated using diagnostic criteria contemporary at the time, will be 
an underestimate of incidence as would be calculated using todays diagnostic criteria. 
This will be the case to a lesser extent for each time period as diagnostic criteria became 
increasingly sensitive. This may have caused some misclassification of those who are 
exposed as unexposed in the earlier time periods covered by ORLS1. However, this will 
be occurring in a non-differential manner, irrespective of TB status. In analyses 
completed using data from ORLS1 with DM as the outcome or the exposure of interest 
risk estimates may have been biased towards the null. This means that risk estimates 
presented in this thesis may be underestimating associations, in a ‘worst case scenario’ 
to a point at which a true association becomes negative, non-significant and goes 
undetected. 
It is not possible to distinguish individuals who have T1DM from those who have 
T2DM using codes in ICD 7, 8 or 9; these ICD versions were used within the ORLS1 
and ORLS2 databases when they were contemporary to classify health events as they 
occurred. It is thus not possible to identify those with T1DM or T2DM prior to the use 
of ICD 10 (1994) without the use of a proxy variable. In order to be able to select for 
T1DM and T2DM as outcomes or exposures of interest in the analyses completed 
utilising data from the ORLS databases age was used as an approximate variable for 
disease sub-type. In westernised countries in particular the mean age at onset of T2DM 
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is decreasing. It is thus plausible that a number of individuals with T2DM have been 
misclassified as having T1DM. This misclassification is unlikely to have occurred in a 
differential manner (in association with TB status). In analyses where T1DM and 
T2DM are exposures of interest misclassification of individuals as unexposed when 
they are actually exposed will lead to an attenuation of calculated risk estimates as will 
misclassification of individuals as exposed when they are unexposed. If this 
misclassification is occurring, within completed analyses, in a worst case scenario 
positive associations may have been falsely identified as null findings. However, as 
T1DM and T2DM rates in ORLS1 and ORLS2 are representative of rates for the UK it 
is unlikely misclassification is occurring to a great extent. 
Alongside bias due to misclassification another potential source of bias in all cohort 
studies is disproportionate losses to follow-up amongst the exposed and unexposed 
groups.
389
 In the studies completed within this thesis individual’s in open cohorts 
constructed in ORLS1, ORLS2 or THIN were; at risk of death, able to migrate into or 
out of the study population, and were able to refuse to allow continued use of their 
health data. If losses to follow-up were related to the exposure, outcome or both then 
calculated effect estimates would potentially have been biased.
389
 However, if the loss 
to follow up was random, meaning that the average characteristics of those ‘lost’ in 
either the exposed or unexposed group were similar to those who remained in either 
group, no bias would have been introduced.
389
 There are no losses to follow up thought 
to have occurred in any of the datasets in a systematic fashion which would have 
affected risk estimates presented. As with all healthcare datasets, changes in 
geographical boundaries may contribute to fluctuations in data within THIN and the 
ORLS databases. Within THIN this should be accounted for by comparative changes in 
the denominator population. For the ORLS there is no true denominator population 
however the use of a referent cohort as a comparator should compensate for any 
migration into or out of the ORLS datasets or fluctuations in geographic boundaries.  
Both the ORLS databases and, to a lesser extent, THIN database lacked information 
upon possible confounding factors for the association between DM and TB. 
Confounders are variables which are not causal themselves but distort the effect or 
association between an exposure and outcome either away from or towards the null.
389
 
Although age, sex and district of residence are controlled for in ORLS analyses and age, 
sex, SES and smoking status within THIN analyses it was not possible to account for; 
alcohol intake, BMI, ethnicity, and sedentary behaviour.  
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Individuals with specific characteristics will have an increased baseline risk of TB and, 
or, DM and when not controlled for could potentially confound risk estimates. Those of 
Asian or African ethnic background have an increased risk of developing TB
430
 and of 
developing DM.
430 431
 Heavy alcohol intake increases an individual’s risk of TB by 
almost 3 fold and increases DM incidence by 43%.
432 433
 
Increasing BMI and sedentary behaviour are associated with an increase in DM risk that 
can be reversed if risk factors are reversed.
434
 Due to the acute nature of active TB 
individuals will often become sedentary and, once on treatment, will see a rapid 
increase in weight.  
It could be argued that SES and ethnicity are accounted for within the ORLS analyses 
due to the population covered who live mainly in market towns, rural areas or relatively 
small conurbations like Oxford, Reading and Northampton which are affluent and 
healthy, compared with the English national average. Of the people in the ORLS1 
dataset, 55% were born in the Oxford Region itself and 94% in the British Isles 
(equivalent data not available for ORLS2) leaving small scope for confounding by 
ethnicity. Also, other work has found this risk factor to have little effect upon estimates 
of the association.
435
 
Data upon ethnicity could have been imputed into THIN datasets however methods 
used for similar datasets (Q-Research) have been somewhat arbitrary assuming that all 
of those with missing data are of ‘white British’ origin.436 There was no a-priori data on 
the pattern of missing-ness for ethnicity data within THIN dataset which would have 
allowed for improved imputation and creation of a proxy ethnicity variable. As such, 
imputation was not completed as it was deemed unlikely to significantly increase the 
validity of risk estimates. 
Completing the analyses of interest within both a national UK (THIN) and regional 
database (ORLS) allowed for a validation of analyses in a geographically and 
temporally different, but related study population. Results that have been validated 
within this way are considered to provide stronger evidence upon the hypotheses tested 
if consistency between results is identified. Confidence that an exposure of interest is 
causing a specific outcome is strengthened when several studies give the same result, in 
particular when the same results are seen across studies that are heterogeneous in design 
and setting.
389
 Some, but not all of the results found within ORLS and THIN analyses 
showed consistency. A lack of consistency does not rule out the presence of an 
association between an exposure and outcome as within different studies different 
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exposure levels and other unknown conditions may reduce the impact of the causal 
factor under investigation.
389
 
Analyses within THIN and the ORLS add to a relatively small evidence base, with 
which our finding that DM leads to an increased risk of TB is consistent. This is only 
the second study upon the association to addresses its magnitude within a 
predominantly ‘white British’ population. Work completed within the ORLS and THIN 
is novel in that it assesse the direction of the association and interactions between 
disease sub-types. Further work needs to be completed in order to clarify these findings. 
Conclusions 
It remains unclear if having had TB disease increases an individual’s risk of developing 
DM. Results presented within this thesis are inconsistent and further research is needed 
in order to validate or refute the findings. 
There is now a growing body of research to show that having DM leads to an increased 
risk of developing TB. Although it remains unclear if this association is specific to 
certain TB and DM sub-types, initial evidence suggests that the association is not sub-
type specific. 
4.2.2 Addressing hypotheses 7; Systematic review of TB outcomes 
It was estimated that globally between 150 and 171 million people had DM in 2000 and,  
as is projected for the UK, the global prevalence of DM is expected to dramatically 
increase by 2030.
46 51 54
 Alongside the epidemic proportions of individuals with DM 
over a third of the global population are latently infected with TB.
55
 In 2010 there were 
8.8 million active disease episodes and 1.45 million deaths attributable to TB 
worldwide.
56
 Given these figures, and the findings within this thesis which show that 
DM causes an increase in risk of developing TB, it is plausible that a substantial 
proportion of new TB cases will be amongst individuals with DM.
47 57 58
 It has been 
estimated that up to 20.2% of incident TB will be attributable to DM.
57 58 130 
 
Identifying whether there are any implications for individuals who have these diseases 
concurrently is important for clinical guidance and practice. In particular, it is important 
to know whether and if so how clinically relevant TB outcomes such as sputum 
clearance rate and mortality are affected.
59-62
 These questions were addressed utilising 
systematic review techniques.  
A search strategy identified 1,868 papers for title and abstract review. Once reviewed by 
two independent investigators 116 publications were identified for full review. After 
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full review by at least 2 of 3 independent investigators 25 studies were identified as 
including relevant data for extraction and analysis.  
The majority of these 25 studies were retrospective cohort studies undertaken utilising 
data from high income countries with DM cases ascertained utilising MRR and TB 
status ascertained using microbiological diagnostic techniques. 
Risk estimates 
Using quantitative systematic review techniques it was found that failure to become 
sputum or culture negative after 3 months was not increased amongst individuals with 
DM and TB comparative to those with TB alone, although the results bordered upon 
statistical significance (OR 1.38 (95%CI 0.97-1.97)). There was also no statistically 
significant increase in the risk of TB relapse or recurrence amongst those with co-
morbid DM and TB when compared to those with TB alone (OR 1.20 (95%CI 0.93-
1.54)). Again the results bordered upon statistical significance. However, risk of death 
(OR 1.97 (95%CI 1.53-2.55)) was significantly increased almost 2 fold amongst 
individuals with co-morbid DM and TB comparative to those with TB alone. As this 
pooled effect estimate is for all cause mortality it is not known if the increased risk of 
death is from TB disease or other causes. It could simply be indicative of the poorer 
underlying health of individuals who present with co-morbid disease or of the increased 
age of individuals in this group.  
There is another systematic review that addresses similar research questions to our 
own.
121
 This review identified a further 8 studies, all non-English language. Data 
extracted upon TB outcomes differed somewhat in the review by Baker et al compared 
to the one presented within this thesis and as such, so did the data that was pooled in the 
meta-analyses.
121
 Data in the review by Baker et al was extracted on; sputum 
conversion rates at 2-3 months after treatment initiation, relapse, failure and death 
during TB treatment, death during TB treatment and drug resistant, recurrent disease.
121
 
The data extracted on sputum conversion was not pooled in the review by Baker et al 
meaning there is no figure for comparison with the results in this thesis.
121
  
In the review by Baker et al no association was found between DM status and drug 
resistant, recurrent disease. This was not explored by the review completed for this 
thesis.
121
 
Baker et al found TB relapse was significantly increased amongst those with DM 
comparative to those without DM, (RR 3.89 (95% CI 2.43-6.23)).
121
 However, results 
from the review presented in this thesis found no significant association between DM 
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status and TB relapse. Pooled risk estimates in this thesis contained data from a smaller 
number of studies, and thus had a smaller number of overall participants in each ‘study 
arm’. This could be causing type II statistical error and might explain the difference in 
results between the two reviews, especially as pooled estimates presented in this thesis 
tend towards statistical significance (OR 1.20 (95%CI 0.93-1.54)).  
Baker et al identified a significant increase in failure and death amongst those with 
comparative to without DM (RR 1.69 (95% CI 1.36-2.12)).
121
 Within this thesis TB 
failure was not assessed, only relapse and recurrence. Baker et al also found an increase 
in death during TB treatment amongst those with DM comparative to without (RR 1.89 
(95% CI 2.43-6.23)).
121
 An increase in all cause mortality throughout study follow up 
was found by the review presented within this thesis (OR 1.97 (95%CI 1.53-2.55)). It is 
surprising to note, that although the outcome definitions utilised for ‘death’ between the 
two reviews are very different, the pooled effect estimates are very similar.
121
 
Further comments, strengths and limitations 
To carry out primary analysis assessing the outcomes of TB amongst those with and 
without DM would require significant research resources. A review of literature is 
relatively cheap and allows for the objective assessment of the effect of DM upon TB 
outcomes through the appraisal of secondary data through the utilisation of quantitative 
systematic review and meta-analytic techniques. 
Although it is believed that a robust, sensitive search strategy was employed to identify 
relevant studies for inclusion within the systematic review it is plausible, due to the 
disparate nature of the studies being reviewed, that articles containing pertinent data 
were missed. Relevant data upon TB outcomes amongst those with DM in published 
papers was often incidental to the main focus of the study meaning that DM went 
unmentioned within the abstract or title. Thus, these articles are unidentifiable from a 
database search utilising a strategy developed to identify studies on DM. However, 
comparing search results for the candidates review to that by Baker et al it can be seen 
that use of an alternative search strategy did not initially identify a greater number of 
papers.
121
 
Inherent to the method, findings of a systematic review are only as robust as those of the 
individual studies from which data is extracted. Given this, it is important to note that 
many of the publications contributing to this review would be classed as ‘low’ or ‘poor 
quality’ and as such interpretation of findings and conclusions drawn from the review 
should be adequately tempered. Of particular note is the fact that the majority of studies 
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included in the review identified cases using non-standard diagnostic measures. This 
may lead to an underestimation of exposure levels in studies giving attenuated risk 
measures and as such an attenuated pooled risk estimate. 
The review presented within this thesis, as has been mentioned, included 8 less papers 
in final full review than the systematic review by Baker et al. The missing papers were 
all non -English language papers excluded due to the two reviews differing exclusion 
criteria. Within the citations returned for the systematic review, as for the semi-
systematic review, there were a large number of Japanese publications which when 
reviewing titles looked likely to be of relevance. If exclusion criteria leads to the 
exclusion of pertinent data a reviews findings can be seriously affected. However, it is 
interesting to note that although the exclusion of non-English language papers had a 
large effect upon the number of identified studies the effect upon the overall pooled risk 
estimates for death was actually quite minimal; Baker et al (RR 1.89 (95% CI 2.43-
6.23))
121
 comparative to thesis results (OR 1.97 (95%CI 1.53-2.55)).  
Pooled risk estimates for all cause mortality are likely to be effected by loss to follow 
up bias within the cohort studies contributing data to the meta-analysis. Of the studies 
found only one used statistical survival analyses techniques which are able to account 
for variant follow up time in their risk estimations. However this study did show an 
increased risk of mortality amongst those with DM and TB comparative to those with 
TB alone.
421
  
As all cause mortality rather than TB specific mortality was assessed (the latter being 
uncommonly reported amongst the identified literature) the increase in risk estimate 
may be reflective of the higher baseline risk of death amongst those with DM, or, the 
older age of those with DM associated TB. 
The increased number of papers identified by Baker et al
121
 for final review yielded a 
larger sample size allowing analysis upon an increased number of outcomes 
comparative to the review in this thesis and allowed further sub-group analysis for 
validation of their meta-analytic findings. 
It is difficult to identify the difference between TB recurrence events and TB relapse 
events as although they are biologically different, they are clinically similar. In the 
studies identified by systematic review individual measures presented are probably a 
combination of both events. Thus, TB recurrence and relapse were combined into a 
single outcome when calculating pooled risk estimates. This should be noted when 
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interpreting this data as findings cannot necessarily be inferred to each separate event 
(recurrence or relapse).  
Conclusions 
Risk of death is increased amongst individuals with co-morbid DM and TB almost two 
fold comparative to those with TB disease alone. However, there are no statistically 
significant associations between the risk of TB treatment failure or TB relapse amongst 
individuals with co-morbid TB and DM comparative to those with TB disease alone.  
4.2.3 Plausible immunological pathways  
Given the findings presented from work in both THIN and ORLS it is interesting to 
think about the plausible biological pathways that may cause an individual with DM to 
be at an increased risk of developing TB comparative to an individual without DM.  
DM is known to cause immune dysfunction and moderate suppression of the immune 
system.
437 438
 There is research to suggest that DM affects innate immune function such 
as the production of antimicrobial peptides which are known to be active in the URT in 
stopping initial TB infection.
439
 
More specifically DM is known to hinder cell mediated immunity and has been 
associated with decreased levels of leucocytes, polymorphonuclear neutrophils (PMNs) 
and a decreased T-helper 1 (Th1) cytokine response in reaction to TB.
438 440 441
 PMNs 
produce cytokines and carry out phagocytosis.
442
  
Th1 type cytokines are vital in the control and inhibition of TB, for example, IFN- is 
important for combating microbial infection and both IFN- and TNFα, another Th1 
cytokine attack TB via the activation of macrophages.
155 440-442
 Activated macrophages 
release reactive oxygen species (ROS) and free radicals such as Nitric Oxide which are 
essential for the control of infection, including TB infection.
441 442
 Not only are 
macrophages the primary site of TB infection but they also instigate the main immune 
response to TB.
28 155
 Individuals with DM show strongly reduced non-specific IFN-  
production.
443
 With a lower production of IFN- and interleukin (IL) 12 being seen in 
diabetic animal models during early TB infection when compared to levels during early 
infection in non-diabetic models.
444 445
 
Also individuals with DM have inhibited macrophage function, with decreased 
production of ROS and decreased phagocytic and chemotactic functions.
252 440 441 
 
Specifically alveloar macrophages in active TB patients with co-morbid DM have been 
identified as being less active.
446
 All of which as stated are important for TB clearance. 
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In human plasma studies, high levels of insulin have been shown to promote a decrease 
in Th1 immunity through a reduction in the number of Th1 cells and the levels of IFN-y 
and IL 4. These studies suggest immune modulation in individuals with DM as a highly 
plausible mechanism for the association seen between DM and TB.
443 447
 
Results from work completed within THIN showed that an individual who has had TB 
may have a higher risk of developing DM comparative to an individual who has not had 
TB. The inflammation caused by IL 6, and TNFα whilst modulating a response to TB 
infection could cause a decrease in insulin production by raising levels of beta cell 
destruction thus causing an increase in blood glucose.
448
 Also, as has already been 
discussed TB medications such as Isoniazid have been shown to have hyperglycaemic 
effects.
40
  
4.2.4 Further work 
Further research is still needed to clarify the specificity and direction of the association 
between TB and DM. Further research is needed into whether risk of developing DM is 
increased amongst those who have had an active TB infection comparative to those who 
have not in order to validate evidence presented and inform upon the complexity of the 
association and its aetiological importance.  
It is thought that environmental triggers such as viral and bacterial infection, or 
nutritional factors can elicit an autoimmune
 
process in individuals genetically 
predisposed to developing T1DM.
215
 This may also hold true for T2DM, however 
associations between infection and DM are not well understood and findings from this 
work do not make this clearer. Further investigation of TB as an infectious risk factor 
for DM is needed alongside current work upon the role of viruses such as; the 
herpesvirus8 and the entero-viruses. 
The effect of key confounders upon the association remains poorly understood. 
Although newer studies have begun to look at the role of variables such as; BMI, 
ethnicity, smoking status and HIV, further work is necessary to build a clear picture of 
the competing factors involved in both TB and DM risk.   
With a plausibly large number of individuals presenting with both DM and TB, and this 
number likely to increase as DM prevalence rises the implications of co-morbidity need 
to be addressed.
47 57 58
 There is a need for appropriate clinical guidance for this specific 
group of individuals allowing for good clinical practice and better disease outcomes.  
 124 
 
As rates of DM increase
23
 the incidence of TB may also increase. Publication by 
Goldhaber-Fiebert et al showed that this has already begun to occur in numerous 
countries.
90
 The prevention of DM associated TB will become increasingly important 
and presents a major public health challenge both in the UK and globally.  
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Appendices  
Appendix A: Breslow and Day Methodology for the Calculation of Rate 
Ratio’s 
For comparison between two levels of exposure, exposed (k = 2) and unexposed (k = 1) 
utilising these pre-programmed methods. Where 01 was regarded as a Poisson variable 
with mean     
  and 02 as Poisson variable with mean     
 . With θ set equal to θl, Ψ = 
Ψ2 = θ2/θ1, and θΨ = θ2, the parameter of interest is the rate ratio Ψ, with θ playing the 
role of a nuisance parameter that interferes with our inferences concerning Ψ. Thus if 
the maximum likelihood estimate of π is  ̂=02/0+ it follows that the maximum 
likelihood estimate of Ψ is as depicted in equation 1. 
Equation 2  
 ̂ = 
 ̂ ̂ 
 
    ̂  ̂ 
  = 
    
 
    
  
Taken from equation 3.8 from Statistical methods in cancer research volume II: The design and 
analysis of cohort studies, Breslow and Day
404
 
Exact 100(1-α)% confidence limits for  may be calculated using the binomial 
parameters πL and πU calculated from equation 2 and 3 where    ⁄  (µ1, µ2) denotes the 
upper     
 ⁄
percentile of the F distribution with µ1 and µ2 degrees of freedom.  
 
Equation 3 and 4            
πL = 
  
            ⁄
           
 
and 
πU = 
         ⁄
           
            ⁄
           
 
Taken from equation 3.9 from Statistical methods in cancer research volume II: The design and 
analysis of cohort studies, Breslow and Day
404
  
Then substitute πL and πU into equation 4 to calculate the CIs for the rate ratio. 
Equation 5 
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Taken from equation 3.6 from Statistical methods in cancer research volume II: The design and 
analysis of cohort studies, Breslow and Day
404
 
Then equation 5 can be used to approximate chi-square statistic based on the observed 
deviation of 02 from its expected where we have used the fact that Var (02) is as defined 
in equation 6.  
Equation 6       
χ2 = 
{|        | 
 
 
}
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}
 
 ̂ 
  
Taken from text of Statistical methods in cancer research volume II: The design and analysis of 
cohort studies, Breslow and Day
404
 
Equation 7   
Var (02) = 0+π0(l-π0) =  ̂ 
  ̂ 
 /( ̂ 
   ̂ 
 ) and 01- ̂ 
 =-(02- ̂ 
 ) 
Taken from equation 3.7 from Statistical methods in cancer research volume II: The design and 
analysis of cohort studies, Breslow and Day
466
  
Then using the appropriate software function (probchi(…)) the p value can be 
calculated. 
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Appendix C: DM Read Codes 
Read Code Description 
C100000 Diabetes mellitus, juvenile type, no mention of complication 
C101000 Diabetes mellitus, juvenile type, with ketoacidosis 
C102000 Diabetes mellitus, juvenile type, with hyperosmolar coma 
C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma 
C104000 Diabetes mellitus, juvenile type, with renal manifestation 
C105000 Diabetes mellitus, juvenile type, + ophthalmic manifestation 
C106000 Diabetes mellitus, juvenile, + neurological manifestation 
C107000 Diabetes mellitus, juvenile +peripheral circulatory disorder 
C108.00 Insulin dependent diabetes mellitus 
C108.11 IDDM-Insulin dependent diabetes mellitus 
C108.12 Type 1 diabetes mellitus 
C108.13 Type I diabetes mellitus 
C108000 Insulin-dependent diabetes mellitus with renal complications 
C108011 Type I diabetes mellitus with renal complications 
C108012 Type 1 diabetes mellitus with renal complications 
C108100 Insulin-dependent diabetes mellitus with ophthalmic comps 
C108111 Type I diabetes mellitus with ophthalmic complications 
C108112 Type 1 diabetes mellitus with ophthalmic complications 
C108200 Insulin-dependent diabetes mellitus with neurological comps 
C108211 Type I diabetes mellitus with neurological complications 
C108212 Type 1 diabetes mellitus with neurological complications 
C108300 Insulin dependent diabetes mellitus with multiple complications 
C108311 Type I diabetes mellitus with multiple complications 
C108312 Type 1 diabetes mellitus with multiple complications 
C108400 Unstable insulin dependent diabetes mellitus 
C108411 Unstable type I diabetes mellitus 
C108412 Unstable type 1 diabetes mellitus 
C108500 Insulin dependent diabetes mellitus with ulcer 
C108511 Type I diabetes mellitus with ulcer 
C108512 Type 1 diabetes mellitus with ulcer 
C108600 Insulin dependent diabetes mellitus with gangrene 
C108611 Type I diabetes mellitus with gangrene 
C108612 Type 1 diabetes mellitus with gangrene 
C108700 Insulin dependent diabetes mellitus with retinopathy 
C108711 Type I diabetes mellitus with retinopathy 
C108712 Type 1 diabetes mellitus with retinopathy 
C108800 Insulin dependent diabetes mellitus - poor control 
C108811 Type I diabetes mellitus - poor control 
C108812 Type 1 diabetes mellitus - poor control 
C108900 Insulin dependent diabetes maturity onset 
C108911 Type I diabetes mellitus maturity onset 
C108912 Type 1 diabetes mellitus maturity onset 
C108A00 Insulin-dependent diabetes without complication 
C108A11 Type I diabetes mellitus without complication 
C108A12 Type 1 diabetes mellitus without complication 
C108B00 Insulin dependent diabetes mellitus with mononeuropathy 
C108B11 Type I diabetes mellitus with mononeuropathy 
C108B12 Type 1 diabetes mellitus with mononeuropathy 
C108C00 Insulin dependent diabetes mellitus with polyneuropathy 
C108C11 Type I diabetes mellitus with polyneuropathy 
C108C12 Type 1 diabetes mellitus with polyneuropathy 
C108D00 Insulin dependent diabetes mellitus with nephropathy 
C108D11 Type I diabetes mellitus with nephropathy 
C108D12 Type 1 diabetes mellitus with nephropathy 
C108E00 Insulin dependent diabetes mellitus with hypoglycaemic coma 
C108E11 Type I diabetes mellitus with hypoglycaemic coma 
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C108E12 Type 1 diabetes mellitus with hypoglycaemic coma 
C108F00 Insulin dependent diabetes mellitus with diabetic cataract 
C108F11 Type I diabetes mellitus with diabetic cataract 
C108F12 Type 1 diabetes mellitus with diabetic cataract 
C108G11 Type I diabetes mellitus with peripheral angiopathy 
C108G12 Type 1 diabetes mellitus with peripheral angiopathy 
C108H00 Insulin dependent diabetes mellitus with arthropathy 
C108H11 Type I diabetes mellitus with arthropathy 
C108H12 Type 1 diabetes mellitus with arthropathy 
C108J11 Type I diabetes mellitus with neuropathic arthropathy 
C108J12 Type 1 diabetes mellitus with neuropathic arthropathy 
C10E.00 Type 1 diabetes mellitus 
C10E.11 Type I diabetes mellitus 
C10E.12 Insulin dependent diabetes mellitus 
C10E000 Type 1 diabetes mellitus with renal complications 
C10E011 Type I diabetes mellitus with renal complications 
C10E012 Insulin-dependent diabetes mellitus with renal complications 
C10E100 Type 1 diabetes mellitus with ophthalmic complications 
C10E111 Type I diabetes mellitus with ophthalmic complications 
C10E112 Insulin-dependent diabetes mellitus with ophthalmic comps 
C10E200 Type 1 diabetes mellitus with neurological complications 
C10E211 Type I diabetes mellitus with neurological complications 
C10E212 Insulin-dependent diabetes mellitus with neurological comps 
C10E300 Type 1 diabetes mellitus with multiple complications 
C10E311 Type I diabetes mellitus with multiple complications 
C10E312 Insulin dependent diabetes mellitus with multiple complications 
C10E400 Unstable type 1 diabetes mellitus 
C10E411 Unstable type I diabetes mellitus 
C10E412 Unstable insulin dependent diabetes mellitus 
C10E500 Type 1 diabetes mellitus with ulcer 
C10E511 Type I diabetes mellitus with ulcer 
C10E512 Insulin dependent diabetes mellitus with ulcer 
C10E600 Type 1 diabetes mellitus with gangrene 
C10E611 Type I diabetes mellitus with gangrene 
C10E612 Insulin dependent diabetes mellitus with gangrene 
C10E700 Type 1 diabetes mellitus with retinopathy 
C10E711 Type I diabetes mellitus with retinopathy 
C10E712 Insulin dependent diabetes mellitus with retinopathy 
C10E800 Type 1 diabetes mellitus - poor control 
C10E811 Type I diabetes mellitus - poor control 
C10E812 Insulin dependent diabetes mellitus - poor control 
C10E900 Type 1 diabetes mellitus maturity onset 
C10E911 Type I diabetes mellitus maturity onset 
C10E912 Insulin dependent diabetes maturity onset 
C10EA00 Type 1 diabetes mellitus without complication 
C10EA11 Type I diabetes mellitus without complication 
C10EA12 Insulin-dependent diabetes without complication 
C10EB00 Type 1 diabetes mellitus with mononeuropathy 
C10EB11 Type I diabetes mellitus with mononeuropathy 
C10EB12 Insulin dependent diabetes mellitus with mononeuropathy 
C10EC00 Type 1 diabetes mellitus with polyneuropathy 
C10EC11 Type I diabetes mellitus with polyneuropathy 
C10EC12 Insulin dependent diabetes mellitus with polyneuropathy 
C10ED00 Type 1 diabetes mellitus with nephropathy 
C10ED11 Type I diabetes mellitus with nephropathy 
C10ED12 Insulin dependent diabetes mellitus with nephropathy 
C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma 
C10EE11 Type I diabetes mellitus with hypoglycaemic coma 
C10EE12 Insulin dependent diabetes mellitus with hypoglycaemic coma 
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C10EF00 Type 1 diabetes mellitus with diabetic cataract 
C10EF11 Type I diabetes mellitus with diabetic cataract 
C10EF12 Insulin dependent diabetes mellitus with diabetic cataract 
C10EG00 Type 1 diabetes mellitus with peripheral angiopathy 
C10EG11 Type I diabetes mellitus with peripheral angiopathy 
C10EH00 Type 1 diabetes mellitus with arthropathy 
C10EH11 Type I diabetes mellitus with arthropathy 
C10EH12 Insulin dependent diabetes mellitus with arthropathy 
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy 
C10EJ11 Type I diabetes mellitus with neuropathic arthropathy 
C10EK00 Type 1 diabetes mellitus with persistent proteinuria 
C10EK11 Type I diabetes mellitus with persistent proteinuria 
C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria 
C10EL11 Type I diabetes mellitus with persistent microalbuminuria 
C10EM00 Type 1 diabetes mellitus with ketoacidosis 
C10EM11 Type I diabetes mellitus with ketoacidosis 
C10EN00 Type 1 diabetes mellitus with ketoacidotic coma 
C10EN11 Type I diabetes mellitus with ketoacidotic coma 
C10EP00 Type 1 diabetes mellitus with exudative maculopathy 
C10EP11 Type I diabetes mellitus with exudative maculopathy 
C10EQ00 Type 1 diabetes mellitus with gastroparesis 
C10y000 Diabetes mellitus, juvenile, + other specified manifestation 
C10z000 Diabetes mellitus, juvenile type, + unspecified complication 
C107300 IDDM with peripheral circulatory disorder 
C108G00 Insulin dependent diab mell with peripheral angiopathy 
C108J00 Insulin dependent diab mell with neuropathic arthropathy 
C10EG12 Insulin dependent diab mell with peripheral angiopathy 
C10EJ12 Insulin dependent diab mell with neuropathic arthropathy 
L180500 Pre-existing diabetes mellitus, insulin-dependent 
ZRbH.00 Perceived control of insulin-dependent diabetes 
ZC2C900 Dietary advice for type I diabetes 
ZC2C911 Diet advice for insulin-dependent diabetes 
66Ag.00 Insulin needles changed daily 
66Ah.00 Insulin needles changed for each injection 
66AH000 Conversion to insulin 
66Aj.00 Insulin needles changed less than once a day 
66Am.00 Insulin dose changed 
66Ap.00 Insulin treatment initiated 
7L10000 Continuous subcutaneous infusion of insulin 
7L19800 Subcutaneous injection of insulin 
66A5.00 Diabetic on insulin 
66AA.11 Injection sites - diabetic 
66An.00 Diabetes type 1 review 
C100011 Insulin dependent diabetes mellitus 
C100100 Diabetes mellitus, adult onset, no mention of complication 
C100112 Non-insulin dependent diabetes mellitus 
C101100 Diabetes mellitus, adult onset, with ketoacidosis 
C102100 Diabetes mellitus, adult onset, with hyperosmolar coma 
C103100 Diabetes mellitus, adult onset, with ketoacidotic coma 
C104100 Diabetes mellitus, adult onset, with renal manifestation 
C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation 
C106100 Diabetes mellitus, adult onset, + neurological manifestation 
C107100 Diabetes mellitus, adult, + peripheral circulatory disorder 
C107200 Diabetes mellitus, adult with gangrene 
C109.00 Non-insulin dependent diabetes mellitus 
C109.11 NIDDM - Non-insulin dependent diabetes mellitus 
C109.12 Type 2 diabetes mellitus 
C109.13 Type II diabetes mellitus 
C109000 Non-insulin-dependent diabetes mellitus with renal comps 
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C109011 Type II diabetes mellitus with renal complications 
C109012 Type 2 diabetes mellitus with renal complications 
C109100 Non-insulin-dependent diabetes mellitus with ophthalm comps 
C109111 Type II diabetes mellitus with ophthalmic complications 
C109112 Type 2 diabetes mellitus with ophthalmic complications 
C109200 Non-insulin-dependent diabetes mellitus with neuro comps 
C109211 Type II diabetes mellitus with neurological complications 
C109212 Type 2 diabetes mellitus with neurological complications 
C109300 Non-insulin-dependent diabetes mellitus with multiple comps 
C109311 Type II diabetes mellitus with multiple complications 
C109312 Type 2 diabetes mellitus with multiple complications 
C109400 Non-insulin dependent diabetes mellitus with ulcer 
C109411 Type II diabetes mellitus with ulcer 
C109412 Type 2 diabetes mellitus with ulcer 
C109500 Non-insulin dependent diabetes mellitus with gangrene 
C109511 Type II diabetes mellitus with gangrene 
C109512 Type 2 diabetes mellitus with gangrene 
C109600 Non-insulin-dependent diabetes mellitus with retinopathy 
C109611 Type II diabetes mellitus with retinopathy 
C109612 Type 2 diabetes mellitus with retinopathy 
C109700 Non-insulin dependent diabetes mellitus - poor control 
C109711 Type II diabetes mellitus - poor control 
C109712 Type 2 diabetes mellitus - poor control 
C109900 Non-insulin-dependent diabetes mellitus without complication 
C109911 Type II diabetes mellitus without complication 
C109912 Type 2 diabetes mellitus without complication 
C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy 
C109A11 Type II diabetes mellitus with mononeuropathy 
C109A12 Type 2 diabetes mellitus with mononeuropathy 
C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy 
C109B11 Type II diabetes mellitus with polyneuropathy 
C109B12 Type 2 diabetes mellitus with polyneuropathy 
C109C00 Non-insulin dependent diabetes mellitus with nephropathy 
C109C11 Type II diabetes mellitus with nephropathy 
C109C12 Type 2 diabetes mellitus with nephropathy 
C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma 
C109D11 Type II diabetes mellitus with hypoglycaemic coma 
C109D12 Type 2 diabetes mellitus with hypoglycaemic coma 
C109E00 Non-insulin depend diabetes mellitus with diabetic cataract 
C109E11 Type II diabetes mellitus with diabetic cataract 
C109E12 Type 2 diabetes mellitus with diabetic cataract 
C109F11 Type II diabetes mellitus with peripheral angiopathy 
C109F12 Type 2 diabetes mellitus with peripheral angiopathy 
C109G00 Non-insulin dependent diabetes mellitus with arthropathy 
C109G11 Type II diabetes mellitus with arthropathy 
C109G12 Type 2 diabetes mellitus with arthropathy 
C109H11 Type II diabetes mellitus with neuropathic arthropathy 
C109H12 Type 2 diabetes mellitus with neuropathic arthropathy 
C109J00 Insulin treated Type 2 diabetes mellitus 
C109J11 Insulin treated non-insulin dependent diabetes mellitus 
C109J12 Insulin treated Type II diabetes mellitus 
C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10F.00 Type 2 diabetes mellitus 
C10F.11 Type II diabetes mellitus 
C10F000 Type 2 diabetes mellitus with renal complications 
C10F011 Type II diabetes mellitus with renal complications 
C10F100 Type 2 diabetes mellitus with ophthalmic complications 
C10F111 Type II diabetes mellitus with ophthalmic complications 
C10F200 Type 2 diabetes mellitus with neurological complications 
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C10F211 Type II diabetes mellitus with neurological complications 
C10F300 Type 2 diabetes mellitus with multiple complications 
C10F311 Type II diabetes mellitus with multiple complications 
C10F400 Type 2 diabetes mellitus with ulcer 
C10F411 Type II diabetes mellitus with ulcer 
C10F500 Type 2 diabetes mellitus with gangrene 
C10F511 Type II diabetes mellitus with gangrene 
C10F600 Type 2 diabetes mellitus with retinopathy 
C10F611 Type II diabetes mellitus with retinopathy 
C10F700 Type 2 diabetes mellitus - poor control 
C10F711 Type II diabetes mellitus - poor control 
C10F900 Type 2 diabetes mellitus without complication 
C10F911 Type II diabetes mellitus without complication 
C10FA00 Type 2 diabetes mellitus with mononeuropathy 
C10FA11 Type II diabetes mellitus with mononeuropathy 
C10FB00 Type 2 diabetes mellitus with polyneuropathy 
C10FB11 Type II diabetes mellitus with polyneuropathy 
C10FC00 Type 2 diabetes mellitus with nephropathy 
C10FC11 Type II diabetes mellitus with nephropathy 
C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
C10FE00 Type 2 diabetes mellitus with diabetic cataract 
C10FE11 Type II diabetes mellitus with diabetic cataract 
C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
C10FF11 Type II diabetes mellitus with peripheral angiopathy 
C10FG00 Type 2 diabetes mellitus with arthropathy 
C10FG11 Type II diabetes mellitus with arthropathy 
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
C10FH11 Type II diabetes mellitus with neuropathic arthropathy 
C10FJ00 Insulin treated Type 2 diabetes mellitus 
C10FJ11 Insulin treated Type II diabetes mellitus 
C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
C10FL11 Type II diabetes mellitus with persistent proteinuria 
C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
C10FN00 Type 2 diabetes mellitus with ketoacidosis 
C10FN11 Type II diabetes mellitus with ketoacidosis 
C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
C10FP11 Type II diabetes mellitus with ketoacidotic coma 
C10FQ00 Type 2 diabetes mellitus with exudative maculopathy 
C10FQ11 Type II diabetes mellitus with exudative maculopathy 
C10FR00 Type 2 diabetes mellitus with gastroparesis 
C10y100 Diabetes mellitus, adult, + other specified manifestation 
C10z100 Diabetes mellitus, adult onset, + unspecified complication 
C107400 NIDDM with peripheral circulatory disorder 
C109F00 Non-insulin-dependent d m with peripheral angiopath 
C109H00 Non-insulin dependent d m with neuropathic arthropathy 
L180600 Pre-existing diabetes mellitus, non-insulin-dependent 
ZC2CA00 Dietary advice for type II diabetes 
ZC2CA11 Dietary advice non-insulin-dependent diabetes 
66A3.00 Diabetic on diet only 
66A4.00 Diabetic on oral treatment 
66Ao.00 Diabetes type 2 review 
C10..00 Diabetes mellitus 
C100.00 Diabetes mellitus with no mention of complication 
C100z00 Diabetes mellitus NOS with no mention of complication 
C101.00 Diabetes mellitus with ketoacidosis 
C101y00 Other specified diabetes mellitus with ketoacidosis 
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C101z00 Diabetes mellitus NOS with ketoacidosis 
C102.00 Diabetes mellitus with hyperosmolar coma 
C102z00 Diabetes mellitus NOS with hyperosmolar coma 
C103.00 Diabetes mellitus with ketoacidotic coma 
C103y00 Other specified diabetes mellitus with coma 
C103z00 Diabetes mellitus NOS with ketoacidotic coma 
C104.00 Diabetes mellitus with renal manifestation 
C104.11 Diabetic nephropathy 
C104y00 Other specified diabetes mellitus with renal complications 
C104z00 Diabetes mellitis with nephropathy NOS 
C105.00 Diabetes mellitus with ophthalmic manifestation 
C105y00 Other specified diabetes mellitus with ophthalmic complicatn 
C105z00 Diabetes mellitus NOS with ophthalmic manifestation 
C106.00 Diabetes mellitus with neurological manifestation 
C106.11 Diabetic amyotrophy 
C106.12 Diabetes mellitus with neuropathy 
C106.13 Diabetes mellitus with polyneuropathy 
C106y00 Other specified diabetes mellitus with neurological comps 
C106z00 Diabetes mellitus NOS with neurological manifestation 
C107.00 Diabetes mellitus with peripheral circulatory disorder 
C107.11 Diabetes mellitus with gangrene 
C107.12 Diabetes with gangrene 
C107y00 Other specified diabetes mellitus with periph circ comps 
C107z00 Diabetes mellitus NOS with peripheral circulatory disorder 
C108y00 Other specified diabetes mellitus with multiple comps 
C108z00 Unspecified diabetes mellitus with multiple complications 
C10y.00 Diabetes mellitus with other specified manifestation 
C10yy00 Other specified diabetes mellitus with other spec comps 
C10yz00 Diabetes mellitus NOS with other specified manifestation 
C10z.00 Diabetes mellitus with unspecified complication 
C10zy00 Other specified diabetes mellitus with unspecified comps 
C10zz00 Diabetes mellitus NOS with unspecified complication 
Cyu2.00 XDiabetes mellitus 
Cyu2000 XOther specified diabetes mellitus 
Cyu2300 XUnspecified diabetes mellitus with renal complications 
C110.00 Hypoglycaemic coma 
C110z00 Hypoglycaemic coma NOS 
C110.11 Insulin coma 
C10ER00 Latent autoimmune diabetes mellitus in adult 
C10M.00 Lipoatrophic diabetes mellitus 
C10M000 Lipoatrophic diabetes mellitus without complication 
66AJ100 Brittle diabetes 
F171100 Autonomic neuropathy due to diabetes 
F345000 Diabetic mononeuritis multiplex 
F35z000 Diabetic mononeuritis NOS 
F372.00 Polyneuropathy in diabetes 
F372.11 Diabetic polyneuropathy 
F372.12 Diabetic neuropathy 
F372000 Acute painful diabetic neuropathy 
F372100 Chronic painful diabetic neuropathy 
F372200 Asymptomatic diabetic neuropathy 
F381300 Myasthenic syndrome due to diabetic amyotrophy 
F381311 Diabetic amyotrophy 
F3y0.00 Diabetic mononeuropathy 
F420.00 Diabetic retinopathy 
F420000 Background diabetic retinopathy 
F420100 Proliferative diabetic retinopathy 
F420200 Preproliferative diabetic retinopathy 
F420300 Advanced diabetic maculopathy 
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F420400 Diabetic maculopathy 
F420500 Advanced diabetic retinal disease 
F420600 Non proliferative diabetic retinopathy 
F420700 High risk proliferative diabetic retinopathy 
F420800 High risk non proliferative diabetic retinopathy 
F420z00 Diabetic retinopathy NOS 
F440700 Diabetic iritis 
F464000 Diabetic cataract 
G73y000 Diabetic peripheral angiopathy 
K01x100 Nephrotic syndrome in diabetes mellitus 
Kyu0300 XGlomerular disorders in diabetes mellitus 
L180X00 Pre-existing diabetes mellitus, unspecified 
Lyu2900 XPre-existing diabetes mellitus, unspecified 
M037200 Cellulitis in diabetic foot 
M271000 Ischaemic ulcer diabetic foot 
M271100 Neuropathic diabetic ulcer - foot 
M271200 Mixed diabetic ulcer - foot 
N030000 Diabetic cheiroarthropathy 
N030011 Diabetic cheiropathy 
N030100 Diabetic Charcot arthropathy 
R054200 DGangrene of toe in diabetic 
R054300 DWidespread diabetic foot gangrene 
ZC2C800 Dietary advice for diabetes mellitus 
ZV65312 VDietary counselling in diabetes mellitus 
889A.00 Diab mellit insulin-glucose infus acute myocardial infarct 
889A.00 Diab mellit insulin-glucose infus acute myocardial infarct 
2BBF.00 Retinal abnormality - diabetes related 
2BBJ.00 O/E - no right diabetic retinopathy 
2BBK.00 O/E - no left diabetic retinopathy 
2BBk.00 O/E - right eye stable treated prolif diabetic retinopathy 
2BBL.00 O/E - diabetic maculopathy present both eyes 
2BBl.00 O/E - left eye stable treated prolif diabetic retinopathy 
2BBM.00 O/E - diabetic maculopathy absent both eyes 
2BBo.00 O/E - sight threatening diabetic retinopathy 
2BBP.00 O/E - right eye background diabetic retinopathy 
2BBQ.00 O/E - left eye background diabetic retinopathy 
2BBR.00 O/E - right eye preproliferative diabetic retinopathy 
2BBS.00 O/E - left eye preproliferative diabetic retinopathy 
2BBT.00 O/E - right eye proliferative diabetic retinopathy 
2BBV.00 O/E - left eye proliferative diabetic retinopathy 
2BBW.00 O/E - right eye diabetic maculopathy 
2BBX.00 O/E - left eye diabetic maculopathy 
2G51000 Foot abnormality - diabetes related 
2G5A.00 O/E - Right diabetic foot at risk 
2G5B.00 O/E - Left diabetic foot at risk 
2G5C.00 Foot abnormality - diabetes related 
2G5D.00 Foot abnormality - non-diabetes 
2G5E.00 O/E - Right diabetic foot at low risk 
2G5F.00 O/E - Right diabetic foot at moderate risk 
2G5G.00 O/E - Right diabetic foot at high risk 
2G5H.00 O/E - Right diabetic foot - ulcerated 
2G5I.00 O/E - Left diabetic foot at low risk 
2G5J.00 O/E - Left diabetic foot at moderate risk 
2G5K.00 O/E - Left diabetic foot at high risk 
2G5L.00 O/E - Left diabetic foot - ulcerated 
2G5V.00 O/E - right chronic diabetic foot ulcer 
2G5W.00 O/E - left chronic diabetic foot ulcer 
66A..00 Diabetic monitoring 
66A1.00 Initial diabetic assessment 
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66A2.00 Follow-up diabetic assessment 
66A8.00 Has seen dietician - diabetes 
66A9.00 Understands diet - diabetes 
66Aa.00 Diabetic diet - poor compliance 
66Ab.00 Diabetic foot examination 
66Ac.00 Diabetic peripheral neuropathy screening 
66AD.00 Fundoscopy - diabetic check 
66Af.00 Patient diabetes education review 
66AG.00 Diabetic drug side effects 
66AH.00 Diabetic treatment changed 
66AI.00 Diabetic - good control 
66Ai.00 Diabetic 6 month review 
66AJ.00 Diabetic - poor control 
66AJ.11 Unstable diabetes 
66AJz00 Diabetic - poor control NOS 
66Ak.00 Diabetic monitoring - lower risk albumin excretion 
66AK.00 Diabetic - cooperative patient 
66Al.00 Diabetic monitoring - higher risk albumin excretion 
66AL.00 Diabetic-uncooperative patient 
66AM.00 Diabetic - follow-up default 
66AN.00 Date diabetic treatment start 
66AO.00 Date diabetic treatment stopped 
66AP.00 Diabetes: practice programme 
66Aq.00 Diabetic foot screen 
66AQ.00 Diabetes: shared care programme 
66AR.00 Diabetes management plan given 
66AS.00 Diabetic annual review 
66AT.00 Annual diabetic blood test 
66AU.00 Diabetes care by hospital only 
66AV.00 Diabetic on insulin and oral treatment 
66AW.00 Diabetic foot risk assessment 
66AX.00 Diabetes: shared care in pregnancy - diabetologist and obstetrician 
66AY.00 Diabetic diet - good compliance 
66AZ.00 Diabetic monitoring NOS 
66b1.00 Diabetic monitoring not required 
6761.00 Diabetic pre-pregnancy counselling 
68A7.00 Diabetic retinopathy screening 
68A9.00 Diabetic retinopathy screening offered 
68AB.00 Diabetic digital retinopathy screening offered 
7276.00 Pan retinal photocoagulation for diabetes 
8A12.00 Diabetic crisis monitoring 
8A13.00 Diabetic stabilisation 
8B3l.00 Diabetes medication review 
8BL2.00 Patient on maximal tolerated therapy for diabetes 
8CA4100 Pt advised re diabetic diet 
8CP2.00 Transition of diabetes care options discussed 
8CR2.00 Diabetes clinical management plan 
8CS0.00 Diabetes care plan agreed 
8H2J.00 Admit diabetic emergency 
8H3O.00 Non-urgent diabetic admission 
8HBG.00 Diabetic retinopathy 12 month review 
8HBH.00 Diabetic retinopathy 6 month review 
8Hg4.00 Discharged from care of diabetes specialist nurse 
8HKE.00 Diabetology D.V. requested 
66A6.00 Last hypo. attack 
66A7.00 Frequency of hypo. attacks 
66A7000 Frequency of hospital treated hypoglycaemia 
66A7100 Frequency of GP or paramedic treated hypoglycaemia 
66Ad.00 Hypoglycaemic attack requiring 3rd party assistance 
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66AJ200 Loss of hypoglycaemic warning 
66AJ300 Recurrent severe hypos 
8HLE.00 Diabetology D.V. done 
8HME.00 Listed for Diabetology admissn 
8I3W.00 Diabetic foot examination declined 
8I3X.00 Diabetic retinopathy screening refused 
8I57.00 Patient held diabetic record declined 
8I6F.00 Diabetic retinopathy screening not indicated 
8I6G.00 Diabetic foot examination not indicated 
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Appendix D:T1DM Read Codes 
Read Code Description 
C100000 Diabetes mellitus, juvenile type, no mention of complication 
C101000 Diabetes mellitus, juvenile type, with ketoacidosis 
C102000 Diabetes mellitus, juvenile type, with hyperosmolar coma 
C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma 
C104000 Diabetes mellitus, juvenile type, with renal manifestation 
C105000 Diabetes mellitus, juvenile type, + ophthalmic manifestation 
C106000 Diabetes mellitus, juvenile, + neurological manifestation 
C107000 Diabetes mellitus, juvenile +peripheral circulatory disorder 
C108.00 Insulin dependent diabetes mellitus 
C108.11 IDDM-Insulin dependent diabetes mellitus 
C108.12 Type 1 diabetes mellitus 
C108.13 Type I diabetes mellitus 
C108000 Insulin-dependent diabetes mellitus with renal complications 
C108011 Type I diabetes mellitus with renal complications 
C108012 Type 1 diabetes mellitus with renal complications 
C108100 Insulin-dependent diabetes mellitus with ophthalmic comps 
C108111 Type I diabetes mellitus with ophthalmic complications 
C108112 Type 1 diabetes mellitus with ophthalmic complications 
C108200 Insulin-dependent diabetes mellitus with neurological comps 
C108211 Type I diabetes mellitus with neurological complications 
C108212 Type 1 diabetes mellitus with neurological complications 
C108300 Insulin dependent diabetes mellitus with multiple complicatn 
C108311 Type I diabetes mellitus with multiple complications 
C108312 Type 1 diabetes mellitus with multiple complications 
C108400 Unstable insulin dependent diabetes mellitus 
C108411 Unstable type I diabetes mellitus 
C108412 Unstable type 1 diabetes mellitus 
C108500 Insulin dependent diabetes mellitus with ulcer 
C108511 Type I diabetes mellitus with ulcer 
C108512 Type 1 diabetes mellitus with ulcer 
C108600 Insulin dependent diabetes mellitus with gangrene 
C108611 Type I diabetes mellitus with gangrene 
C108612 Type 1 diabetes mellitus with gangrene 
C108700 Insulin dependent diabetes mellitus with retinopathy 
C108711 Type I diabetes mellitus with retinopathy 
C108712 Type 1 diabetes mellitus with retinopathy 
C108800 Insulin dependent diabetes mellitus - poor control 
C108811 Type I diabetes mellitus - poor control 
C108812 Type 1 diabetes mellitus - poor control 
C108900 Insulin dependent diabetes maturity onset 
C108911 Type I diabetes mellitus maturity onset 
C108912 Type 1 diabetes mellitus maturity onset 
C108A00 Insulin-dependent diabetes without complication 
C108A11 Type I diabetes mellitus without complication 
C108A12 Type 1 diabetes mellitus without complication 
C108B00 Insulin dependent diabetes mellitus with mononeuropathy 
C108B11 Type I diabetes mellitus with mononeuropathy 
C108B12 Type 1 diabetes mellitus with mononeuropathy 
C108C00 Insulin dependent diabetes mellitus with polyneuropathy 
C108C11 Type I diabetes mellitus with polyneuropathy 
C108C12 Type 1 diabetes mellitus with polyneuropathy 
C108D00 Insulin dependent diabetes mellitus with nephropathy 
C108D11 Type I diabetes mellitus with nephropathy 
C108D12 Type 1 diabetes mellitus with nephropathy 
C108E00 Insulin dependent diabetes mellitus with hypoglycaemic coma 
C108E11 Type I diabetes mellitus with hypoglycaemic coma 
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C108E12 Type 1 diabetes mellitus with hypoglycaemic coma 
C108F00 Insulin dependent diabetes mellitus with diabetic cataract 
C108F11 Type I diabetes mellitus with diabetic cataract 
C108F12 Type 1 diabetes mellitus with diabetic cataract 
C108G11 Type I diabetes mellitus with peripheral angiopathy 
C108G12 Type 1 diabetes mellitus with peripheral angiopathy 
C108H00 Insulin dependent diabetes mellitus with arthropathy 
C108H11 Type I diabetes mellitus with arthropathy 
C108H12 Type 1 diabetes mellitus with arthropathy 
C108J11 Type I diabetes mellitus with neuropathic arthropathy 
C108J12 Type 1 diabetes mellitus with neuropathic arthropathy 
C10E.00 Type 1 diabetes mellitus 
C10E.11 Type I diabetes mellitus 
C10E.12 Insulin dependent diabetes mellitus 
C10E000 Type 1 diabetes mellitus with renal complications 
C10E011 Type I diabetes mellitus with renal complications 
C10E012 Insulin-dependent diabetes mellitus with renal complications 
C10E100 Type 1 diabetes mellitus with ophthalmic complications 
C10E111 Type I diabetes mellitus with ophthalmic complications 
C10E112 Insulin-dependent diabetes mellitus with ophthalmic comps 
C10E200 Type 1 diabetes mellitus with neurological complications 
C10E211 Type I diabetes mellitus with neurological complications 
C10E212 Insulin-dependent diabetes mellitus with neurological comps 
C10E300 Type 1 diabetes mellitus with multiple complications 
C10E311 Type I diabetes mellitus with multiple complications 
C10E312 Insulin dependent diabetes mellitus with multiple complicat 
C10E400 Unstable type 1 diabetes mellitus 
C10E411 Unstable type I diabetes mellitus 
C10E412 Unstable insulin dependent diabetes mellitus 
C10E500 Type 1 diabetes mellitus with ulcer 
C10E511 Type I diabetes mellitus with ulcer 
C10E512 Insulin dependent diabetes mellitus with ulcer 
C10E600 Type 1 diabetes mellitus with gangrene 
C10E611 Type I diabetes mellitus with gangrene 
C10E612 Insulin dependent diabetes mellitus with gangrene 
C10E700 Type 1 diabetes mellitus with retinopathy 
C10E711 Type I diabetes mellitus with retinopathy 
C10E712 Insulin dependent diabetes mellitus with retinopathy 
C10E800 Type 1 diabetes mellitus - poor control 
C10E811 Type I diabetes mellitus - poor control 
C10E812 Insulin dependent diabetes mellitus - poor control 
C10E900 Type 1 diabetes mellitus maturity onset 
C10E911 Type I diabetes mellitus maturity onset 
C10E912 Insulin dependent diabetes maturity onset 
C10EA00 Type 1 diabetes mellitus without complication 
C10EA11 Type I diabetes mellitus without complication 
C10EA12 Insulin-dependent diabetes without complication 
C10EB00 Type 1 diabetes mellitus with mononeuropathy 
C10EB11 Type I diabetes mellitus with mononeuropathy 
C10EB12 Insulin dependent diabetes mellitus with mononeuropathy 
C10EC00 Type 1 diabetes mellitus with polyneuropathy 
C10EC11 Type I diabetes mellitus with polyneuropathy 
C10EC12 Insulin dependent diabetes mellitus with polyneuropathy 
C10ED00 Type 1 diabetes mellitus with nephropathy 
C10ED11 Type I diabetes mellitus with nephropathy 
C10ED12 Insulin dependent diabetes mellitus with nephropathy 
C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma 
C10EE11 Type I diabetes mellitus with hypoglycaemic coma 
C10EE12 Insulin dependent diabetes mellitus with hypoglycaemic coma 
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C10EF00 Type 1 diabetes mellitus with diabetic cataract 
C10EF11 Type I diabetes mellitus with diabetic cataract 
C10EF12 Insulin dependent diabetes mellitus with diabetic cataract 
C10EG00 Type 1 diabetes mellitus with peripheral angiopathy 
C10EG11 Type I diabetes mellitus with peripheral angiopathy 
C10EH00 Type 1 diabetes mellitus with arthropathy 
C10EH11 Type I diabetes mellitus with arthropathy 
C10EH12 Insulin dependent diabetes mellitus with arthropathy 
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy 
C10EJ11 Type I diabetes mellitus with neuropathic arthropathy 
C10EK00 Type 1 diabetes mellitus with persistent proteinuria 
C10EK11 Type I diabetes mellitus with persistent proteinuria 
C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria 
C10EL11 Type I diabetes mellitus with persistent microalbuminuria 
C10EM00 Type 1 diabetes mellitus with ketoacidosis 
C10EM11 Type I diabetes mellitus with ketoacidosis 
C10EN00 Type 1 diabetes mellitus with ketoacidotic coma 
C10EN11 Type I diabetes mellitus with ketoacidotic coma 
C10EP00 Type 1 diabetes mellitus with exudative maculopathy 
C10EP11 Type I diabetes mellitus with exudative maculopathy 
C10EQ00 Type 1 diabetes mellitus with gastroparesis 
C10y000 Diabetes mellitus, juvenile, + other specified manifestation 
C10z000 Diabetes mellitus, juvenile type, + unspecified complication 
C107300 IDDM with peripheral circulatory disorder 
C108G00 Insulin dependent diab mell with peripheral angiopathy 
C108J00 Insulin dependent diab mell with neuropathic arthropathy 
C10EG12 Insulin dependent diab mell with peripheral angiopathy 
C10EJ12 Insulin dependent diab mell with neuropathic arthropathy 
L180500 Pre-existing diabetes mellitus, insulin-dependent 
ZRbH.00 Perceived control of insulin-dependent diabetes 
ZC2C900 Dietary advice for type I diabetes 
ZC2C911 Diet advice for insulin-dependent diabetes 
66Ag.00 Insulin needles changed daily 
66Ah.00 Insulin needles changed for each injection 
66AH000 Conversion to insulin 
66Aj.00 Insulin needles changed less than once a day 
66Am.00 Insulin dose changed 
66Ap.00 Insulin treatment initiated 
7L10000 Continuous subcutaneous infusion of insulin 
7L19800 Subcutaneous injection of insulin 
66A5.00 Diabetic on insulin 
66AA.11 Injection sites - diabetic 
66An.00 Diabetes type 1 review 
C100011 Insulin dependent diabetes mellitus 
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Appendix E: T2DM Read Codes 
Read Code Description 
C100100 Diabetes mellitus, adult onset, no mention of complication 
C100112 Non-insulin dependent diabetes mellitus 
C101100 Diabetes mellitus, adult onset, with ketoacidosis 
C102100 Diabetes mellitus, adult onset, with hyperosmolar coma 
C103100 Diabetes mellitus, adult onset, with ketoacidotic coma 
C104100 Diabetes mellitus, adult onset, with renal manifestation 
C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation 
C106100 Diabetes mellitus, adult onset, + neurological manifestation 
C107100 Diabetes mellitus, adult, + peripheral circulatory disorder 
C107200 Diabetes mellitus, adult with gangrene 
C109.00 Non-insulin dependent diabetes mellitus 
C109.11 NIDDM - Non-insulin dependent diabetes mellitus 
C109.12 Type 2 diabetes mellitus 
C109.13 Type II diabetes mellitus 
C109000 Non-insulin-dependent diabetes mellitus with renal comps 
C109011 Type II diabetes mellitus with renal complications 
C109012 Type 2 diabetes mellitus with renal complications 
C109100 Non-insulin-dependent diabetes mellitus with ophthalm comps 
C109111 Type II diabetes mellitus with ophthalmic complications 
C109112 Type 2 diabetes mellitus with ophthalmic complications 
C109200 Non-insulin-dependent diabetes mellitus with neuro comps 
C109211 Type II diabetes mellitus with neurological complications 
C109212 Type 2 diabetes mellitus with neurological complications 
C109300 Non-insulin-dependent diabetes mellitus with multiple comps 
C109311 Type II diabetes mellitus with multiple complications 
C109312 Type 2 diabetes mellitus with multiple complications 
C109400 Non-insulin dependent diabetes mellitus with ulcer 
C109411 Type II diabetes mellitus with ulcer 
C109412 Type 2 diabetes mellitus with ulcer 
C109500 Non-insulin dependent diabetes mellitus with gangrene 
C109511 Type II diabetes mellitus with gangrene 
C109512 Type 2 diabetes mellitus with gangrene 
C109600 Non-insulin-dependent diabetes mellitus with retinopathy 
C109611 Type II diabetes mellitus with retinopathy 
C109612 Type 2 diabetes mellitus with retinopathy 
C109700 Non-insulin dependent diabetes mellitus - poor control 
C109711 Type II diabetes mellitus - poor control 
C109712 Type 2 diabetes mellitus - poor control 
C109900 Non-insulin-dependent diabetes mellitus without complication 
C109911 Type II diabetes mellitus without complication 
C109912 Type 2 diabetes mellitus without complication 
C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy 
C109A11 Type II diabetes mellitus with mononeuropathy 
C109A12 Type 2 diabetes mellitus with mononeuropathy 
C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy 
C109B11 Type II diabetes mellitus with polyneuropathy 
C109B12 Type 2 diabetes mellitus with polyneuropathy 
C109C00 Non-insulin dependent diabetes mellitus with nephropathy 
C109C11 Type II diabetes mellitus with nephropathy 
C109C12 Type 2 diabetes mellitus with nephropathy 
C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma 
C109D11 Type II diabetes mellitus with hypoglycaemic coma 
C109D12 Type 2 diabetes mellitus with hypoglycaemic coma 
C109E00 Non-insulin depend diabetes mellitus with diabetic cataract 
C109E11 Type II diabetes mellitus with diabetic cataract 
C109E12 Type 2 diabetes mellitus with diabetic cataract 
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C109F11 Type II diabetes mellitus with peripheral angiopathy 
C109F12 Type 2 diabetes mellitus with peripheral angiopathy 
C109G00 Non-insulin dependent diabetes mellitus with arthropathy 
C109G11 Type II diabetes mellitus with arthropathy 
C109G12 Type 2 diabetes mellitus with arthropathy 
C109H11 Type II diabetes mellitus with neuropathic arthropathy 
C109H12 Type 2 diabetes mellitus with neuropathic arthropathy 
C109J00 Insulin treated Type 2 diabetes mellitus 
C109J11 Insulin treated non-insulin dependent diabetes mellitus 
C109J12 Insulin treated Type II diabetes mellitus 
C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10F.00 Type 2 diabetes mellitus 
C10F.11 Type II diabetes mellitus 
C10F000 Type 2 diabetes mellitus with renal complications 
C10F011 Type II diabetes mellitus with renal complications 
C10F100 Type 2 diabetes mellitus with ophthalmic complications 
C10F111 Type II diabetes mellitus with ophthalmic complications 
C10F200 Type 2 diabetes mellitus with neurological complications 
C10F211 Type II diabetes mellitus with neurological complications 
C10F300 Type 2 diabetes mellitus with multiple complications 
C10F311 Type II diabetes mellitus with multiple complications 
C10F400 Type 2 diabetes mellitus with ulcer 
C10F411 Type II diabetes mellitus with ulcer 
C10F500 Type 2 diabetes mellitus with gangrene 
C10F511 Type II diabetes mellitus with gangrene 
C10F600 Type 2 diabetes mellitus with retinopathy 
C10F611 Type II diabetes mellitus with retinopathy 
C10F700 Type 2 diabetes mellitus - poor control 
C10F711 Type II diabetes mellitus - poor control 
C10F900 Type 2 diabetes mellitus without complication 
C10F911 Type II diabetes mellitus without complication 
C10FA00 Type 2 diabetes mellitus with mononeuropathy 
C10FA11 Type II diabetes mellitus with mononeuropathy 
C10FB00 Type 2 diabetes mellitus with polyneuropathy 
C10FB11 Type II diabetes mellitus with polyneuropathy 
C10FC00 Type 2 diabetes mellitus with nephropathy 
C10FC11 Type II diabetes mellitus with nephropathy 
C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
C10FE00 Type 2 diabetes mellitus with diabetic cataract 
C10FE11 Type II diabetes mellitus with diabetic cataract 
C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
C10FF11 Type II diabetes mellitus with peripheral angiopathy 
C10FG00 Type 2 diabetes mellitus with arthropathy 
C10FG11 Type II diabetes mellitus with arthropathy 
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
C10FH11 Type II diabetes mellitus with neuropathic arthropathy 
C10FJ00 Insulin treated Type 2 diabetes mellitus 
C10FJ11 Insulin treated Type II diabetes mellitus 
C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
C10FL11 Type II diabetes mellitus with persistent proteinuria 
C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
C10FN00 Type 2 diabetes mellitus with ketoacidosis 
C10FN11 Type II diabetes mellitus with ketoacidosis 
C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
C10FP11 Type II diabetes mellitus with ketoacidotic coma 
C10FQ00 Type 2 diabetes mellitus with exudative maculopathy 
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C10FQ11 Type II diabetes mellitus with exudative maculopathy 
C10FR00 Type 2 diabetes mellitus with gastroparesis 
C10y100 Diabetes mellitus, adult, + other specified manifestation 
C10z100 Diabetes mellitus, adult onset, + unspecified complication 
C107400 NIDDM with peripheral circulatory disorder 
C109F00 Non-insulin-dependent d m with peripheral angiopath 
C109H00 Non-insulin dependent d m with neuropathic arthropathy 
L180600 Pre-existing diabetes mellitus, non-insulin-dependent 
ZC2CA00 Dietary advice for type II diabetes 
ZC2CA11 Dietary advice non-insulin-dependent diabetes 
66A3.00 Diabetic on diet only 
66A4.00 Diabetic on oral treatment 
66Ao.00 Diabetes type 2 review 
 
  
 144 
 
Appendix F: TB Read Codes 
Read Code Description 
4E38.00 Sputum: tubercle on Z-N stain 
65V9.00 Notification of tuberculosis 
65V9.11 TB - tuberculosis notification 
65Y0.00 Tuberculosis index case 
65Y1.00 On tuberculosis chemoprophylaxis 
65Y2.00 Streptomycin resistant tuberculosis 
65Y3.00 Rifampicin resistant tuberculosis 
65Y4.00 Pyrazinamide resistant tuberculosis 
65Y5.00 Isoniazid resistant tuberculosis 
65Y6.00 Ethionamide resistant tuberculosis 
65Y7.00 Ethambutol resistant tuberculosis 
65Y8.00 Ciprofloxacin resistant tuberculosis 
65Y9.00 Inactive tuberculosis 
65Y9.11 Latent tuberculosis 
745F.00 Tuberculosis support 
745Fy00 Other specified tuberculosis support 
745Fz00 Tuberculosis support NOS 
A1...00 Tuberculosis 
A10..00 Primary tuberculous infection 
A100.00 Primary tuberculous complex 
A101.00 Tuberculous pleurisy in primary progressive tuberculosis 
A10y.00 Other primary progressive tuberculosis 
A10z.00 Primary tuberculous infection NOS 
A11..00 Pulmonary tuberculosis 
A11..11 Lung tuberculosis 
A110.00 Infiltrative lung tuberculosis 
A111.00 Nodular lung tuberculosis 
A112.00 Tuberculosis of lung with cavitation 
A113.00 Tuberculosis of bronchus 
A114.00 Tuberculous fibrosis of lung 
A115.00 Tuberculous bronchiectasis 
A116.00 Tuberculous pneumonia 
A117.00 Tuberculous pneumothorax 
A11y.00 Other specified pulmonary tuberculosis 
A11z.00 Pulmonary tuberculosis NOS 
A12..00 Other respiratory tuberculosis 
A120.00 Tuberculous pleurisy 
A120000 Tuberculosis of pleura 
A120100 Tuberculous empyema 
A120200 Tuberculous hydrothorax 
A120z00 Tuberculous pleurisy NOS 
A121.00 Tuberculosis of intrathoracic lymph nodes 
A121000 Tuberculosis of hilar lymph nodes 
A121100 Tuberculosis of mediastinal lymph nodes 
A121200 Tuberculosis of tracheobronchial lymph nodes 
A121z00 Tuberculosis of intrathoracic lymph nodes NOS 
A122.00 Isolated tracheal or bronchial tuberculosis 
A122000 Isolated tracheal tuberculosis 
A122100 Isolated bronchial tuberculosis 
A122z00 Isolated tracheal or bronchial tuberculosis NOS 
A123.00 Tuberculous laryngitis 
A124100 Tuberculosis of lung, confirmed by culture only 
A124200 Tuberculosis of lung, confirmed histologically 
A124300 Tuberculosis of lung, confirmed by unspecified means 
A124500 Tuberculosis of larynx, trachea & bronchus conf bact/hist'y 
A124600 Tuberculous pleurisy, conf bacteriologically/histologically 
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A125000 Tuberculosis of lung, bacteriologically & histolog'y neg 
A125100 Tuberculosis lung bact and histological examin not done 
A12y.00 Other specified respiratory tuberculosis 
A12y000 Tuberculosis of mediastinum 
A12y100 Tuberculosis of nasopharynx 
A12y200 Tuberculosis of nasal septum 
A12y300 Tuberculosis of nasal sinus 
A12yz00 Other specified respiratory tuberculosis NOS 
A13..00 Tuberculosis of meninges and central nervous system 
A130.00 Tuberculous meningitis 
A130000 Tuberculosis of cerebral meninges 
A130100 Tuberculosis of spinal meninges 
A130200 Tuberculous leptomeningitis 
A130300 Tuberculous meningoencephalitis 
A130z00 Tuberculous meningitis NOS 
A131.00 Tuberculoma of meninges 
A132.00 Tuberculoma of brain 
A133.00 Tuberculous abscess of brain 
A134.00 Tuberculoma of spinal cord 
A135.00 Tuberculous abscess of spinal cord 
A136.00 Tuberculous encephalitis or myelitis 
A136000 Tuberculous encephalitis 
A136100 Tuberculous myelitis 
A136z00 Tuberculous encephalitis or myelitis NOS 
A13y.00 Other specified tuberculosis of central nervous system 
A13z.00 Tuberculosis of central nervous system NOS 
A14..00 Tuberculosis of intestines, peritoneum and mesenteric glands 
A140.00 Tuberculous peritonitis 
A14y.00 Other gastrointestinal tract tuberculosis 
A14y000 Tuberculosis of anus 
A14y100 Tuberculosis of large intestine 
A14y200 Tuberculosis of small intestine 
A14y300 Tuberculosis of mesenteric lymph glands 
A14y400 Tuberculosis of rectum 
A14y500 Tuberculosis of retroperitoneal lymph nodes 
A14yz00 Other gastrointestinal tract tuberculosis NOS 
A14z.00 Tuberculosis of gastrointestinal tract NOS 
A15..00 Tuberculosis of bones and joints 
A15..11 Tuberculous osteomylelytis 
A15..12 Tuberculous arthritis 
A15..13 Tuberculous synovitis 
A150.00 Tuberculosis of vertebral column - Pott's 
A151.00 Tuberculosis of hip 
A152.00 Tuberculosis of knee 
A153.00 Tuberculosis limb bones - Tuberculous dactylitis 
A154.00 Tuberculous mastoiditis 
A15x.00 Tuberculosis of other specified bones 
A15y.00 Tuberculosis of other specified joint 
A15z.00 Tuberculosis of bones or joints NOS 
A16..00 Tuberculosis of genitourinary system 
A160.00 Tuberculosis of kidney 
A160.11 Renal tuberculosis 
A160000 Tuberculous nephropathy 
A160100 Tuberculous pyelitis 
A160200 Tuberculous pyelonephritis 
A160z00 Tuberculosis of kidney NOS 
A161.00 Tuberculosis of bladder 
A162.00 Tuberculosis of ureter 
A163.00 Tuberculosis of other urinary organs 
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A164.00 Tuberculosis of epididymis 
A165.00 Tuberculosis of other male genital organs 
A165000 Tuberculosis of prostate 
A165100 Tuberculosis seminal vesicle 
A165200 Tuberculosis of testis 
A165z00 Tuberculosis of other male genital organs NOS 
A166.00 Tuberculous oophoritis or salpingitis 
A166000 Tuberculous oophoritis 
A166100 Tuberculous salpingitis 
A166111 Fallopian tube tuberculosis 
A166z00 Tuberculous oophoritis or salpingitis NOS 
A167.00 Tuberculosis of other female genital organs 
A167000 Tuberculous cervicitis 
A167100 Tuberculous endometritis 
A167z00 Tuberculosis of other female genital organs NOS 
A168.00 Tuberculosis of urinary tract 
A16z.00 Genitourinary tuberculosis NOS 
A17..00 Tuberculosis of other organs 
A170.00 Tuberculosis of skin and subcutaneous tissue 
A170.11 Lupus - tuberculous 
A170000 Tuberculosis - lupus exedens 
A170100 Tuberculosis - lupus vulgaris 
A170200 Tuberculosis - scrofuloderma 
A170300 Tuberculosis - lupus NOS 
A170400 Tuberculosis colliquativa 
A170500 Tuberculosis cutis 
A170600 Tuberculosis lichenoides 
A170700 Tuberculosis papulonecrotica 
A170800 Tuberculosis verrucosa cutis 
A170z00 Tuberculosis of skin and subcutaneous tissue NOS 
A171.00 Tuberculosis with erythema nodosum hypersensitivity reaction 
A171100 Tuberculous erythema nodosum 
A171z00 Erythema nodosum with tuberculosis NOS 
A172.00 Tuberculosis of peripheral lymph nodes 
A172000 Tuberculous - cervical lymphadenitis 
A172011 Scrofula - tuberculous cervical lymph nodes 
A172100 Scrofulous tuberculous abscess 
A172200 Tuberculous adenitis 
A172z00 Tuberculosis of peripheral lymph nodes NOS 
A173.00 Tuberculosis of eye 
A173000 Tuberculous chorioretinitis 
A173100 Tuberculous episcleritis 
A173200 Tuberculous interstitial keratitis 
A173300 Tuberculous chronic iridocyclitis 
A173400 Tuberculous keratoconjunctivitis 
A173z00 Tuberculosis of eye NOS 
A174.00 Tuberculosis of ear 
A175.00 Tuberculosis of thyroid gland 
A176.00 Tuberculosis of adrenal glands - Addison's disease 
A177.00 Tuberculosis spleen 
A178.00 Tuberculosis oesophagus 
A17y.00 Tuberculosis of other specified organs 
A17y000 Tuberculosis endocardium 
A17y100 Tuberculosis myocardium 
A17y200 Tuberculosis pericardium 
A17y300 Tuberculosis of stomach 
A17y400 Tuberculosis of liver 
A17yz00 Tuberculosis of other specified organs NOS 
A17z.00 Tuberculosis of other organs NOS 
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A18..00 Miliary tuberculosis 
A180.00 Acute miliary tuberculosis 
A180000 Acute miliary tuberculosis of a single specified site 
A180100 Acute miliary tuberculosis of multiple sites 
A18y.00 Other specified miliary tuberculosis 
A18z.00 Miliary tuberculosis NOS 
A1y..00 Other specified tuberculosis 
A1z..00 Tuberculosis NOS 
AE0..00 Late effects of tuberculosis 
AE00.00 Late effects of respiratory tuberculosis 
AE01.00 Late effects of central nervous system tuberculosis 
AE02.00 Late effects of genitourinary system tuberculosis 
AE03.00 Late effects of tuberculosis of bones and joints 
AE04.00 Late effects of tuberculosis of other specified organs 
AE0z.00 Late effects of tuberculosis NOS 
Ayu1.00 XTuberculosis 
Ayu1000 XOther resp tubercul,confirmd bacteriologicly+histologicly 
Ayu1100 XResp tuberculos unspcfd,confirmd bacteriolog+histologicly 
Ayu1200 XOth resp tubercul, w'out m/bacteriol or histol confirmatn 
Ayu1400 XOther tuberculosis of nervous system 
Ayu1500 XTuberculosis of nervous system, unspecified 
Ayu1600 XTuberculosis of other specified organs 
Ayu1700 XAcute miliary tuberculosis, unspecified 
Ayu1800 XOther miliary tuberculosis 
Ayu1900 XMiliary tuberculosis, unspecified 
AyuJ000 XSequelae of central nervous system tuberculosis 
AyuJ100 XSequelae of genitourinary tuberculosis 
AyuJ200 XSequelae of tuberculosis of bones and joints 
AyuJ300 XSequelae of tuberculosis of other organs 
AyuJ400 XSequelae of respiratory and unspecified tuberculosis 
F004.00 Meningitis - tuberculous 
F033300 Encephalitis due to tuberculosis 
F033311 Tuberculous encephalitis 
F040600 Tuberculous intracranial abscess 
F041300 Tuberculous intraspinal abscess 
F4A5500 Keratitis due to tuberculosis 
G500300 Acute pericarditis - tuberculous 
G520600 Acute myocarditis - tuberculous 
H450.00 Pneumoconiosis associated with tuberculosis 
J550200 Peritonitis - tuberculous 
J615E00 Cardituberculous cirrhosis 
Jyu9300 XTuberculous disorders of intestine and mesentery 
K154800 Cystitis in tuberculosis 
K214300 Prostatitis in tuberculosis 
K43..00 Female tuberculous pelvic inflammatory disease 
L173.00 Maternal tuberculosis in pregnancy/childbirth/puerperium 
L173000 Maternal tuberculosis,unspec whether in pregnancy/puerperium 
L173100 Maternal tuberculosis during pregnancy - baby delivered 
L173200 Maternal tuberculosis in puerperium - baby delivered 
L173300 Maternal tuberculosis in pregnancy - baby not yet delivered 
L173400 Maternal tuberculosis in puerperium - baby previously deliv. 
L173z00 Maternal tuberculosis in pregnancy/childbirth/puerperium NOS 
M151400 Erythema tuberculatum 
N018.00 Tuberculous arthritis 
N22yD00 Tuberculous infection of tendon sheath 
N304.00 Tuberculosis of spine (Pott's) 
N304.11 Tuberculosis of spine 
N304000 Tuberculosis of cervical spine 
N304100 Tuberculosis of thoracic spine 
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N304200 Tuberculosis of lumbar spine 
N304300 Tuberculosis of sacrum/coccyx 
N305.00 Tuberculosis of limb bones 
N305000 Tuberculosis of unspecified limb bone 
N305100 Tuberculosis of the upper arm bone 
N305200 Tuberculosis of the forearm bone 
N305300 Tuberculosis of the pelvic and thigh bones 
N305400 Tuberculosis of the lower leg bone 
N305500 Tuberculosis of other limb bones 
N305600 Tuberculosis of multiple limb bones 
N305z00 Tuberculosis of limb bones NOS 
N306.00 Tuberculosis of other bones 
N306000 Tuberculosis of bone, site unspecified 
N306100 Tuberculosis of the bones of the shoulder region 
N306200 Tuberculosis of the bones of the hand 
N306300 Tuberculosis of the bones of the ankle and foot 
N306400 Tuberculosis of the bones of other sites 
N306500 Tuberculosis of the bones of multiple sites 
N306z00 Tuberculosis of bone NOS 
Q402400 Congenital tuberculosis 
65V9.11 TB - tuberculosis notification 
8BAD100 TB chemotherapy 
A124.00 Resp TB bacteriologically and histologically confirmed 
A124000 TB lung confirm sputum microscopy with or without culture 
A124400 TB intrathoracic lymph nodes confirm bact histologically 
A124700 Primary respiratory TB confirm bact and histologically 
A125.00 Respiratory TB not confirmed bact or histologically 
A125200 Prim respiratory TB without mention of bact or hist confirm 
A125X00 Resp TB unspcf,w'out mention/bacterial or histol confrmtn 
Ayu1300 XResp TB unspcf,w'out mention/bacterial or histol confrmtn 
G500311 TB - acute pericarditis 
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Appendix G: PTB Read Codes 
Read Code Description 
A11y.00 Other specified pulmonary tuberculosis 
A11z.00 Pulmonary tuberculosis NOS 
A122.00 Isolated tracheal or bronchial tuberculosis 
A124300 Tuberculosis of lung, confirmed by unspecified means 
A125000 Tuberculosis of lung, bacteriologically & histolog'y neg 
A125100 Tuberculosis lung bact and histological examin not done 
A124000 TB lung confirm sputum microscopy with or without culture 
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Appendix H: EPTB Read Codes 
Read Code Description 
A120.00 Tuberculous pleurisy 
A120000 Tuberculosis of pleura 
A120100 Tuberculous empyema 
A120200 Tuberculous hydrothorax 
A120z00 Tuberculous pleurisy NOS 
A121.00 Tuberculosis of intrathoracic lymph nodes 
A121000 Tuberculosis of hilar lymph nodes 
A121100 Tuberculosis of mediastinal lymph nodes 
A121200 Tuberculosis of tracheobronchial lymph nodes 
A121z00 Tuberculosis of intrathoracic lymph nodes NOS 
A123.00 Tuberculous laryngitis 
A124500 Tuberculosis of larynx, trachea & bronchus conf bact/hist'y 
A124600 Tuberculous pleurisy, conf bacteriologically/histologically 
A12y000 Tuberculosis of mediastinum 
A12y100 Tuberculosis of nasopharynx 
A12y200 Tuberculosis of nasal septum 
A12y300 Tuberculosis of nasal sinus 
A13..00 Tuberculosis of meninges and central nervous system 
A130.00 Tuberculous meningitis 
A130000 Tuberculosis of cerebral meninges 
A130100 Tuberculosis of spinal meninges 
A130200 Tuberculous leptomeningitis 
A130300 Tuberculous meningoencephalitis 
A130z00 Tuberculous meningitis NOS 
A131.00 Tuberculoma of meninges 
A132.00 Tuberculoma of brain 
A133.00 Tuberculous abscess of brain 
A134.00 Tuberculoma of spinal cord 
A135.00 Tuberculous abscess of spinal cord 
A136.00 Tuberculous encephalitis or myelitis 
A136000 Tuberculous encephalitis 
A136100 Tuberculous myelitis 
A136z00 Tuberculous encephalitis or myelitis NOS 
A13y.00 Other specified tuberculosis of central nervous system 
A13z.00 Tuberculosis of central nervous system NOS 
A14..00 Tuberculosis of intestines, peritoneum and mesenteric glands 
A140.00 Tuberculous peritonitis 
A14y.00 Other gastrointestinal tract tuberculosis 
A14y000 Tuberculosis of anus 
A14y100 Tuberculosis of large intestine 
A14y200 Tuberculosis of small intestine 
A14y300 Tuberculosis of mesenteric lymph glands 
A14y400 Tuberculosis of rectum 
A14y500 Tuberculosis of retroperitoneal lymph nodes 
A14yz00 Other gastrointestinal tract tuberculosis NOS 
A14z.00 Tuberculosis of gastrointestinal tract NOS 
A15..00 Tuberculosis of bones and joints 
A15..11 Tuberculous osteomylelytis 
A15..12 Tuberculous arthritis 
A15..13 Tuberculous synovitis 
A150.00 Tuberculosis of vertebral column - Pott's 
A151.00 Tuberculosis of hip 
A152.00 Tuberculosis of knee 
A153.00 Tuberculosis limb bones - Tuberculous dactylitis 
A154.00 Tuberculous mastoiditis 
A15x.00 Tuberculosis of other specified bones 
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A15y.00 Tuberculosis of other specified joint 
A15z.00 Tuberculosis of bones or joints NOS 
A16..00 Tuberculosis of genitourinary system 
A160.00 Tuberculosis of kidney 
A160.11 Renal tuberculosis 
A160000 Tuberculous nephropathy 
A160100 Tuberculous pyelitis 
A160200 Tuberculous pyelonephritis 
A160z00 Tuberculosis of kidney NOS 
A161.00 Tuberculosis of bladder 
A162.00 Tuberculosis of ureter 
A163.00 Tuberculosis of other urinary organs 
A164.00 Tuberculosis of epididymis 
A165.00 Tuberculosis of other male genital organs 
A165000 Tuberculosis of prostate 
A165100 Tuberculosis seminal vesicle 
A165200 Tuberculosis of testis 
A165z00 Tuberculosis of other male genital organs NOS 
A166.00 Tuberculous oophoritis or salpingitis 
A166000 Tuberculous oophoritis 
A166100 Tuberculous salpingitis 
A166111 Fallopian tube tuberculosis 
A166z00 Tuberculous oophoritis or salpingitis NOS 
A167.00 Tuberculosis of other female genital organs 
A167000 Tuberculous cervicitis 
A167100 Tuberculous endometritis 
A167z00 Tuberculosis of other female genital organs NOS 
A168.00 Tuberculosis of urinary tract 
A16z.00 Genitourinary tuberculosis NOS 
A17..00 Tuberculosis of other organs 
A170.00 Tuberculosis of skin and subcutaneous tissue 
A170.11 Lupus - tuberculous 
A170000 Tuberculosis - lupus exedens 
A170100 Tuberculosis - lupus vulgaris 
A170200 Tuberculosis - scrofuloderma 
A170300 Tuberculosis - lupus NOS 
A170400 Tuberculosis colliquativa 
A170500 Tuberculosis cutis 
A170600 Tuberculosis lichenoides 
A170700 Tuberculosis papulonecrotica 
A170800 Tuberculosis verrucosa cutis 
A170z00 Tuberculosis of skin and subcutaneous tissue NOS 
A171.00 Tuberculosis with erythema nodosum hypersensitivity reaction 
A171100 Tuberculous erythema nodosum 
A171z00 Erythema nodosum with tuberculosis NOS 
A172.00 Tuberculosis of peripheral lymph nodes 
A172000 Tuberculous - cervical lymphadenitis 
A172011 Scrofula - tuberculous cervical lymph nodes 
A172100 Scrofulous tuberculous abscess 
A172200 Tuberculous adenitis 
A172z00 Tuberculosis of peripheral lymph nodes NOS 
A173.00 Tuberculosis of eye 
A173000 Tuberculous chorioretinitis 
A173100 Tuberculous episcleritis 
A173200 Tuberculous interstitial keratitis 
A173300 Tuberculous chronic iridocyclitis 
A173400 Tuberculous keratoconjunctivitis 
A173z00 Tuberculosis of eye NOS 
A174.00 Tuberculosis of ear 
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A175.00 Tuberculosis of thyroid gland 
A176.00 Tuberculosis of adrenal glands - Addison's disease 
A177.00 Tuberculosis spleen 
A178.00 Tuberculosis oesophagus 
A17y.00 Tuberculosis of other specified organs 
A17y000 Tuberculosis endocardium 
A17y100 Tuberculosis myocardium 
A17y200 Tuberculosis pericardium 
A17y300 Tuberculosis of stomach 
A17y400 Tuberculosis of liver 
A17yz00 Tuberculosis of other specified organs NOS 
A17z.00 Tuberculosis of other organs NOS 
A18..00 Miliary tuberculosis 
A180.00 Acute miliary tuberculosis 
A180000 Acute miliary tuberculosis of a single specified site 
A180100 Acute miliary tuberculosis of multiple sites 
A18y.00 Other specified miliary tuberculosis 
A18z.00 Miliary tuberculosis NOS 
A1y..00 Other specified tuberculosis 
AE01.00 Late effects of central nervous system tuberculosis 
AE02.00 Late effects of genitourinary system tuberculosis 
AE03.00 Late effects of tuberculosis of bones and joints 
AE04.00 Late effects of tuberculosis of other specified organs 
AE0z.00 XOther tuberculosis of nervous system 
Ayu1.00 XTuberculosis of nervous system, unspecified 
Ayu1000 XTuberculosis of other specified organs 
Ayu1100 XAcute miliary tuberculosis, unspecified 
Ayu1200 XOther miliary tuberculosis 
Ayu1400 XMiliary tuberculosis, unspecified 
Ayu1500 XSequelae of central nervous system tuberculosis 
Ayu1600 XSequelae of genitourinary tuberculosis 
Ayu1700 XSequelae of tuberculosis of bones and joints 
Ayu1800 XSequelae of tuberculosis of other organs 
Ayu1900 XSequelae of respiratory and unspecified tuberculosis 
AyuJ000 Meningitis - tuberculous 
AyuJ100 Encephalitis due to tuberculosis 
AyuJ200 Tuberculous encephalitis 
AyuJ300 Tuberculous intracranial abscess 
AyuJ400 Tuberculous intraspinal abscess 
F004.00 Keratitis due to tuberculosis 
F033300 Acute pericarditis - tuberculous 
F033311 Acute myocarditis - tuberculous 
F040600 Pneumoconiosis associated with tuberculosis 
F041300 Peritonitis - tuberculous 
F4A5500 Cardituberculous cirrhosis 
G500300 XTuberculous disorders of intestine and mesentery 
G520600 Cystitis in tuberculosis 
H450.00 Prostatitis in tuberculosis 
J550200 Female tuberculous pelvic inflammatory disease 
L173100 Erythema tuberculatum 
L173200 Tuberculous arthritis 
L173300 Tuberculous infection of tendon sheath 
L173400 Tuberculosis of spine (Pott's) 
L173z00 Tuberculosis of spine 
M151400 Tuberculosis of cervical spine 
N018.00 Tuberculosis of thoracic spine 
N22yD00 Tuberculosis of lumbar spine 
N304.00 Tuberculosis of sacrum/coccyx 
N304.11 Tuberculosis of limb bones 
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N304000 Tuberculosis of unspecified limb bone 
N304100 Tuberculosis of the upper arm bone 
N304200 Tuberculosis of the forearm bone 
N304300 Tuberculosis of the pelvic and thigh bones 
N305.00 Tuberculosis of the lower leg bone 
N305000 Tuberculosis of other limb bones 
N305100 Tuberculosis of multiple limb bones 
N305200 Tuberculosis of limb bones NOS 
N305300 Tuberculosis of other bones 
N305400 Tuberculosis of bone, site unspecified 
N305500 Tuberculosis of the bones of the shoulder region 
N305600 Tuberculosis of the bones of the hand 
N305z00 Tuberculosis of the bones of the ankle and foot 
N306.00 Tuberculosis of the bones of other sites 
N306000 Tuberculosis of the bones of multiple sites 
N306100 Tuberculosis of bone NOS 
N306200 Congenital tuberculosis 
A124700 TB - acute pericarditis 
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Appendix I: Smoking Status 
Current Smoker Past Smoker Non Smoker 
Read Codes 
137..11 1377.00 1371.00 
137f.00 137N.00 1371.11 
67H1.00 745H400 9kn..00 
H310100 9OO..11 1371.00 
137Y.00 9OOA.00 AHD Code/V Code 
E251100 1378.00 1003040000/3 
Eu17y00 137O.00  
1372.00 745Hy00  
137G.00 9OO..12  
8HkQ.00 9OOZ.00  
ZG23300 1379.00  
SMC..00 137S.00  
E251200 745Hz00  
Eu17z00 9OO1.00  
1372.11 38DH.00  
137H.00 137B.00  
8HTK.00 13p..00  
ZRaM.00 8CAL.00  
137..00 9OO3.00  
E251z00 745H100  
J036400 137A.00  
1373.00 137T.00  
137J.00 8CAg.00  
8I6H.00 9OO2.00  
ZRaM.11 745H000  
137a.00 137l.00  
Eu17.00 745H.00  
SMC..00 9OO..00  
137C.00 137L.00  
137R.00 13p3.00  
9kf1.11 9kc0.00  
137a.00 9OO7.00  
6893.00 8B3f.00  
Eu17400 67H6.00  
137c.00 13p2.00  
137V.00 9kc..00  
9kf2.00 9OO6.00  
137g.00 8B2B.00  
68T..00 8I39.00  
Eu17500 9km..00  
137d.00 13p1.00  
6791.00 8HBM.00  
9kf2.11 9OO5.00  
137M.00 745H300  
E251.00 137F.00  
Eu17600 13p0.00  
137e.00 8H7i.00  
67A3.00 9OO4.00  
9ko..00 745H200  
137X.00 8I2I.00  
E251000 E251300  
Eu17700 137j.00  
1375.00 13p5.00  
137P.11 9N4M.00  
9hG0.00 9OO9.00  
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ZRao.11 8BP3.00  
137h.00 137K.00  
Eu17100 13p4.00  
ZV4K000 9N2k.00  
1374.00 9OO8.00  
137P.00 8B3Y.00  
9hG..00 E023.00  
ZRao.00 AHDCode/VCode  
137D.00 1003040000/2  
Eu17000   
ZV11600   
137b.00   
137Q.11   
9kf1.00   
ZRh4.11   
63C5.00   
Eu17300   
1376.00   
137Q.00   
9hG1.00   
ZRh4.00   
137Z.00   
Eu17200   
ZV6D800   
AHDCode/VCode   
1003040000/1   
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Appendix J: Systematic review study Inclusion form (abstract review) 
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Appendix K: Systematic review data extraction form 
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Appendix L:Plots of outcome counts against a normal curve 
 
Figure 15: A plot of TB counts alongside a normal curve (DM as a risk factor for 
TB) 
 
Figure 16: A plot of TB counts alongside a normal curve (T1DM as a risk factor 
for TB) 
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Figure 17: A plot of TB counts alongside a normal curve (T2DM as a risk factor 
for TB) 
 
 
Figure 18: A plot of PTB counts alongside a normal curve (DM as a risk factor for 
PTB) 
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Figure 19: A plot of PTB counts alongside a normal curve (T1DM as a risk factor 
for PTB) 
  
Figure 20: A plot of PTB counts alongside a normal curve (T2DM as a risk factor 
for PTB) 
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Figure 21: A plot of EPTB counts alongside a normal curve (DM as a risk factor 
for EPTB) 
 
Figure 22: A plot of EPTB counts alongside a normal curve (T1DM as a risk factor 
for EPTB) 
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Figure 23: A plot of EPTB counts alongside a normal curve (T2DM as a risk factor 
for PTB) 
  
  
Figure 24: A plot of DM counts alongside a normal curve (TB as a risk factor for 
DM) 
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Figure 25: A plot of DM counts alongside a normal curve (PTB as a risk factor for 
DM) 
 
 
Figure 26: A plot of DM counts alongside a normal curve (EPTB as a risk factor 
for DM) 
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Figure 27: A plot of T1DM counts alongside a normal curve (TB as a risk factor 
for T1DM) 
 
Figure 28: A plot of T1DM counts alongside a normal curve (PTB as a risk factor 
for T1DM) 
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Figure 29: A plot of T1DM counts alongside a normal curve (EPTB as a risk factor 
for T1DM) 
 
 
Figure 30: A plot of T2DM counts alongside a normal curve (TB as a risk factor 
for T2DM) 
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Figure 31: A plot of T2DM counts alongside a normal curve (PTB as a risk factor 
for T2DM) 
 
Figure 32: A plot of T2DM counts alongside a normal curve (EPTB as a risk factor 
for T2DM) 
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Appendix M: Invited Presentations and Peer Reviewed Publications 
Presentations 
A review of co-morbidity between infectious and chronic disease. The Annual Society 
for Social Medicine Conference (9/9/2009 Newcastle) 
Publications from this thesis 
1. Young, F. et al. Diabetes & tuberculosis: a dangerous liaison & no white tiger. 
Indian Journal of Medical Research, 2009. 130: p. 1-4. 
2. Young, F. et al. Increased risk of tuberculosis disease in people with diabetes 
mellitus: record-linkage study in a UK population. Journal of Epidemiology and 
Community Health, doi:10.1136/jech.2010.114595 
Publications produced throughout candidates time as an integrated MRes PhD 
student at Newcastle University 
1. Young, F. et al. Coronary Mortality Declines in the U.S. Between 1980 and 
2000: Quantifying the Contributions from Primary and Secondary Prevention. 
American Journal of Preventive Medicine. 39(3): p. 228-234. 
2. Young, F. et al. A review of co-morbidity between infectious and chronic 
disease in Sub Saharan Africa: TB and Diabetes Mellitus, HIV and Metabolic 
Syndrome, and the impact of globalization. Globalization and Health, 2009. 5(1): p. 9. 
3. Young, F et al. Globalization and the dual disease burden in Sub-Saharan Africa. 
Diabetes Voice, 2010. 55(1). 
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